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Abstract: 
The La/SS-B protein is well documented as an autoantigen for autoimmune 
conditions such as systemic lupus erythematosus (SLE). Recently, a link 
between La and viruses has been reported, an interesting observation given the 
fact that viral infection is a significant risk factor in SLE. However, the direct 
mechanism by which La functions in the innate immune response to viral 
challenge remains elusive. As such, we sought to investigate whether La 
directly regulates the induction of the anti-viral cytokines, type I Interferons, 
(IFNs) by direct modulation of innate immune toll-like receptor (TLR) or RIG-I-
like receptor (RLR) signalling pathways.  
     Our findings have highlighted a dual and complex role for La in the 
regulation of IFN production. Initial studies demonstrated a role for La in the 
specific attenuation of IFN promoter transcriptional activity downstream of RLR 
activation. In confirmation of this, elevated IFN levels were observed following 
La knockdown in resting cells, compared with controls. Studies in a cohort of 
SLE patients supported these findings, with decreased La expression observed 
in SLE patients compared with healthy controls in basal cells, both at an mRNA 
and protein level. However upon activation of the anti-viral RIG-I receptor, La 
was shown to promote anti-viral responses by direct interaction with RIG-I 
receptor, enhancing complex formation between RIG-I and its ligand as well as 
downstream adaptor protein IPS-1, the overall consequence of which was 
increased IFN induction. Sendai virus infection experiments supported these 
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findings with depletion of La leading to increased viral infection efficiency and 
decreased IFN and IFN stimulated gene (ISG) expression. 
     Thus a dual role exists for La in the context of RIG-I-mediated IFN 
production, with the protein capable of both inhibiting basal type I IFN in 
resting cells, most likely in an attempt to prevent inappropriate IFN induction 
and maintain innate immune balance. In the context of infection, however, La is 
a potent activator of IFN responses, promoting RIG-I binding to its ligand and 
enhanced type I and type III IFN production, in an effort to protect the host by 
limiting viral replication and promoting the clearance of the pathogen. 
Interestingly, we have observed that phosphorylation of La by casein kinase 2 
(CK2) may be the regulatory switch that turns La from being active to inactive, 
and that in cells treated with a CK2-specific inhibitor, La has a higher affinity for 
RIG-I. With respect to a potential involvement of this protein in SLE we have 
observed that a higher ratio of expression of a potentially active form of La 
(neo-La) is observed in SLE patients, suggesting that this imbalance between 
full length and neo-La in SLE patients contributes to the dysregulated IFN 
expression observed in patients. Our work has important implications for our 
understanding of pathways regulating IFN production in the context of SLE. 
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Chapter 1: 
General Introduction 
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1.1  The immune system 
The immune system is the collection of organs, tissues, cells and molecules 
that protect against disease. As vertebrates, humans are constantly challenged 
by pathogenic micro-organisms such as viruses, bacteria and fungi and, as 
such, have evolved extremely sophisticated defence mechanisms to protect 
against disease. The vertebrate immune system can be broadly divided into 
innate and adaptive immunity. Innate immunity is the first line of defence and 
is typically triggered following microbe recognition by pathogen recognition 
receptors (PRRs). The adaptive (acquired) immune response is a slower but 
highly antigen-specific response which leads to immunological memory and 
culminates in the production of antibodies. The cells of the immune system 
originate in the bone marrow and migrate from here to guard peripheral tissues 
via the lymphatic system, a network of organs and vessels that drain 
extracellular fluid from tissues, via the thoracic duct, to the blood.  
The myeloid progenitor, derived from hematopoietic stem cells, is the 
precursor of the majority of cells of the innate immune system. In the bone 
marrow, the myeloid progenitor differentiates into the granulocyte or 
polymorphonuclear leukocyte (PML) which, following migration to the blood, 
differentiates into neutrophils, eosinophils and basophils. These cells collectively 
function in phagocytosis, degranulation, neutrophil extracellular trap (NET)-
mediated pathogen destruction, reactive oxygen species (ROS) production and 
cytokine induction (Hogan et al., 2008; Nakanishi, 2010; Schroeder, 2009; 
Segal, 2005). Myeloid progenitor differentiation also gives rise to mast cells 
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and, perhaps most importantly, monocytes. Mast cells play a role in the release 
of histamine, thereby contributing to a local inflammatory response. Within the 
tissues, monocytes give rise to macrophages and dendritic cells which are 
crucial for phagocytosis, antigen uptake and antigen presentation (Ziegler-
Heitbrock et al., 2010). 
The lymphoid progenitor, also derived from the hematopoietic stem cells, 
differentiates into innate immune precursor natural killer (NK) and plasmacytoid 
dendritic cells (DCs) but predominantly gives rise to cells of the adaptive 
immune system, specifically B and T cells. B cells are responsible for antigen 
recognition via membrane bound immunoglobulin (Ig), known as the B cell 
receptor (BCR), and antibody secretion (Mauri and Bosma, 2012). Antibodies 
are secreted Ig molecules composed of two distinct parts; a variable region, 
which determines antigen specificity and a constant region, which determines 
antigen disposal following binding. Upon antigen binding, the B cell is activated 
to divide and give rise to many identical progeny or clones, which can in turn 
secrete antibodies with specificity identical to that of the surface receptor that 
initiated clonal expansion. This “clonal selection hypothesis” was first described 
by Macfarlane Burnet in the 1950s and is arguably the single most important 
principle in adaptive immunity. T cells can be subdivided into two classes; 
cytotoxic T cells, expressing the CD8 cell-surface molecule, kill virally infected 
cells while the other class of T cells, which possess the CD4 cell-surface 
molecule, activate other immune cells (Barry and Bleackley, 2002; Dasgupta 
and Saxena, 2012). Depending on the cytokine environment, naive CD4-positive 
T cells can then differentiate into Th1, Th2 or Th17 lineages. Th1 cells are 
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responsible for macrophage activation, cytokine and chemokine release and 
thus attraction of macrophages to site of infection while Th2 cells are involved 
in B cell stimulation and antibody production (Nakayamada et al., 2012). Th17 
cells naturally function in the recruitment, activation and migration of 
neutrophils following infection but have also been strongly implicated in 
autoimmune disease by driving excessive inflammation (Harrington et al., 2005; 
Steinman, 2007; Stockinger et al., 2007). T cells recognise their targets by the 
detection of peptide fragments derived from pathogenic proteins and they do so 
via the membrane glycoprotein, major histocompatibility complex (MHC), which 
collects peptides derived from proteins synthesised either in the cytosol (MHC 
class I) or within intracellular vesicles (MHC class II).  
1.2 Autoimmunity  
 While the immune system is critically important in protecting the host 
from microbial infection, it is of utmost importance that it is tightly regulated, in 
order to prevent uncontrolled or inappropriate activation of immune cells and 
exacerbated cytokine, chemokine and anti-microbial peptide induction. 
Autoimmune disease stems from a breakdown of immune tolerance resulting in 
a dysregulated and over-active immune response against host cells and tissues. 
Autoimmunity has many different causes including T-cell bypass, T-cell/B-cell 
misregulation, aberrant B cell receptor-mediated feedback, molecular mimicry, 
epitope cross reaction, epitope spreading and cytokine dysregulation (Edwards 
and Cambridge, 2006; Green et al., 2007; Kubach et al., 2005). Disease can be 
broadly categorised into local, affecting a specific organ or tissue, and systemic, 
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where effects are widespread and not confined to a specific organ. Examples of 
local autoimmune diseases include the neurological condition; myasthenia 
gravis, the endocrine condition; diabetes mellitus type 1 and gastrointestinal 
conditions such as Crohn’s disease and Coeliac disease. Examples of systemic 
conditions include rheumatoid arthritis (RA), Sjögren’s syndrome (SS) and 
systemic lupus erythematosus (SLE).  
1.3 Systemic Lupus Erythematosus (SLE) 
 Systemic lupus Erythematosus (SLE) is a complex heterogenous 
autoimmune condition which presents most typically as a “butterfly” rash across 
the face, joint pain and chronic fatigue but can develop into severe 
inflammation leading to deterioration of kidney function (glomerulonephritis) 
and further organ damage. Renal disease is a significant cause of morbidity and 
mortality among SLE patients: it develops in approximately 60% of patients, 
among which 5–22% progress to end-stage renal disease thus requiring dialysis 
or transplant (Wissing et al., 2000). SLE is characterised by autoantibodies to 
nuclear antigens, abnormally activated T cells and antigen presenting cells, 
activation of complement and imbalanced cytokine production (Figure 1.1). Due 
to disease complexity, a heterogenous patient population, and limited 
understanding of pathogenesis, there is currently no cure for SLE (Eisenberg, 
2009). Standard therapy includes corticosteroids such as prednisone, non-
steroidal anti-inflammatory drugs (NSAIDs) to relieve joint pain and arthritis, 
hydroxychloroquine to combat arthritis or skin problems and 
immunosuppressants such as cyclophosphamide to limit organ damage. While 
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corticosteroid treatment has been the mainstay for managing symptoms, these 
drugs increase risk factors for cardiovascular involvement such as serum lipids, 
blood pressure, weight and glucose levels and, in fact, the majority of organ 
deterioration associated with SLE can be attributed to corticosteroid use 
(Magder and Petri, 2012; Thamer et al., 2009). 
 
 
Figure 1.1: SLE symptom presentation; SLE presents most commonly as skin 
rash, joint pain and chronic fatigue but can develop into systemic autoimmunity which 
affects the kidneys, heart, lungs and in some cases even the nervous system 
(www.bio.davidson.edu) 
 
1.3.1 Autoantibodies 
 The signature hallmark of SLE is elevated serum levels of autoantibodies 
directed against extractable nuclear antigens (ENAs) (Holman, 1965) and, as 
such, anti-ENA autoantibodies are one of the diagnostic criteria of disease 
(Hochberg, 1997; Kavanaugh et al., 2000), with autoantibodies typically 
developing in patients several years (mean 3.3) before clinical symptoms 
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appear (Arbuckle et al., 2001; Arbuckle et al., 2003). Autoantibodies are 
targeted against two ribonucleoprotein (RNP) complexes – the U1-small nuclear 
ribonucleoprotein (snRNP) complex and the Ro/La complex (Figure 1.2). The 
U1-snRNP complex is composed of RNP proteins such as RNP70, RNP A, RNP B 
and RNP C as well as the Smith antigen (Sm) (Migliorini et al., 2005). The 
Ro/La complex consists of 4 small cytoplasmic RNAs (hYRNA) as well as Ro60, 
Ro52 and La/SSB (Buyon et al., 1989; Franceschini and Cavazzana, 2005). 
 
Figure 1.2: Autoantigen-containing complexes; (A) The U1-snRNP complex is 
composed of RNP proteins such as RNP70, RNP A, RNP B and RNP C as well as the 
Smith antigen (Sm) (Migliorini et al., 2005). (B) The Ro/La complex consists of 4 small 
cytoplasmic RNAs (hYRNA) as well as Ro60, Ro52 and La/SSB (Franceschini et al., 
2005). 
 
1.3.2 Pathogenesis  
 In SLE patients, there is an increased amount of apoptosis along with 
impairment in the clearance of resulting debris, thereby leading to over-
activation of B cells (Hermann et al., 1998; Janko et al., 2008). Increased 
apoptosis has been reported in a variety of SLE cells including lymphocytes 
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(Emlen et al., 1994; Grondal et al., 2002), neutrophils (Courtney et al., 1999; 
McConnell et al., 2002), and monocytes (Ren et al., 2003; Shoshan et al., 
2001), with increased expression of apoptotic ligands TNF-related apoptosis-
inducing ligand (TRAIL), TNF-related weak inducer of apoptosis (TWEAK) and 
Fas ligand observed on T cells from lupus patients (Kaplan et al., 2002). 
Monocytes from SLE patients are less phagocytic, have decreased expression of 
Fcγ receptors II and III and demonstrate a prolonged clearance time of labelled 
anti-IgG sensitised erythrocytes (Hermann et al., 1998). Normally the SLE 
autoantigens are intracellular, and therefore hidden from immune detection. 
Following cell injury however, the nucleic acid-binding elements of the Ro/La 
and RNP complexes are specifically targeted to the surface of apoptotic bodies, 
where they form immunogenic complexes with circulating autoantibodies 
(Casciola-Rosen et al., 1994; LeFeber et al., 1984; Ohlsson et al., 2002; Reed et 
al., 2008). These immune complexes subsequently become internalised by Fcγ 
receptors and trigger activation of PRRs on or within antigen presenting cells 
which in turn triggers cytotoxicity (Boule et al., 2004; Means et al., 2005; 
Means and Luster, 2005; Salmon et al., 1996; Savarese et al., 2008; Vollmer et 
al., 2005). Consequently, an immunogenic cycle results whereby inflammation-
induced cell death results in release of these autoantigens, which consequently 
amplifies the response (Figure 1.3). 
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Figure 1.3: Immunogenic cycle of autoimmunity in SLE; Following cell injury, 
the SLE autoantigens, normally hidden from immune detection, are targeted to the 
surface of apoptotic bodies. Circulating antibodies then form complexes with the 
autoantigens. These immune complexes are then internalised by Fc receptors on the 
surface of neighbouring cells and trigger activation of PRRs, which in turn triggers 
cytotoxicity through IFN and pro-inflammatory cytokine release, thus feeding back into 
the cycle. 
 
1.3.3 Viral infection and SLE 
 There are a number of well-established risk factors which contribute to 
SLE such as genetic predisposition, diet, female gender and viral infection 
(Borba and Bonfa, 1997; Bruce, 2005; Byrne et al., 2012; Chung et al., 2007; 
Klack et al., 2012; Mok et al., 1999a; Mok et al., 1999b; Nussinovitch and 
Shoenfeld, 2011; Sestak et al., 2011; Smith et al., 2013). Viral infection is a 
significant cause of mortality in SLE patients contributing to death in over a 
quarter of 1000 European SLE patients followed over a 10-year period (Alarcon 
et al., 2001; Goldblatt et al., 2009; Noel et al., 2001). Infections are also 
responsible for 14-50% of hospitalisations in SLE (Duffy et al., 1991; Edwards 
et al., 2003; Petri and Genovese, 1992). Some of the most commonly 
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encountered viral infections are Herpes zoster virus (Kang et al., 2005), human 
papillomavirus (HPV) (Nath et al., 2007), human cytomegalovirus (HCMV) 
(Rider et al., 1997), parvovirus B-19 (Hemauer et al., 1999; Ramos-Casals et 
al., 2008) and Epstein-Barr Virus (EBV). A large number of studies have 
demonstrated a link between EBV infection and SLE development, with a 
significantly higher (up to 40-fold increase) EBV load in peripheral blood 
mononuclear cells (PBMCs) of SLE patients compared with healthy controls, an 
increase which positively correlates with disease activity (Gross et al., 2005; 
Kang et al., 2004; Moon et al., 2004; Yu et al., 2005). In addition, EBV-derived 
DNA was obtained from the serum of 42% of SLE patients, compared with only 
3% of healthy control serum, suggesting active replication of the virus in SLE 
(Lu et al., 2007). Furthermore, SLE patients were demonstrated to have 
particularly high mRNA expression of several EBV-derived species including 
BZLF1 (required for lytic replication) gp350 (glycoprotein involved in viral 
entry), LMP1/2 (anti-apoptotic) and EBNA1 (nuclear antigen) (Gross et al., 
2005; Poole et al., 2009). A further link between EBV infection and SLE is the 
observation that antibodies to EBNA1 and viral capsid antigen have been found 
in the sera of paediatric and adult SLE patients (James et al., 1997; James et 
al., 2001; McClain et al., 2006). Viral infection culminates in the activation of 
innate immune receptors, thereby initiating downstream signalling and 
contributing to the increased inflammation and elevated interferon signature 
characteristically observed in SLE patients.  
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1.3.4 Interferons (IFNs) in SLE 
 A unifying feature of disease in SLE patients is the presence of 
consistently high levels of type I Interferons (IFNs). IFNs, so named due to 
their ability to interfere with viral replication, are a class of potent anti-viral 
cytokines (discussed in detail in chapter three). These proteins play diverse and 
essential roles in innate immune responses, such as inhibition of transcription 
and translation of viral proteins (Clemens and Elia, 1997; Stark et al., 1998), 
inhibiting viral-induced apoptosis (Chesler and Reiss, 2002a), MHC class I 
expression (Epperson et al., 1992; Hermann et al., 1998; Honda et al., 2005a; 
Le Bon et al., 2006a; Le Bon et al., 2006b), NK cell activation (Salazar-Mather 
et al., 1996; Trinchieri et al., 1981), maturation of DCs (Le Bon et al., 2003), B 
cell responses (Le Bon et al., 2001; Le Bon et al., 2006b), anti-tumour and 
apoptotic effects (Donnelly and Kotenko, 2010; Li et al., 2008; Maher et al., 
2008). Since the 1970s, detrimentally high serum and intracellular levels of IFN 
have been observed in the serum and immune cells of SLE patients (Blanco et 
al., 2001; Hooks et al., 1979; Niewold et al., 2008; Niewold et al., 2007; 
Niewold and Swedler, 2005; Ronnblom et al., 1990; Weckerle et al., 2011). 
Microarray studies have shown an overexpression of type I IFNs in peripheral 
blood mononuclear cells (PBMCs) from SLE patients compared with cells from 
healthy controls (Baechler et al., 2003; Crow et al., 2003). Interestingly, some 
patients suffering from chronic viral infections developed SLE following 
recombinant human IFN-α injections (Niewold and Swedler, 2005; Ronnblom et 
al., 1990). In addition, significantly higher serum levels of IFN-α are found in 
first-degree healthy relatives of SLE patients, as compared with unrelated 
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healthy controls, suggesting an inherited risk factor of high IFN levels for SLE 
(Niewold et al., 2007; Weckerle et al., 2011).  
 Type II IFNs have also been shown to play a role in SLE, with increased 
IFN-γ levels observed in the serum and PBMCs of lupus patients, particularly 
those in active stages of disease (al-Janadi et al., 1993; Gerez et al., 1997; 
Tokano et al., 1999). Murine models of lupus were in agreement with these 
studies, with high mRNA, protein and cytokine levels of IFN-γ observed in MRL-
Faslpr mice (animal model whereby MRL gene overexpression is responsible for 
renal injury and SLE-like phenotype and the single gene mutation in Fas 
exacerbates and speeds up tissue destruction), particularly at late stages of 
disease (Fan and Wuthrich, 1997; Manolios et al., 1989; Murray and Martens, 
1990; Prud'homme and Chang, 1999; Shirai et al., 1995; Umland et al., 1989). 
IFN-γ was definitively shown to be necessary for lupus pathogenesis in mice by 
a number of studies in MRL-Faslpr and B × W mice (New Zealand mouse model 
in which a spontaneous autoimmune SLE-like disorder develops), in which the 
IFN-γ or IFN-γR genes were deleted (Balomenos et al., 1998; Haas et al., 1998; 
Peng et al., 1997; Schwarting et al., 1998). These groups demonstrated 
decreased IgG titres, anti-dsDNA and anti-histone antibodies and TNF-α, as well 
as less kidney destruction and extended survival. Remarkably, 
glomerulonephritis and early death were prevented in mice that were only 
heterozygous for the IFN-γ gene (Balomenos et al., 1998). 
 More recently, type III IFNs have been associated with SLE, with IFNλ-1 
mRNA and serum expression increased in SLE patients, compared with controls. 
This increase was also shown to positively correlate with disease activity as 
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measured by the Systemic Lupus Erythematosus Disease Activity Index 
(SLEDAI) score as well as anti-dsDNA antibody and C-reactive protein (CRP, 
blood protein which activates the complement system) levels. In addition, this 
study showed that SLE patients with renal involvement or arthritis had elevated 
levels of IFNλ-1 (Wu et al., 2011). The consequence of this collective build-up 
of all classes of IFN is increased inflammation, cytotoxicity and autoantibody 
generation, thus contributing to the systemic pathogenesis of the disease as 
schematically summarised in Figure 1.3 (Baechler et al., 2003). 
 With this in mind, anti-IFN therapy for SLE has been explored in recent 
years and a number of antibodies targeting IFN-α sub-types, such as 
Sifalimumab, Rontalizumab and AGS-009, are currently in clinical trials. These 
antibodies are designed to bind and neutralise virtually all IFN-α subtypes, 
appear to show efficacy and are well tolerated (Merrill et al., 2011; Petri et al., 
2013). 
1.4 Pathogen Recognition Receptors (PRRs)  
In order to fully understand how IFNs are affecting lupus progression and/or 
severity, we must focus on how these proteins are induced and regulated. IFN 
induction is mediated via pathogen recognition receptors (PRRs) possessed by 
innate immune cells such as macrophages, dendritic cells and natural killer (NK) 
cells. These PRRs include Toll-like receptors (TLRs), Nod-like receptors (NLRs), 
cytosolic DNA receptors and RIG-like receptors (RLRs) which are collectively 
responsible for the production of IFN as well as pro-inflammatory cytokines. 
This process is initiated by detection of conserved motifs known as pathogen 
associated molecular patterns (PAMPs) within viruses, bacteria, fungi and 
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parasites and leads to activation of adaptive immune response, clearance of 
viral pathogen and protection from disease.   
1.4.1 Toll-like receptors (TLRs)  
Toll-like receptors (TLRs), first identified based on their homology with the Toll 
receptors from the fruit fly Drosophila  (Medzhitov et al., 1997; Schneider et al., 
1991), are a family of germline encoded transmembrane proteins which 
recognise different pathogen associated molecular patterns (PAMPs) and 
respond by initiating a signalling cascade leading to activation of transcription 
factors, production of anti-microbial peptides and secretion of cytokines such as 
type I IFN, members of the Interleukin (IL) family and Tumour Necrosis Factor-
α (TNF-α), which results in successful removal of the specific pathogen (Bowie 
and O'Neill, 2000). 
 TLRs recognise a broad range of PAMPs from a variety of different 
pathogens. Bacterial motifs sensed include bacterial cell wall component, 
lipopolysaccharide (LPS), peptidoglycan, flagellin and nonmethylated cytosine-
guanosine motifs (CpG DNA), detected by TLR-4, TLR-2, TLR-5 and TLR-9, 
respectively. The bacterial TLRs have been reported to be important for optimal 
defence against Salmonella, Pseudomonas, Escherichia coli, Mycobacterium and 
Staphylococcus species (Andersen-Nissen et al., 2007a; Andersen-Nissen et al., 
2007b; Feuillet et al., 2006; Gerold et al., 2007; Saiga et al., 2011; Takeuchi et 
al., 2000; Weiss et al., 2004). At least five TLRs; TLR-2, TLR-4, TLR-6, TLR-7, 
and TLR-9, are capable of detecting fungal pathogens e.g. Candida species 
which contain a variety of PAMPS including mannan, chitin, β-glucan and 
nucleic acids (Netea and Marodi, 2010; Romani, 2011). Protozoan parasite 
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derivatives such as glycosylphosphatidylinositol (GPI), thiol-disulfide 
oxidoreductase protein (Tc52) and hemozoin from Trypanosoma cruzi, 
Toxoplasma gondii, and Plasmodium falciparum are also sensed by TLR-2, TLR-
4 and TLR-9 (Coban et al., 2005; Gazzinelli and Denkers, 2006; Yarovinsky et 
al., 2005). Viral ssRNA and dsRNA from reoviruses, influenza A virus (IAV), 
encephalomyocarditis virus (EMCV), West Nile virus (WNV), herpes simplex 
virus 1 (HSV-1), murine cytomegarovirus (MCMV), human immunodeficiency 
virus (HIV) and vesicular stomatitis virus (VSV) (Akira, 2006; Blasius and 
Beutler, 2010; Gilliet et al., 2008; Reizis et al., 2011) are recognised by TLR-3, 
TLR-7 and TLR-8. Of particular interest to us are the nucleic acid binding TLRs; 
TLR-3, TLR-7, TLR-8 and TLR-9, as these receptors have been widely implicated 
in SLE pathogenesis. 
 TLRs can be broadly divided on the basis of their cellular localisation; cell 
surface TLRs include TLR-4, TLR-5, TLR-6, TLR-2 and TLR-1, while the anti-viral 
TLRs; TLR-3, TLR-7, TLR-8 and TLR-9, are sequestered in the endoplasmic 
reticulum (ER) and are delivered to endosomes via the Golgi apparatus, where 
they recognise and respond to their ligands. A number of proteins have been 
reported to be essential in mediating TLR localisation. UNC93B1 is a 12 
membrane-spanning protein present in the ER which interacts with TLRs and 
regulates their trafficking to endosomal compartments (Brinkmann et al., 2007; 
Kim et al., 2008; Tabeta et al., 2006). In addition, PRAT4A regulates the exit of 
TLR-1, TLR-2, TLR-4, TLR-7, and TLR-9 from the ER and their appropriate 
localisation to the membrane and endosomes. Furthermore, gp96, a member of 
the heat-shock protein 90 family, functions as a general chaperone for most 
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TLRs, including cell surface TLR-1, TLR-2, TLR-4, and TLR-5 and intracellular 
TLR-7 and TLR-9 (Saitoh and Miyake, 2009).  
1.4.1.1 MyD88-dependent signalling 
 With the exception of TLR-3, all the TLRs recruit MyD88 (Barton and 
Medzhitov, 2003; Muzio et al., 1998; O'Neill and Bowie, 2007) which associates 
with members of the IL-1R associated kinase (IRAK) family such as IRAK-1 
(Figure 1.4). This triggers IRAK-1 auto-phosphorylation and additional 
phosphorylation by IRAK-4 (Cao et al., 1996; Li et al., 2000; Li et al., 2002b; 
Muzio et al., 1997). IRAK-1 then dissociates from MyD88 and interacts with 
downstream adaptor, Tumour Necrosis Factor-receptor associated factor 6 
(TRAF-6) (Kawai et al., 2004). TRAF-6 then recruits a complex containing the 
MAP3 kinase, transforming growth factor-β-activating kinase (TAK-1), TAK-
binding protein 1 (TAB1), TAB2 and TAB3 (Mendoza et al., 2008) which 
promotes downstream activation of IκB kinases (IKKs), IKKα, IKKβ and IKK-
γ/NEMO. The IKKs directly phosphorylate IκB, an inhibitory protein which 
sequesters NF-κB in an inactive form in the cytosol, resulting in poly-
ubiquitination of IκB and its degradation by the proteosome (Yi and Krieg, 
1998). Phosphorylated NF-κB is now free to translocate to the nucleus, where it 
induces the production of pro-inflammatory cytokines such as TNF-α, IL-1 and 
IL-6. IRF-7 is also activated downstream of MyD88, thereby leading to type I 
IFN induction. Furthermore, TAK-1 activation results in activation of MAP 
kinases JNK, p38 and ERK, which in turn leads to phosphorylation and nuclear 
translocation of AP-1 (Wang et al., 2001), thereby contributing further to pro-
inflammatory cytokine production. MyD88 has also been reported to associate 
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with Mal (Fitzgerald et al., 2001) which initiates two separate signalling 
cascades: (i) Mal can activate the Fas/Apo-1-associated death domain (FADD) 
protein and lead to recruitment and activation of caspase 8, ultimately 
culminating in apoptosis (Kaiser and Offermann, 2005) and (ii) Mal can interact 
with Rac1 which, mediated by PI3 kinase, Akt and IKK, leads to IκB 
degradation and NF-κB translocation to the nucleus (Arbibe et al., 2000; 
Santos-Sierra et al., 2009; Sarkar et al., 2004). 
1.4.1.2 TRIF-dependent signalling  
 In contrast, TLR-3 signals in a MyD88-independent manner via TRIF (de 
Bouteiller et al., 2005; Oshiumi et al., 2003; Yamamoto et al., 2003). Three 
signalling pathways exist downstream of TRIF: (i) TRIF can interact with TRAF-
6 bringing about classical activation of NF-κB, as explained in detail above (ii) 
TRIF can interact with TRAF-3, leading to phosphorylation of TANK-binding 
kinase 1 (TBK-1) and activation of IRF-3 and IRF-7 (Cao et al., 1996; Hacker et 
al., 2006; Kawai and Akira, 2008) (iii) TRIF has also been shown to activate AP-
1 by interaction with RIP1 and TRADD leading to phosphorylation of the ERK, 
JNK and p38 kinases (Kaiser and Offermann, 2005) (Figure 1.4). In the TLR-3 
pathway, recognition of viral dsRNA triggers phosphorylation of a 
serine/threonine cluster in the C-terminal of IRF-3 (Doyle et al., 2002). This 
causes a conformational change which leads to translocation of IRF-3 to the 
nucleus and binding of the transcription factor to promoters containing IRF-3 
binding site, such as the IFN-β promoter. The synergistic activity of the IRF-3 
and IRF-7 transcription factors is crucial for the efficient early response to viral 
infection.  
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Figure 1.4: Toll-like Receptor (TLR) Signalling Pathway; TLRs detect a variety 
of PAMPs such as LPS, Flagellin and viral nucleic acids and signal through adaptor 
proteins MyD88, Mal, TRIF and TRAM to activate transcription factors such as IRF-3, 
IRF-7, AP-1 and NF-κB, leading to the induction of type I IFNs and pro-inflammatory 
cytokines and, ultimately, removal of the pathogen. 
 
1.4.1.3 Anti-viral TLRs in SLE 
There are several genetic and functional studies which demonstrate an 
important role for anti-viral TLRs; TLR-3, TLR-7, TLR-8 and TLR-9, in SLE 
pathogenesis, as detailed in table 1.1. TLR-9 was originally thought to be 
protective in lupus-like autoimmunity. One study by Christensen et al., found 
that in the absence of TLR-9, an exacerbation of autoimmunity was observed 
with more activated lymphocytes and plasmacytoid DCs, higher IgG levels in 
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the serum and increased IFN-α levels (Christensen and Shlomchik, 2007). An 
animal study by Wu and colleagues showed that TLR-9-deficient MRL mice were 
prone to more severe lupus, with increased autoantibodies in the sera, 
increased IgG serum levels, more enlarged lymph nodes, inflammatory 
infiltrates in the salivary gland and kidney, proteinuria, and increased mortality 
compared to control TLR-9-sufficient mice (Wu and Peng, 2006). The titre of 
anti-dsDNA autoantibodies was also significantly higher in TLR-9–/– C57BL/6-
lpr/lpr mice. This group also noted a higher rate of mesangial proliferation in 
the kidney of TLR-9-deficient animals (Lartigue et al., 2006). However more 
recent studies have demonstrated that TLR-9 is, in fact, pathogenic for SLE, 
with TLR-9 expression found to be significantly increased in SLE patients, 
compared with controls. In addition, a significant positive correlation was 
observed between TLR-9 expression and SLEDAI score and anti-DNA 
(Capolunghi et al., 2010; Ghaly et al., 2012; Mu et al., 2012).  
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Table 1.1: Endosomal TLRs implicated in SLE 
TLR 
Role in 
SLE 
Mechanism Reference 
TLR-3 
Pathogenic • Recognition of internalised 
RNA/autoantigen complexes leading to 
B cell autoreactivity 
• Hyper-activation of TBK-1 and 
enhanced IRF-3 binding to the IL-
23p19 promoter following TLR-3 
stimulation in SLE patients 
• Increased expression (mRNA and 
protein) in juvenile SLE patients 
compared with controls   
• Aggravation of lupus by viral RNA is 
mediated by TLR-3 
(Green et al., 
2012; Midgley et 
al., 2012; Patole et 
al., 2005; Smith et 
al., 2012; Yu et al., 
2012) 
 
TLR-7 
Pathogenic • TLR-7-mediated TNF-α induction 
causes bone marrow damage in SLE 
• Expression on B cells drives anti-RNA 
autoantibody & exacerbates disease in 
conditional TLR-7 transgenic Tg7 mice 
• Drives accumulation of age-associated 
B cells (ABCs) and autoantibody 
production 
• Polymorphisms associated with SLE 
development 
• Promotes glomerular C3 deposition via 
recognition of anti-dsDNA and anti-
histone antibodies of IgG1 and IgG2b 
isotype varieties 
• TLR-7-dependent type I IFN 
production, monocyte recruitment and 
autoantibody production following 
pristane model of lupus in mice 
(Christensen and 
Shlomchik, 2007; 
Hwang et al., 
2012; Kono et al., 
2009; Lee et al., 
2008; Pan et al., 
2010; Rubtsov et 
al., 2013; 
Santiago-Raber et 
al., 2010; Savarese 
et al., 2008; 
Zhuang et al., 
2013) 
 
TLR-8 
Pathogenic • Detects specific RNA sequences within 
snRNP/autoantibody complexes 
following internalisation by FcγRIIA 
(Vollmer et al., 
2005) 
TLR-9 
Pathogenic • Activates B-cell activating factor 
(BAFF)  
• Polymorphisms associated with SLE 
pathogenesis 
• Positive correlation between TLR-9 
expression and SLEDAI score as well 
as anti-DNA in active and inactive SLE 
patients  
• Required for anti-nucleosome antibody 
production in C57BL-/6-lpr/lpr mice 
• TLR-9 signalling through MyD88 
required for class-switching to IgG2a 
and 2b autoantibodies in SLE 
(Abu-Rish et al., 
2013; Capolunghi 
et al., 2010; Chen 
et al., 2011; Ehlers 
et al., 2006; Ghaly 
et al., 2012; 
Komatsuda et al., 
2008; Lartigue et 
al., 2006; 
Piotrowski et al., 
2013; Zhang et al., 
2013)  
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1.4.2 Nucleotide binding and oligomerisation domain (NOD)-like 
receptors (NLRs) 
Nucleotide binding and oligomerisation domain (NOD)-like receptors (NLRs), a 
family of intracellular receptors characterised by the presence of a NOD 
(Inohara and Nunez, 2001), were originally thought to be predominantly 
involved in anti-bacterial innate immune responses, however emerging data is 
revealing an important role for this class of receptor in response to a diverse 
spectrum of PAMPs and danger associated molecular patterns (DAMPs) such as 
bacterial and viral DNA or RNA, flagellin, reactive oxygen species (ROS) and 
ATP. Their general structure comprises an N-terminal effector domain 
comprising CARDs, pyrin (PYD) and/or baculovirus inhibitor repeat (BIR) 
domains, responsible for protein-protein interactions, a central NOD domain 
plus a variety of C-terminal leucine rich repeat (LRR) motifs which function in 
detection of conserved microbial patterns and modulation of NLR activity. These 
receptors are classified into three subfamilies based on their N terminal domain; 
CARD-containing NODs, PYD-containing NALPs, or BIR-containing NAIPs.  
 In resting cells, the C-terminal LRRs are folded onto the central NOD 
domains, thereby preventing spontaneous or inappropriate activation. Upon 
PAMP detection by the LRR regions, conformational rearrangement leads to 
oligomerisation via the NODs as well as exposure and activation of CARD and 
PYD effector domains. NLR proteins, NOD1 and NOD2 subsequently induce NF-
κB via interaction with serine-threonine kinase, RIP2, polyubiquitination of IKK-
γ, phosphorylation of TAK1 and degradation of IκB (Abbott et al., 2004; Inohara 
et al., 1999; Ogura et al., 2001; Windheim et al., 2007). MAPK signalling is also 
initiated by NOD1 and NOD2, with activation of p38, ERK, and JNK (Girardin et 
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al., 2003; Kobayashi et al., 2005; Park et al., 2007; Pauleau and Murray, 2003). 
Activation of these signalling cascades results in enhanced pro-inflammatory 
cytokine production and stimulation of innate and adaptive responses. NLR 
family members Ipaf1 (NLRC4), Nalp1 (NLRP1) and Cryopyrin (also known as 
NALP3) are evolutionarily conserved proteases which function in activation of 
inflammatory caspases.  These NLRs recruit the adaptor protein, apoptosis-
associated speck-like protein containing a CARD (ASC), to a large multi-protein 
complex known as the “inflammasome” (Martinon et al., 2002), thereby leading 
to recruitment and activation of caspase-1 and, via a series of zymogen 
cleavage and activation steps, production of IL-1β and IL-18 (Lamkanfi et al., 
2002; Mariathasan et al., 2004), as illustrated in Figure 1.5. 
 Viral infection has recently been demonstrated by several groups to 
activate three distinct inflammasomes, following challenge with IAV, SeV, VSV, 
RSV, HCV, ECMV, rabies, measles and adenovirus (Cui et al., 2010; Delaloye et 
al., 2009; Ichinohe et al., 2010; Kanneganti et al., 2006a; Kuenzel et al., 2010; 
Muruve et al., 2008; Rathinam et al., 2010; Rintahaka et al., 2008). These 
include the NALP3 inflammasome, the RIG-I inflammasome and the AIM2 
inflammasome, whereby ASC interacts homotypically with PYD and CARD motifs 
of these individual proteins (Allen et al., 2009; Burckstummer et al., 2009; 
Fernandes-Alnemri et al., 2009; Hornung et al., 2009; Ichinohe et al., 2009; 
Kanneganti et al., 2006a; Kanneganti et al., 2006b; Poeck et al., 2010; Thomas 
et al., 2009), as schematically summarised in Figure 1.5. The requirement for 
inflammasome signalling in viral infection is best characterised for IAV, with 
Nalp3-/- mice having increased mortality, decreased neutrophil infiltration to the 
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lungs and decreased IL-1β, IL-18 and CXCL-2 following IAV infection, when 
compared with wild-type mice (Allen et al., 2009; Thomas et al., 2009). Further 
support for a link between NLR signalling and viral infection stems from recent 
observations showing that type I IFN production is induced downstream of M. 
tuberculosis-induced NOD2 activation of RIP2 and IRF-5 and also by IPS-1-
dependent activation of IRF-3 (Pandey et al., 2009). In support of this, NOD2-
deficient mice displayed decreased type I IFN, attenuated IRF-3 activation, 
increased lung disease and viral susceptibility following VSV, IAV and 
parainfluenza infection (Sabbah et al., 2009). 
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Figure 1.5: NOD-like receptor signalling; Upon PAMP detection, NLR proteins, 
NOD1 and NOD2, induce NF-κB via interaction with RIP2, polyubiquitination of IKK-γ, 
phosphorylation of TAK1 and degradation of IκB. MAPK signalling is also initiated by 
NOD1 and NOD2, with activation of p38, ERK, and JNK. In addition, RIP2 leads to 
activation of IRF-3 and IRF-5 via an IPS-1-dependent mechanism. These signalling 
cascades culminate in gene expression of pro-inflammatory cytokines and type I IFNs. 
IPAF1, NALP1 and NALP3 are proteases which function in activation of inflammatory 
caspases.  These NLRs recruit ASC to the inflammasome, thereby leading to 
recruitment and activation of caspase-1 and production of IL-1β and IL-18. RIG-I and 
AIM2 also form distinct inflammasomes downstream of viral infection. 
 
1.4.3 DNA receptors 
Since the discovery of TLR-9, it has become apparent that microbial and self 
DNA can be recognised via TLR-9-indepedent mechanisms. For example, 
infection of TLR-9-deficient cells by DNA virus, HSV-1, or intracellular bacteria 
such as Listeria monocytogenes still resulted in DNA-dependent type I IFN 
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production (Hochrein et al., 2004; Stetson and Medzhitov, 2006). In addition, 
transfection of cells with synthetic double-stranded DNA (dsDNA) activated 
TLR-9-independent type I IFN responses (Ishii et al., 2006). Finally, DNase II-
deficient macrophages, which are unable to clear DNA from phagocytosed 
apoptotic cells, lead to a build-up of cytosolic DNA which was capable of 
inducing TLR-9-independent type I IFN gene expression (Okabe et al., 2005; 
Yasuda et al., 2005). Collectively, these studies suggested the presence of an 
additional IFN-inducing cytosolic DNA receptor or receptors.  
Indeed soon after these studies, Takaoaka and colleagues carried out a 
cDNA microarray analysis screening for IFN-inducible genes containing DNA 
binding domains, from which DNA-dependent activator of IFN-regulatory factors 
(DAI) was identified (Figure 1.6). This receptor was shown to induce IFN-α, 
IFN-β, IL-6 and CXCL-10 in response to poly (dA:dT) DNA stimulation (Ishii et 
al., 2006; Takaoka et al., 2007). The D3, Zα and Zβ DNA binding regions, 
located within the N-terminal of DAI, have been reported as crucial in mediating 
the immune response (Wang et al., 2008). Following DAI activation and 
oligomerisation, IRF-3-dependent type I IFN induction is mediated via 
recruitment of TBK-1 and IKK-ε to the C-terminal region of the receptor (Ishii et 
al., 2008). Interestingly, there is some evidence to suggest a role for IPS-1  
(Kumar et al., 2006) and stimulator of IFN genes/mediator of IRF-3 activation 
(STING/MITA) (Ishikawa and Barber, 2008; Zhong et al., 2008) adaptor 
proteins in the DAI pathway of type I IFN induction. DAI is also capable of 
activating NF-κB and, although the signalling pathways leading to this are not 
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well understood, there is some evidence that RIP1 and RIP3 may be involved 
(Kaiser et al., 2008; Takaoka et al., 2007). 
Another cytosolic DNA receptor is the absent in melanoma 2 (AIM2) 
(Burckstummer et al., 2009; Fernandes-Alnemri et al., 2009; Hornung et al., 
2009). Once dsDNA from viruses such as vaccinia virus and adenovirus is 
sensed by AIM2, the inflammasome is activated resulting in production and 
secretion of IL-1β. The HIN200 and pyrin domain are synergistically important 
for AIM2 function as they interact with ASC to mediate cytokine production, as 
described previously. Another member of the HIN 200 family is p202, which 
binds cytoplasmic dsDNA but represses caspase activation (Rathinam et al., 
2010; Roberts et al., 2009). 
Interestingly, RNA polymerase III (RNA pol III), an enzyme involved in 
the transcription of non-coding RNA, can also act as a DNA sensor and 
modulate innate immune signalling (Ablasser et al., 2009; Cao, 2009a; Chiu et 
al., 2009; Choi et al., 2009; Wilkins and Gale, 2010). Ablasser and colleagues 
found that RNA pol III was transcribing AT-rich dsDNA into the 5’ppp-dsRNA 
format, for recognition by RIG-I and subsequent IFN induction.  
Other DNA receptors which positively regulate type I IFN signalling 
include IFI16 and DDX41, both of which directly interact with DNA and induce 
IRF-3 and NF-κB activation through recruitment of STING (Unterholzner et al., 
2010; Zhang et al., 2011b), Ku70, which activates IRF-1 and IRF-7 leading to 
IFN-λ1 induction (Zhang et al., 2011a) and leucine-rich repeat flightless-
interacting protein 1 (LRRFIP1), which binds both exogenous dsRNA and dsDNA 
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leading to increased IFN-β (Yang et al., 2010), as schematically summarised in 
Figure 1.6. 
Negative regulators of DNA-mediated immune signalling have also been 
reported in the literature. 3’ repair exonuclease (Trex1), was recently identified 
as a DNA receptor due to its IFN-stimulatory DNA (ISD)-inducible and ISD-
binding properties. This enzyme is capable of binding to single-stranded DNA 
(ssDNA) and preventing type I IFN induction, with Trex1-deficient mice 
developing lethal autoimmunity characterised by high type I IFN and 
autoantibody production (Stetson et al., 2008). The importance of this enzyme 
in IFN regulation is underlined by the finding that mutations in the TREX1 
human gene result in the autoimmune diseases, Aicardi–Goutieres syndrome 
and chilblain lupus, conditions characterised by abnormally elevated type I IFN 
production (Crow et al., 2006). Additionally, adenosine deaminase acting on 
RNA1 (ADAR1) is thought to inhibit signalling by competing with DNA receptors 
for their ligands. ADAR1-deficient fibroblasts show dramatically enhanced IFN-
β following both DNA stimulation and HSV-1 infection (Wang et al., 2008). The 
cytosolic DNA receptors are illustrated in Figure 1.6. 
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Figure 1.6: Cytosolic dsDNA receptors; Cytosolic DNA receptors bind dsDNA which 
results in downstream activation of NF-κB and/or IRF-1/-3/-7 and induction of type I 
IFNs and pro-inflammatory cytokines through mediators such as STING, β-catenin, 
IKK-ε and TBK-1. 
 
1.4.4 RIG-I-like Receptors (RLR)  
RIG-I like receptors (RLRs) are a family of PRRs that have evolved to 
specifically detect and mediate clearance of viral pathogens. The RLRs are RNA 
helicase cytosolic receptors and consist of Retinoic acid-inducible gene I (RIG-
I), Melanoma differentiation associated gene 5 (MDA-5) and inhibitory family 
member, Laboratory of Genetics and Physiology (LGP-2) (Cui et al., 2001; Kang 
et al., 2002; Yu et al., 1997). RNA helicases have an essential function in 
unwinding double-stranded RNA molecules through ATP hydrolysis (Tanner and 
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Linder, 2001). 
1.4.4.1. Structure 
All three receptors harbour a well-conserved central DExD/H-box helicase 
domain, known to be important for RNA binding. At the N-terminus, both RIG-I 
and MDA-5 receptors contain two caspase activation and recruitment domains 
(CARDs) in tandem, which are essential for downstream protein interactions 
and pathway activation. LGP-2 lacks any CARD domains. The regulatory C-
terminal of the proteins comprise an auto-inhibitory repressor domain, 
responsible for keeping the receptor inactive by interaction with both CARD and 
helicase domains (Cui et al., 2008; Saito et al., 2007; Yoneyama et al., 2004) 
The structure of all RLRs is schematically represented in Figure 1.7. 
 
 
Figure 1.7: Structure of RIG-Like Receptors RLR proteins consist of two N-
terminal CARD domains in tandem (with the exception of LGP-2), a central helicase 
domain, necessary for ligand binding and a C-terminal repressor domain important for 
rendering the receptor inactive through interactions with the CARD and helicase 
domains. 
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1.4.4.2 LGP-2  
The LGP-2 receptor is reported to be a regulatory inhibitor which 
possesses no CARD domains (Yoneyama et al., 2005). Rothenfusser and 
colleagues demonstrated that LGP-2 negatively regulates RIG-I recognition of 
dsRNA by binding to viral dsRNA and shielding it from RIG-I or MDA-5 detection 
(Pippig et al., 2009; Rothenfusser et al., 2005). Another study proposes that 
LGP-2 inhibits multimerisation of RIG-I and its interaction with IPS-1 (Saito et 
al., 2007). One further model proposed by Komuro and colleagues suggests 
that LGP-2 competes with IKK-ε for IPS-1 recruitment and thereby suppresses 
RLR signalling (Komuro and Horvath, 2006). In vivo functional studies, 
however, have proven somewhat contradictory. While Venkataraman and 
colleagues showed that Lgp2-/- mice display enhanced induction of type 1 IFNs 
in response to poly(I:C) and VSV infection, the response to EMCV was shown to 
be suppressed (Venkataraman et al., 2007). In addition, Satoh et al observed 
that dendritic cells and fibroblasts obtained from Lgp2-/- mice show impaired 
IFN-β production following picornavirus infection (Satoh et al., 2010). 
Altogether these studies suggest a more complex role for LGP-2 in the antiviral 
signalling pathway than merely an inhibitory receptor and it is possible that the 
dual role LGP-2 has been found to play in both positive and negative regulation 
of the pathway may be attributed to the particular RNA virus and/or RNA ligand 
recognised. 
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1.4.4.3 Ligand and strain specificity  
 RLRs recognise distinct patterns specific to viral RNA.  The exact kind of 
RNA recognised by RIG-I is controversial. Up to now, at least six different 
ligands have been proposed; (i) 5’ppp-ssRNA, (ii) 5’ppp-dsRNA, (iii) 5’ppp-
ssRNA with A/U rich 3’ ends, (iv) 300-2000bp dsRNA without 5’ triphosphate, 
(v) blunt-end dsRNA 23-30bp long with no triphosphate and finally (vi) blunt-
end dsRNA 23-30bp long with a 5’ monophosphate (Chiu et al., 2009; Cui et al., 
2008; Hornung et al., 2006; Kato et al., 2008; Kim et al., 2004; Pichlmair et al., 
2006). In addition, replicating RNA, rather than full-length genomic, 
preferentially leads to activation of RIG-I (Ablasser et al., 2009; Baum et al., 
2010). While the RIG-I ligand has caused much debate in the literature, the 
current view on MDA-5 activation is that long dsRNAs over 2kb, such as 
poly(I:C), are required to assemble in a web format (Kato et al., 2008; 
Pichlmair et al., 2009). Through analysis of Rig-I-/- and Mda5-/- mice, RIG-I has 
been shown to be essential for IFN production in response to paramyxoviruses, 
such as Vesicular Stomatitis Virus (VSV), Sendai Virus (SeV) and Influenza virus 
(IAV), as well as flaviviruses, such as Japanese encephalitis virus (JEV) and 
Hepatitis C virus (HCV) (Hornung et al., 2006; Kato et al., 2005; Kato et al., 
2006; Melchjorsen et al., 2005; Spiropoulou et al., 2009; Sumpter et al., 2005), 
while MDA-5 is critical for detection of picornaviridae, such as 
encephalomyocarditis virus (EMCV), Mengovirus and Theiler’s virus (Gitlin et al., 
2006; Kato et al., 2006). Some viruses, such as West Nile virus, Dengue virus 
and some strains of measles are detected by both RIG-I and MDA-5 
(Fredericksen et al., 2008; Loo et al., 2008; Shingai et al., 2007). It is most 
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likely that co-operation between RIG-I and MDA-5 has evolved in order to 
provide the infected host with optimum protection against invading viruses. 
1.4.4.4 Signal transduction 
Although RIG-I and MDA-5 recognise distinct viral ligands from different 
viral families, they share a common signal transduction pathway following 
activation which leads to IRF-3, IRF-7 and NF-κB activation culminating in type 
I IFN and pro-inflammatory cytokine production, summarised schematically in 
Figure 1.8. In healthy cells, RIG-I and MDA-5 exist in “closed” conformation, 
whereby the CARD domains are masked.  Following the observation that RIG-I 
mutants lacking the CARD domains were incapable of initiating the anti-viral 
response (Yoneyama et al., 2004), suggesting that CARDs were a crucial 
effector domain for downstream signalling, IFN-β promoter stimulator 1 (IPS-1, 
also known as MAVS, VISA and Cardif) was identified in 2005 by four groups 
independently (Kawai et al., 2005; Meylan et al., 2005; Seth et al., 2005; Xu et 
al., 2005). Highlighting the importance of IPS-1 downstream of RLRs, mice 
lacking IPS-1 were shown to have an impaired IFN response downstream of 
RIG-I and MDA-5 (Kumar et al., 2006; Sun et al., 2006). IPS-1 contains a single 
CARD domain in its N-terminal, as well as a proline-rich central domain and a 
hydrophobic C-terminal region, which localises the protein to the mitochondria 
(Seth et al., 2005). More recently, IPS-1 was also reported to localise to the 
peroxisome, where it mediates rapid IRF-1 and IRF-3-dependent expression of 
ISGs (such as viperin, IFIT1, and IFIT2) independent of type I IFN (Dixit et al., 
2010). 
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Upon RIG/MDA-5 recognition of their ligand, an ATP-dependant 
conformational change is triggered, which releases the second CARD for 
downstream interaction with the CARD of IPS-1. Following RIG-I/MDA-5-IPS-1 
interaction, subsequent association with individual members of the TRAF family 
is required to propagate the downstream signalling cascade. Within its proline-
rich region, IPS-1 contains a TRAF-interacting motif (TIM), enabling interaction 
with TRAF-3, which is vital for activation of IFN-β, as well as TRAF-6 and TRAF-
2, necessary for NF-κB activation (Hacker et al., 2006; Oganesyan et al., 2006; 
Saha et al., 2006; Xu et al., 2005). TRAF-3, in a complex together with NAP-1 
(Sasai et al., 2005), SINTBAD (Ryzhakov and Randow, 2007) and/or TANK 
(Chariot et al., 2002; Gatot et al., 2007; Guo and Cheng, 2007; Hemmi et al., 
2004; Li et al., 2002a; Perry et al., 2004), plays a role in assembly and 
activation of downstream IKK-related kinases, TBK-1 and IKK-ε, which, in turn, 
phosphorylate IRF-3 and IRF-7 (Fitzgerald et al., 2003; Sharma et al., 2003). 
Upon phosphorylation, IRF-3 and IRF-7 form homo-/hetero-dimers and 
translocate to the nucleus, culminating in production of IFN-α and IFN-β and 
ISGs (Honda et al., 2005a; Honda et al., 2005b; Taniguchi, 2005). Conversely, 
the interaction of IPS-1 with TRAF-6 transmits a signal to the IKK complex, 
comprising scaffold protein NEMO, IKK-α and IKK-β, resulting in 
phosphorylation of IκB and downstream activation and translocation to the 
nucleus of NF-κB (Karin and Ben-Neriah, 2000). Fas-associated death domain 
(FADD) and receptor interacting protein 1 (RIP1) also associate with the IPS-
1/RIG-I signalling complex, activating the NF-κB side of the pathway 
(Balachandran et al., 2004; Takahashi et al., 2006), while TNFR-associated DD 
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(TRADD) complexes with IPS-1, TRAF3 and TANK to activate both NF-κB and 
IRF-3 (Michallet et al., 2008). 
 
 
Figure 1.8: RIG-I like receptor (RLR) Signalling Pathway; RIG-I and MDA-5 
mediate their anti-viral response by interaction with IPS-1 at the mitochondria, leading 
to two distinct pathways involving the recruitment of TRAF-3, culminating in type I 
IFN, and TRAF-6, resulting in pro-inflammatory cytokine production. 
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1.4.4.5 A role for RLRs in SLE? 
While extensive genetic and functional evidence exists for an involvement of 
the anti-viral TLRs, the literature surrounding the role of RIG-I in SLE 
pathogenesis is relatively scarce. Liu and colleagues identified 4 SNPs in the 
IPS-1 gene from 123 SLE patients; rs17857295, rs2326369, rs7262903, and 
rs7269320. This study found that rs17857295 and rs2326369 were associated 
with renal nephritis and arthritis in SLE patients, respectively, suggesting that 
polymorphisms in the IPS-1 gene are related to disease susceptibility and 
progression of SLE (Liu et al., 2011a). A further study by Pothlichet and 
colleagues show that a loss of function SNP identified in the IPS-1 gene (C79F) 
results in decreased IFN signalling and has an association with an SLE sub-
phenotype found exclusively in African-American population. This phenotype is 
associated with low type I IFN production and absence of anti-RNA-binding 
protein autoantibodies, thus suggesting this mutation is protective against lupus 
(Pothlichet et al., 2011). These studies represent a link for the first time 
between irregularities in the RLR system and SLE pathogenesis. 
 
1.5 Regulation of IFN signalling 
In order to prevent uncontrolled or inappropriate activation of the innate 
immune system leading to loss of homeostasis and development of 
autoimmunity, it is of utmost importance that the PRR signalling pathways 
leading to inflammatory mediators and IFN production are tightly regulated. As 
such, various regulatory processes such as ubiquitination, phosphorylation, 
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miRNA regulation, and protein-protein interactions exist within these signalling 
pathways. These modifications, summarised schematically in Figure 1.9, will be 
explored in greater detail in later chapters.  
 
 
Figure 1.9: Regulation of RLR signalling; A host of proteins are responsible for 
fine-tuning RLR signalling by processes such as ubiquitination (red), phosphorylation 
(blue), direct binding (green), ISG-ylation and micro RNA regulation (black). 
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1.5.1 Autoantigens in IFN regulation 
 In addition to the modifications listed above, the SLE autoantigens 
themselves have been demonstrated to play a role in the negative regulation of 
IFN production and, as such, have been proposed as valid therapeutic targets 
for treatment of disease (Yoshimi et al., 2012). As previously mentioned, the E3 
ligase and autoantigen Ro52/TRIM21, has recently been shown to play a role in 
direct regulation of type I IFN levels by targeting IRF-3, IRF-5, IRF-7 and IRF-8 
for ubiquitination (Espinosa et al., 2009; Espinosa et al., 2011; Higgs et al., 
2008; Kong et al., 2007; Yang et al., 2009; Yoshimi et al., 2009). Highlighting 
their importance in modulating IFN levels in the cell, TRIM21-/- mice present 
with an SLE-like phenotype, demonstrating severe dermatitis at the site of 
tissue injury, hypergammaglobulinemia, autoantibodies to DNA, proteinuria, 
kidney pathology and an increase in pro-inflammatory cytokines such as IL-6, 
IL-17 and IL-23p19 (Espinosa et al., 2009). Furthermore, Kvarnstrom and 
colleagues demonstrated that antibody-mediated blockage of the TRIM21 RING 
domain, which is the functionally active domain with E3 ligase activity, was 
significantly correlated with disease activity (Kvarnstrom et al., 2013). In 
addition, a link between Ro60, another of the autoantigens in SLE, and IFN has 
been reported. Ro60 knockout mice have been reported to spontaneously 
develop an IFN-regulated autoimmune condition characterised by 
autoantibodies, glomerulonephritis and increased sensitivity to UV irradiation, 
suggesting that Ro60, like Ro52, regulates IFN production (Xue et al., 2003). 
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1.6 La autoantigen  
 The human La protein (also known as Sjogren’s Syndrome Antigen B or 
SS-B) was first identified as an autoantigen in patients suffering from SLE and 
SS (Alspaugh and Tan, 1975; Mattioli and Reichlin, 1974).  La is a 48kDa highly 
abundant protein encoded on the q arm of chromosome 2. It is confined to the 
nucleus or nucleolus in virtually all cell types (Habets et al., 1983; Hendrick et 
al., 1981; Marchetti et al., 2000; Rosenblum et al., 1997; Yoo and Wolin, 1994). 
In fractionation experiments, however, the protein was also observed in the 
cytoplasm (Lerner et al., 1981; Stefano, 1984). In addition, La has been shown 
to re-distribute to the cytoplasm following viral infection (Costa-Mattioli et al., 
2004; Domitrovich et al., 2005; Meerovitch et al., 1993). This re-distribution is 
presumably due to cleavage of the protein which results in loss of the nuclear 
localisation sequence (NLS). Indeed, following stimulation of HeLa cells with 
poliovirus, cleavage between Glycine 358 and 359 was demonstrated to give 
rise to a cytosolic in vitro cleavage product lacking the NLS-containing 50AA C-
terminal region (Shiroki et al., 1999). 
In structure, the 408 amino acid protein has an N-terminal domain 
composed of the highly conserved La motif and the first RNA recognition motif 
(RRM). Both of these domains are synergistically required for high affinity RNA 
binding (Chang et al., 1994; Goodier et al., 1997). The highly charged, weakly 
conserved C-terminal domain consists of a second RRM, the precise function of 
which is still unclear. While seemingly dispensable for specific RNA binding, it 
has shown to have a positive modulatory effect on RNA binding activity 
(Ohndorf et al., 2001), contributes to interactions with viral RNA (Ali et al., 
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2000; Chang et al., 1994) and has been postulated to play a role in protein-
protein interactions (Ohndorf et al., 2001). Also located within the C-terminal 
domain is the short basic motif (SBM), containing the Walker A motif, believed 
to be important in 5’ triphosphate recognition, the NLS and the nuclear 
retention element (NRE) (Simons et al., 1996). Figure 1.10 illustrates La 
structure. 
 
Figure 1.10: Structure of La protein; The 48kDa protein’s N-terminal domain is 
composed of the highly evolutionary conserved La motif and the less well conserved 
central RNA recognition motif (RRM). The highly charged, weakly conserved C-terminal 
domain consists of a second RRM, the short basic motif (SBM) (containing the Walker 
A motif), the nuclear localisation sequence (NLS) and the nuclear retention element 
(NRE). 
 
There are two distinct forms of La; phosphorylated La (pLa), found 
exclusively in the nucleus, and the non-phosphorylated form of the protein 
(npLa), found in both the cytoplasm and nucleolus (Coudevylle et al., 2006). 
The ability of La to interact with RNA transcripts in the cytoplasm is achieved by 
npLa as phosphorylation at serine 366 has been shown to abrogate both 5’ and 
3’ binding activity (Fairley et al., 2005; Fan et al., 1997). La is phosphorylated 
by two known kinases; casein kinase 2 (CK2) phosphorylates La at C-terminal 
site serine 366 and, in doing so, limits binding of La to 5’ TOP mRNA, 
suggesting that phosphorylation of La can affect production of the translational 
machinery (Schwartz et al., 2004). More recently, Akt phosphorylation at 
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Threonine 301 has been shown by Brenet and colleagues to regulate nuclear 
trafficking of La by exporting the protein from the nucleus to the cytoplasm 
following platelet derived growth factor stimulation of Akt (Brenet et al., 2009). 
 Bachmann and colleagues identified 5 La cDNA forms in the peripheral 
blood lymphocytes of SS patients (Bachmann et al., 1996). In 2 out of 5 
patients, exon 1 was replaced with alternative exon 1’, a result of alternative 
splicing. In addition, one of the exon 1’ La cDNA constructs contained a 
frameshift mutation in exon 7 of the La gene, whereby the 12 amino acids from 
AA 192-204 are replaced with novel amino acids and a premature stop codon 
within the reading frame of the protein. This stop codon results in a truncation 
mutant form of La which lacks the C terminal domain and therefore the NLS 
resulting in a 29kDa mutant which remains cytoplasmic (Bachmann et al., 
1997). Bachmann and colleagues postulated that mutant forms of the protein 
may have a direct effect on survival of autoreactive cells, thereby contributing 
to autoimmunity, and subsequently detected anti-neo-La (i.e. 29kDa mutant 
form of La) antibodies not only in the serum of the patient with the mutation 
but also in approximately 30% of all anti-La+ autoimmune patients studied, 
suggesting that this mutant isoform of La was successfully translated and that 
expression of this mutant favours development of systemic autoimmunity. It 
remains to be seen whether neo-La function is hyperactive, underactive or 
unchanged in comparison to the full-length protein. 
 La has been implicated in many RNA-associated processes, the best 
established of which is binding to and stabilisation of nascent RNA pol III 
transcripts (Bogenhagen and Brown, 1981; Fairley et al., 2005; Fan et al., 
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1998; Fan et al., 1997; Franceschini and Cavazzana, 2005; Hendrick et al., 
1981; Intine et al., 2000; Maraia and Intine, 2001; Maraia et al., 1994; Stefano, 
1984; Yoo and Wolin, 1994, 1997). La binds RNA via the UUU-OH poly-
pyrimidine tract, the RNA pol III termination signal at the 3’ end of transcripts. 
As these uridylates, and hence the La binding site, are removed during 
maturation, La does not bind mature RNA (Reddy et al., 1983; Stefano, 1984). 
Both the La motif and the central RRM are believed to be synergistically crucial 
for UUU-OH binding (Chang et al., 1994; Chang et al., 1995; Goodier et al., 
1997). In yeast, Lhp1p (yeast La homolog) stabilises pre tRNAs in 
conformations which allow 3’ end maturation to occur by endonucleolytic 
cleavage (Yoo and Wolin, 1997) and facilitates Sm binding by stabilising U4 
RNA (Wolin and Cedervall, 2002). Furthermore, U3-3’I and ‘II (major extended 
forms of U3 RNA) are stabilised against continued degradation by Lhp1p (Kufel 
et al., 2000). As previously mentioned, La also binds to the hY RNAs present in 
the RNP complex (Figure 1.2). 
 Moreover, La is important in termination and re-initiation of transcription 
by RNA pol III (Chu et al., 1997; Fan et al., 1997; Goodier et al., 1997; Goodier 
and Maraia, 1998; Gottlieb and Steitz, 1989a, b; Maraia, 1996; Maraia et al., 
1994). Gottlieb and colleagues showed that La depletion in the HeLa cell line, 
achieved by use of human and mouse monoclonal antibodies, resulted in loss of 
>99% of transcriptional activity of class III genes, with fewer uridylate residues 
on the 3’ end of transcripts produced. Reconstitution of these La-depleted cells 
with biochemically purified La completely restores transcript length (Gottlieb 
and Steitz, 1989a, b). The Maraia group performed studies whereby 
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transcription complexes were depleted of RNA pol III after a single round of 
RNA synthesis and isolated complexes were then complemented with highly 
purified RNA pol III and/or recombinant La. They found that VA1, 7SL, and Bl 
transcription complexes could not be transcribed by RNA pol III addition in 
single or multiple-round transcription assays, unless La was also provided, and 
subsequently demonstrated that La mediates concentration-dependent 
activation of RNA pol III initiation (Maraia, 1996; Maraia et al., 1994). In 
addition, recycling efficiency of the B1-Alu genes is correlated with the ability of 
La to access the 3’ end of the nascent transcript and protect it from 3’-5’ 
exonucleolytic processing thus re-inforcing a role for La in re-initiation of 
transcription by pol III (Goodier and Maraia, 1998). La also has a conserved 
function as a molecular chaperone for RNA (Boelens et al., 1995; Lin-Marq and 
Clarkson, 1998; Pannone et al., 1998). 
 Typically during the maturation step of miRNA biogenesis, the RNA 
molecules are bound by RNA-binding proteins/chaperones to protect from 
degradation. Given the known role for La in binding to nascent transcripts of 
RNA pol III and protecting the RNA from non-specific exonuclease digestion, 
Liang et al., recently carried out a study to investigate whether La was one 
such chaperone in miRNA generation (Liang et al., 2013). They observed that 
addition of La could indeed stabilise pre-miRNA and enhance miRNA production 
in both Drosophila S2 and HeLa cells. In addition, La was observed to bind pre-
miRNA and compete for binding with Dicer complex, with the La motif, RRM1 
and RRM2 crucial for interaction. Upon siRNA knockdown of La in HeLa cells, 
miRNA levels of 58% of the 377 mature miRNAs measured were significantly 
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decreased in expression, when assessed by q-PCR profiling and northern 
blotting including let-7A, -16, -17, -20, -21 and -30. Furthermore, La has been 
reported to enhance RISC activity by binding to Ago2, increasing efficiency and 
facilitating release of cleaved mRNA (Liu et al., 2011b). Liu and colleagues 
showed that knockdown of La compromised RNA silencing in vivo. In summary, 
these studies demonstrate a novel function for La in RNA interference by both 
binding and stabilising pre-miRNAs and increasing RISC activity. 
 Soon after La was shown to interact with a large variety of nascent 
RNAs, as detailed above, it emerged that La also binds to a number of viral 
encoded RNAs such as adenovirus-encoded VA RNA I and VA RNA II, EBV-
encoded EBER 1 & 2 RNA and leader RNA of negative strand viruses (Kurilla et 
al., 1984; Kurilla and Keene, 1983; Lerner et al., 1981; Wilusz and Keene, 
1984; Wilusz et al., 1983). Up until recently however, the reason for this 
binding was not fully understood. La has been described as being manipulated 
by viruses in an attempt to block the anti-viral response and is thereby 
proposed to be essential for enhancing viral replication and/or release. This is 
reportedly achieved by binding and sequestration of the dsRNA ligand for RIG-I, 
thus preventing activation of the pathway (Bitko et al., 2008; Chang et al., 
1994; Costa-Mattioli et al., 2004; Domitrovich et al., 2005; Nitta et al., 2011). 
In striking contrast, a role for La in promoting the anti-viral response to a self-
replicating flock house virus (FHV) has also been demonstrated, with La 
depletion resulting in increased FHV expression (Liu et al., 2011b). Regardless 
of the contradictions in the literature, the precise mechanism behind which La 
affects viral replication (either positively or negatively) remains elusive. The link 
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between La and viruses is especially interesting for us given the aforementioned 
reports that viral infection is a significant risk factor in SLE. 
1.7 Hypothesis & Aims 
This project seeks to evaluate the hypothesis that La directly regulates IFN 
production downstream of anti-viral innate immune receptors.  
The project will focus on: 
• the ability of La to regulate IFN production downstream of TLR and RLR 
activation 
• the mechanism by which La exerts its regulatory effects 
• the role which modification of this protein, particularly phosphorylation, 
plays in this process 
• the relevance of La function in human health and disease 
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Chapter 2: 
Materials and Methods 
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2.1 Materials 
 
2.1.1 General Chemicals and Conditions 
 
This section includes a list of products and instruments used in this study, 
including the supplier they came from. The full names and addresses of 
suppliers are listed at the end of this section (2.1.6). All solutions were 
prepared using pure deionised water. Room temperature (RT) was 20 +/- 5°C. 
All pH values given are those obtained at RT. 
Product/Equipment      Supplier 
ABI 7500 RT-PCR System      Life Technologies 
Acetone         Sigma Aldrich 
Ammonium persulfate (APS)      Sigma Aldrich 
Ampicillin        Sigma Aldrich 
Atto Polyacrylamide Gel Electrophoresis Cell   Atto Corporation 
BL21 (DE3) pLysS E.Coli Competent Cells   Merck Chemicals 
BCA Protein Assay Kit      Merck Biosciences 
Bovine Serum Albumin (BSA)     Sigma Aldrich 
Bromophenol Blue       Sigma Aldrich 
Chloroform        Sigma Aldrich 
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Coelenterazine       Cambridge  
         BioSciences 
D-Luciferin Firefly       Biosynth 
DNA ladder (1kb)        Promega 
dNTP mix        New England 
         Biolabs 
Dithiothreitol        Sigma Aldrich 
DMEM High Glucose       Biosera 
Ethanol        Sigma Aldrich 
Ethylenediaminetetraacetic acid (EDTA)    Sigma Aldrich 
Ficoll Paque PLUS       GE Healthcare 
Foetal Calf Serum (FCS)      Biosera 
Gelcode Blue Stain Reagent     Medical Supplies 
         Company 
Gentamicin        Sigma Aldrich 
Glacial Acetic Acid       Sigma Aldrich 
Glucose        Sigma Aldrich 
Glycerol        Sigma Aldrich 
Glycine        Sigma Aldrich 
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Go Taq Polymerase       Promega 
HIS-Select® Nickel Affinity Gel     Sigma Aldrich 
Human Rantes Ready Set Go ELISA kit             eBioscience 
Human IL-29 Ready Set Go ELISA kit    eBioscience 
Hydrochloric Acid (HCl)      Sigma Aldrich 
Immobilon Western HRP Substrate     Millipore 
Isopropyl-beta-D-thiogalactopyranoside (IPTG)   Medical Supplies 
         Company 
Kanamycin        Sigma Aldrich 
LB Agar        Sigma Aldrich 
LB Broth        Sigma Aldrich 
Leupeptin        Sigma Aldrich 
LSM 710 Meta Laser Scanning Microscope   Carl Zeiss 
Metafectene         Biontex 
Methanol        Sigma Aldrich 
Mini-Trans Blot Electrophoretic Transfer Cell   Bio-Rad 
Mitotracker® Red CMX-Ros      Life Technologies 
ML-60218         Merck Chemicals 
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Nanodrop1000        Mason Technology 
NP-40 (Igepal)       Sigma Aldrich 
Nunc Maxisorp 96-well plates     eBiosciences 
PageRuler ™ Prestained Protein Ladder    Thermo Fisher 
         Scientific 
Paraformaldehyde       Sigma Aldrich 
Passive lysis buffer       Promega 
PCR Horizon 58 Gel Rig       Life Technologies 
Penicillin/Streptomycin Solution 100x    Biosera 
Pepstatin        Sigma Aldrich 
Phenylmethylsulfonyl fluoride (PMSF)    Sigma Aldrich 
Phosphate Buffered Saline (PBS)     Biosera 
Polyvinylidene fluoride membrane (PVDF)   Millipore 
Potassium Chloride (KCl)      Sigma Aldrich 
Potassium Fluoride (KF)      Sigma Aldrich 
Potassium Phosphate (KH2PO4)     Sigma Aldrich 
Probe sonicator        Branson 
ProLong® Gold with DAPI  Invitrogen 
50 
 
Protein A Sepharose      Sigma Aldrich 
Protein G Sepharose 4 Fast flow beads    GE Healthcare 
Primers        Sigma Aldrich 
Protogel        BioSciences 
PureYield® Plasmid Maxiprep System    Promega  
Red Cell Lysis Buffer      Sigma Aldrich 
GoScript ™ Reverse Transcription Kit  Promega 
Sodium Azide (NaN3)  Sigma Aldrich 
Sodium Chloride (NaCl)  Sigma Aldrich 
Sodium Deoxycholate (C24H39NaO4)  Sigma Aldrich 
Sodium Dodecyl Sulphate (CH3(CH2)11OSO3Na)  Sigma Aldrich 
Sodium Hydroxide (NaOH)  Sigma Aldrich 
Sodium Orthovanadate (Na3VO4)  Sigma Aldrich 
Sodium Phosphate (NaH2PO42H2O)  Sigma Aldrich 
Subcloning Efficiency™ DH5α™ Chemically  
Competent Cells       Invitrogen 
Super RX X-Ray Film      Fujifilm 
Sybr Green Kit       Sigma Aldrich 
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Sybr Safe Gel Stain       Invitrogen 
4,5,6,7-Tetrabromo-2-azabenzimidazole (TBB)   Sigma Aldrich 
Tetramethylethylenediamine (TEMED)    Sigma Aldrich 
Tris base        Sigma Aldrich 
Triton-X        Sigma Aldrich 
Trizol™        Sigma Aldrich 
Trypan Blue        Biosera 
Trypsin-EDTA       Biosera 
Tween 20        Sigma Aldrich 
Victor Wallac Multiplate Reader     PerkinElmer 
70 micron nylon filters      BD Biosciences 
 
 
 
 
 
 
 
 
 
2.1.2 Antibody conditions 
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Table 2.1: Antibody suppliers, dilutions and epitopes 
 
The SW5 monoclonal La antibody was generated by Professor Michael 
Bachmann at the Technical University of Dresden and was a kind gift from Dr. 
Shannon Maier-Moore, Oklahoma Sjögren’s Syndrome Research Centre, 
Oklahoma Medical Research Foundation, Oklahoma City, OK 73104-5097 (Pruijn 
et al., 1995). 
 
 
Antibody name Supplier Dilution Secondary Epitope 
α-actinin (H-300) Santa Cruz 1:1000 Anti-Rabbit AA 593-892 
β-actin  Abcam 1:1000– 
1:5000 
Anti-Rabbit AA 1-100 
FLAG (M2) Santa Cruz 1:1000 Anti-Mouse N-DYKDDDDK-C 
IPS-1 (Adri-1) Enzo 1:1000 Anti-Mouse AA 160-450 
IRF-3 (FL-425) Santa Cruz 1:1000 Anti-Rabbit AA 1-425 
La (H-300) Santa Cruz 1:1000 Anti-Rabbit AA1-300 
pLa Abcam 1:500 Anti-Rabbit Phosphorylated 
Serine 366 
MyD88 (HFL-296) Santa Cruz 1:1000 Anti-Rabbit AA 1-296 
RIG-I (Alme-1) Enzo 1:1000- 
1:5000 
Anti-Mouse AA 201-713 
SW5 (La) Dr S. Maier-
Moore 
1:40000 Anti-Mouse AA 112-183 
TBK-1 Alexis 1:500 Anti-Mouse AA 563-577 
pTBK-1 BD Pharm 1:250-1:500 Anti-Mouse Phosphorylated 
Serine 172 
TRAF-3 (sc-949) Santa Cruz 1:1000 Anti-Rabbit C- terminus 
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2.1.3 Plasmid constructs  
 
Table 2.2: Plasmid names, vector, antibiotic resistance, tag and source 
Plasmid Name Vector Antibiotic 
Resistance 
Tag Source 
hLa pCMV Ampicillin Flag Dr. Richard Maraia, NIH, 
Bethesda, Maryland, 
USA 
GFP-La pEGFP Kanamycin GFP Dr. Karl Albert Brokstad, 
University of Bergen, 
Germany 
Empty Vector (EV) pcDNA3.1 Ampicillin Flag Invitrogen 
TRIF pcDNA3.1 Ampicillin Flag Dr. Kate Fitzgerald, 
UMASS Med School, 
Worcester, MA 
TBK-1 pcDNA3.1 Ampicillin Flag Dr. K Fitzgerald 
TRAF-3 pcDNA3.1 Ampicillin Flag Dr. K Fitzgerald 
RIG-I pEF-BOS Ampicillin Flag Dr. K Fitzgerald 
RIG-I CARDs pEF-BOS Ampicillin Flag Dr. K Fitzgerald 
RIG-I helicase pEF-BOS Ampicillin Flag Dr. K Fitzgerald 
MDA-5 pcDNA3.1 Ampicillin Flag Dr. K Fitzgerald 
Lgp-2 pcDNA3.1 Ampicillin Flag Dr. K Fitzgerald 
IPS-1 pcDNA3.1 Ampicillin Flag Dr. K Fitzgerald 
Renilla pGL4 Ampicillin N/A Dr. K Fitzgerald 
P125 luciferase pcDNA3.1 Ampicillin Flag Dr. K Fitzgerald 
PRD II luciferase pcDNA3.1 Ampicillin Flag Dr. K Fitzgerald 
PRD IV luciferase pcDNA3.1 Ampicillin Flag Dr. K Fitzgerald 
PRD III-I luciferase pcDNA3.1 Ampicillin Flag Dr. K Fitzgerald 
La shRNA pLKO.1 Ampicillin N/A Sigma Aldrich 
Scrambled shRNA pLKO.1 Ampicillin N/A Sigma Aldrich 
MyD88 pcDNA3.1 Ampicillin Myc Dr. Aisling Dunne, 
Trinity College Dublin 
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Vector maps for all plasmids can be found in the appendix. 
2.1.4 Cells  
 
HEK 293T cells were purchased from Unitech Ltd. 
HeLa Cells were purchased from ATCC. 
2.1.5 Ligand information 
 
Table 2.3: PRR ligand suppliers and working concentration 
Ligand PRR 
stimulated 
Supplier Working 
concentration 
5’ppp-dsRNA RIG-I Cayla - InvivoGen 1 µg 
Polyinosinic-polycytidylic 
acid (Poly(I:C)) 
TLR-3/RIG-I Cayla – InvivoGen 1 µg 
Lipopolysaccharide (LPS) TLR-4 Cayla – InvivoGen 20 µg 
Imiquimod TLR-7 Cayla – InvivoGen 10 µg 
CpGA TLR-9 Cayla - InvivoGen 5 µM 
 
2.1.6 List of Suppliers 
 
• Abcam plc, 332 Cambridge Science Park, Milton Road, Cambridge CB4 
0FW, UK. 
• Alexis Biochemicals/Enzo Life Sciences, Palatine House, Matford Court, 
Exeter EX2 8NL. 
• ATCC LGC Standards, Queens Road, Teddington, Middlesex TW11 0LY, 
UK. 
• Atto, 1-25-23 Hongo, Bunkyo-ku, Tokyo 113-8425, Japan. 
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• BD Biosciences, 3 Charlemont Terrace, Crofton Road, Dun Laoghaire, 
Dublin. 
• Biontex Laboratories GmbH, Am Klopferspitz 19, 82152 
Martinsried/Planegg, Germany. 
• Bio-Rad Laboratories Ltd., Bio-Rad House, Maylands Avenue, Hemel 
Hampstead, Hertfordshire HP2 7TD, UK. 
• Biosera, 1 Acorn House, The Broyle, Ringmer, East Sussex, BN8 5NN, 
UK. 
• Biosynth AG, Rietlistrasse 4, P.O. Box 125, 9422 Staad, Switzerland. 
• Cambridge Biosciences, 24-25 Signet Court Newmarket Road, 
Cambridge, CB5 8LA, UK. 
• Carl Zeiss Ltd, 509 Coldhams Lane, Cambridge CB1 3JS, UK. 
• Cayla - InvivoGen Europe, 5, rue Jean Rodier, F-31400 Toulouse, France. 
• eBioscience, 2nd Floor, Titan Court, 3 Bishop Square, Hatfield, Al10 9NA, 
UK. 
• FUJIFILM UK Limited, Unit 10A, St Martins Business Centre, St Martin’s 
Way, Bedfordshire, MK42 0LF, UK. 
• GE Healthcare Life Sciences, Amersham Place, Little Chalfont, 
Buckinghamshire, HP7 9NA, UK. 
• Invitrogen Corporation, 3 Fountain Drive, Inchinnan Business Park, 
Paisley PA4 9RF, UK. 
• Life Technologies, 5791 Van Allen Way, PO Box 6482, Carlsbad, 
California, USA.  
• Mason Technology, 228 South Circular Road, Dublin 8, Ireland. 
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• Medical Supply Company (MSC), Damastown, Mulhaddart, Dublin 15. 
• Merck Biosciences, Boulevard Industrial Park, Padge Road, Beeston, 
Nottingham NG9 2JR, UK. 
• Millipore, Tullagreen, Carrigtwohill, Co. Cork, Ireland. 
• National Diagnostics (UK) Ltd - AGTC Bioproducts, Unit 4 Fleet Business 
Park, Itlings Lane, Hessle, East Riding of Yorkshire HU139LX, UK. 
• New England Biolabs, 240 County Road Ipswich, UK. 
• PerkinElmer, 940 Winter Street , Waltham, Massachusetts 02451, USA. 
• Promega Ltd., Delta House, Enterprise Road, Chilworth Research Centre, 
Southhampton, SO1 7NS, UK. 
• Qiagen, Qiagen House, Fleming Way, Crawley, West Sussex, RH10 9NQ, 
UK. 
• Santa Cruz Biotechnology, Inc., 2145 Delaware Avenue, Santa Cruz, CA 
95060, USA. 
• Sigma-Aldrich Company Ltd., Fancy Road, Poole, Dorset BH12 4QH, UK. 
• Thermo Fisher Scientific Inc., PO Box 117, Rockford, IL 61105, USA.        
• Unitech, Unitech House, Magna Drive, Magna Business Park, Citywest, 
Dublin 24, Ireland.   
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2.2 Methods 
 
2.2.1 Cell Culture 
 
2.2.1.1 Growth and maintenance of HEK-293T and HeLa cell lines  
 
HEK 293T and HeLa cell lines were cultured in Dulbecco’s Modified Essential 
Medium (DMEM) containing stable 2 mM L-glutamine, 10% (v/v) foetal calf 
serum (FCS), 100 units/ml Penicillin, 100 µg/ml Streptomycin and 100 µg/ml 
gentamicin. Cells were maintained at 37°C in a humidified atmosphere of 5% 
CO2.  
For use in transfection assays, HEK 293T and HeLa cells were typically seeded 
at 2 × 105/ml 24hr prior to transfection. For continuing cell culture, cells were 
seeded at 1 × 105/ml and sub-cultured two to three times a week. HEK 293T 
and HeLa cells were removed from the surface of the flask by incubation with 3 
ml trypsin-EDTA (0.05 mg/ml) for 5 min at 37°C. 7 ml of complete medium was 
then added and the cells were centrifuged at 1,400 rpm for 5 minutes at RT. 
Supernatant was removed and the pellet re-suspended in 5 ml of complete 
medium.  
2.2.1.2 Cell Counting and Viability 
Estimation of the number of cells present in the cell suspension was carried out 
using a haemocytometer to ensure a specific number of cells were used in each 
well for all experiments. Cell quantification and viability was determined using 
Trypan blue dye, (which is excluded from healthy cells but is taken up by non-
viable cells), a haemocytometer and a bright light microscope. Only those cells 
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which did not stain blue were counted as viable. Briefly 10 µl cell suspension 
was added to 10 µl Trypan blue, mixed thoroughly and then 10 µl of this 
solution was added to the haemocytometer. Using the microscope, the 5 
squares numbered in the diagram below were counted from 1 chamber of the 
haemocytometer. 
1        2 
     
     5   
     
   3        4 
 
The number obtained was then multiplied as follows to calculate the total 
number of cells/ml 
 = (No. of cells counted) × 5 ×2 × 10,000 
Where 5 is to work out the number of cells in all 25 squares, 2 is the dilution 
factor with Trypan blue and 10,000 is the correction factor provided with the 
haemocytometer. Cells were then seeded at the desired density. 
 
 
59 
 
2.2.2 Isolation of Peripheral Blood Mononuclear Cells  
60 ml of blood was collected using a syringe containing 6 ml of 3.8% anti-
coagulant monosodium citrate (NaH2C6H5O7) and separated by density gradient 
separation using Ficoll Paque PLUS reagent. Granulocytes and erythrocytes 
have a higher density than mononuclear cells at the osmotic pressure of Ficoll 
Paque PLUS, and thus sediment through the Ficoll Paque PLUS layer during 
centrifugation. Lighter density mononuclear cells remain at the plasma-Ficoll 
Paque PLUS interface and can therefore be selectively isolated from this layer 
(Figure 2.1). Blood was separated into four 15 ml aliquots in 50 ml falcon tubes 
and diluted 1:1 with PBS. This mixture was then carefully poured on top of four 
15 ml aliquots of Ficoll Paque PLUS reagent (GE Healthcare) to form the density 
gradient, with caution exercised to prevent mixing of the two solutions. Tubes 
were spun at 300 × g for 30 min with no brake. The white blood cell ring 
(shown in Figure 2.1), representing the total peripheral blood mononuclear cells 
PBMCs fraction, was then carefully removed using a sterile Pasteur pipette from 
each tube and combined in a new 50 ml falcon tube. The cells were washed by 
adjusting the volume to 50 ml per tube using Phosphate Buffered Saline (PBS) 
and samples were spun for 5 min at 400 × g with a brake. The supernatant was 
poured into sterile 50ml falcon tubes and red cells were lysed, where necessary, 
by re-suspending the pellet in 5ml of Red Cell Lysis Buffer (Sigma), a hypotonic 
solution, containing 8.3 g/L ammonium chloride in 0.01 M Tris-HCl buffer. 
Incubation of the cells within this solution results in the disruption of the 
osmotic balance within the red cells. Red cells take up the solution by osmosis 
which results in the rupture of their membrane and subsequent lysis and 
 removal from solution. After red cell lysis
to 50 ml using PBS and tubes were spun for an additional 5 min at 400 
Supernatants were discarded and PBMC pellets combined in 10 ml of RPMI 
medium supplemented with 10% FCS, 
Streptomycin and 100 µg/ml gentamicin.
2.2.1.2. 
                       
Figure 2.1: Schematic of density gradient separation of whole blood
Paque PLUS reagent. Adapted from 
 
2.2.3 Cell Proliferation (MTT) Assay
 
MTT (3-(4,5-Dimethylthiazol
is yellow in colour and can be reduced to purple formazan by an active enzyme 
inside the mitochondria of living cells. The absorbance of this co
can be quantified by measuring wavelengths between 500 and 600
chemical reduction, resulting in colour change, only takes place in the presence
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 Cells were counted as described in 
(Fuss et al., 2009)
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of active mitochondrial reductase enzymes, and is therefore correlated with cell 
viability.  
 Mitochondrial dehydrogenases of viable cells cleave the tetrazolium ring, 
yielding purple MTT formazan crystals which are insoluble in aqueous solutions. 
The crystals can be dissolved in acidified isopropanol. The resulting purple 
solution is spectrophotometrically measured. An increase in cell number results 
in an increase in the amount of MTT formazan formed and an increase in 
absorbance (Scudiero et al., 1988; Slater et al., 1963; van de Loosdrecht et al., 
1994). We employed this assay to test the effect of commercial CK2-specific 
ATP/GTP-competitive inhibitor TBB on cell viability. 
 Cells were seeded in a 96-well plate at 1 × 105 cells/ml, as described 
previously. The following day, cells were treated with indicated concentrations 
of TBB and incubated for 6 hours at 37°C. Following this culture period, 20 µl of 
5 mg/ml MTT (dissolved in ethanol) was added to each well. Importantly, a 
triplicate set of wells with media plus MTT, but no cells, was used as the control 
for this assay. Cells were then incubated for a further 3.5 hours at 37°C. Media 
was then carefully removed from all wells prior to addition of 150 µl MTT 
solvent (4 mM HCl, 0.1% Igepal, dissolved in isopropanol). The 96-well plate 
was then covered with tinfoil and agitated on an orbital shaker at approximately 
900 rpm for 15 min. Absorbance was subsequently measured at 590 nm and 
percentage viability was then measured by normalising values to the non-
treated control cells. 
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2.2.4 Plasmid Purification 
2.2.4.1 Transformation of Ultra Competent Cells 
Following quantification of plasmid concentration on the Nanodrop 1000, 10 ng 
of DNA was added in a volume not amounting to more than 10% of the 50 µl 
aliquots of competent cells. The contents of the tube were mixed by gentle 
swirling and then stored on ice for 30 min. The cells were heat shocked by 
incubation at 43° C for 2 min and then cooled on ice for a further 2 min. This 
process allows the cell membranes to become permeable to the plasmid DNA, 
allowing efficient uptake. 1 ml LB broth without antibiotic (to allow antibiotic 
resistance gene on the plasmid to express) was added to the tube and the cells 
were incubated at 37°C for 1 hour to allow cells to recover. 100 µl of cell 
suspension were then plated onto LB agar plates containing 100 µg/ml 
ampicillin or 50 µg/ml kanamycin and incubated at 37° C overnight to enable 
selection of transformed cells and colony growth. 
2.2.4.2 Maxi-scale preparation of plasmid from Escherichia coli 
The selected colony was grown overnight in 100 ml LB medium, containing 100 
µg/ml ampicillin or 50 µg/ml kanamycin, at 37° C in a shaking incubator at 300 
revolutions per minute (rpm) for 12-16 hr. Cells were pelleted at 6,000 × g for 
15-20 min. Plasmid was purified using the PureYield® Plasmid Maxiprep 
System, as per the manufacturer’s instructions. Briefly, this system is a simple 
bind-wash-elute procedure, whereby bacterial cells are pelleted by 
centrifugation and lysed. Following lysis, samples centrifuged at 14,000 × g for 
20 min at room temperature, in order to remove the bulk of the cellular debris. 
Plasmid DNA from the lysates is then bound to a column and washed several 
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times by vacuum to remove substantial unwanted protein, RNA and endotoxin 
contaminants, resulting in a pure plasmid DNA product.  
2.2.5 Transient transfection 
Metafectene (Biontex) is a polycationic liposomal-based transfection reagent. 
The molecular structure of the cationic lipid allows entry of plasmid DNA or RNA 
into cells by condensing the DNA into compact structures and by endosome 
buffering. The "Repulsive Membrane Acidolysis" (RMA) technology then allows 
destabilisation of the lipid membrane coating the DNA within the cells by 
generating repulsive electrostatic forces in weakly endosomal acidic 
environments, thereby releasing the DNA allowing transcription and translation 
to take place (Metafectene user manual). This liposomal-based system was 
used for transfection of both HEK 293T cells and HeLa cells. For 96-well plate 
transfections, cells were seeded at 2 × 105 cells/ml and grown overnight. Cells 
were transfected in triplicate with (typically) 250 ng DNA per transfection. In all 
cases, the amount of DNA used per transfection was normalised using an 
appropriate amount of relevant empty vector control, pcDNA3.1. The volume, 
per transfection, was brought to 10 µl with serum-free DMEM. 0.8 µl 
Metafectene was mixed with 9.2 µl serum-free DMEM per transfection and 
incubated at RT for 5 min. 30 µl of this mixture was added to triplicate amounts 
of DNA and incubated for 20 min at RT. 10 µl per well of DNA/ Metafectene/ 
serum-free DMEM (transfection mix) was then added to each of the wells of a 
96-well plate and cells were subsequently incubated in the transfection mixture 
for 18-24 hr at 37°C and 5% CO2. For 6-well plate transfections, the total DNA 
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used was typically 2 µg DNA per well. 8 µl Metafectene in a total volume of 200 
µl transfection mix was used per well. For transfection of 10 cm plates, 4 µg 
DNA was used in combination with 16 µl Metafectene in a total volume of 500 
µl transfection mix per plate. All experiments were harvested 18-24 hr post-
transfection. Plasmid expression was verified for all plasmids by transfection 
and western blot, as demonstrated in Figure 2.2. 
 
Figure 2.2: Expression blots for La-flag, RIG-I-flag, MDA-5-flag LGP-2-flag 
and IPS-1-flag; HEK 293T cells were seeded at a density of 2.5 × 105 cells per ml 
and transiently transfected the following day with increasing amounts of (A) flag-
tagged La, (B) flag-tagged RIG-I, (C) flag-tagged MDA-5, (D) flag-tagged LGP-2 and 
(E) flag-tagged IPS-1 from 100 ng-2 µg as indicated. 18 hours post-transfection cells 
were washed, lysed, re-suspended in 1 × sample buffer and analysed by western 
blotting.  
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2.2.5.1 Reporter gene assays 
The luciferase reporter gene assay uses two reporter enzymes, Firefly and 
Renilla, both of which are situated within specific light-emitting plasmids. The 
amount of light emitted directly correlates to the activity of the system being 
studied. The Renilla enzyme acts as an internal control to serve as a baseline 
response and is under the control of the HSV-thymidine kinase promoter. The 
Firefly enzyme is under the control of the promoter being studied and its 
activity correlates directly to the specific experimental conditions. By 
normalising the activity of the Firefly enzyme to that of the Renilla enzyme, 
experimental variability caused by cell viability or transfection efficiency is 
minimised. For these assays, HeLa or HEK 293T cells were transfected in 96-
well plates as described above. 18 hr post-transfection, medium was removed 
and the cells were lysed for 15 min on a rocking platform at room temperature 
with 50 µl 1 × Passive Lysis Buffer (Promega). 20 µl of the supernatant was 
used to determine Firefly luciferase activity and an equivalent amount used for 
determination of Renilla luciferase activity. 
Firefly luciferase activity was assayed by the addition of 40 µl of 
luciferase assay mix (20 mM tricine, 1.07 mM (MgCO3)4 Mg(OH)2.5H2O, 2.67 
mM MgSO4, 0.1 mM EDTA, 33.3 mM DTT, 270 mM coenzyme A, 470 mM 
luciferin, 530 mM ATP) to the sample and Renilla luciferase was assayed by the 
addition of 4 µl of a 1:1000 dilution of Coelenterazine (Argus Fine Chemicals)  in 
PBS. Luminescence was read using the Victor Wallac Multiplate Reader 
(PerkinElmer). Firefly luminescence readings were corrected for Renilla activity 
and expressed as fold stimulation over unstimulated empty vector (EV) control. 
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2.2.6 SDS PAGE and Western Blot Analysis 
 
Western blotting is used to detect proteins in tissue or cell lysate. 
Polyacrylamide gel electrophoresis (PAGE) is used to separate proteins based 
on their molecular weight. The gel is transferred to a membrane using electrical 
current, allowing for staining with a specific antibody to the protein of interest. 
2.2.6.1 Preparation of Whole Cell Lysates 
Cells were seeded as detailed in Methods 2.2.1.1. After appropriate stimulation 
or transfection, cells were washed with phosphate buffered saline (PBS) and 
lysed in 100-500 µl EBC lysis buffer (Deionised water, 50 mM Tris (pH8.0), 150 
mM NaCl, 1% Nonidet P40, 0.5% (w/v) sodium deoxycholate and 0.1% SDS) 
containing 1 mM of protein tyrosine phosphatase, sodium orthovanadate 
(Na3VO4), 1 mM serine protease inhibitor, Phenylmethylsulfonylfluoride (PMSF) 
and 1 mM Potassium fluoride (KF) which is an inhibitor of both serine and 
threonine protein phosphatases, at 4°C for 30 min on a roller before 
centrifugation at 13,000 rpm and 4°C for 10 min. Protein concentration was 
then determined using the Bicinchoninic Acid Assay described below. 
Alternatively, cells could be lysed directly in 100-500 µl 1 × SDS sample buffer 
(50 mM Tris-HCl, pH 6.8, 2% SDS, 0.1% Bromophenol blue, 10% Glycerol). 50 
µl 1 M reducing agent DTT was added per ml of sample buffer (to give a final 
concentration of 50 nM) immediately prior to use. Samples were then sonicated 
for 15 sec at 10-30% strength, boiled at 95°C for 10 min and centrifuged at 
13,000 rpm for 5 min. 
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2.2.6.2 Bicinchoninic Acid (BCA) Protein Assay  
Using the bicinchoninic acid (BCA) Protein Assay kit, protein concentration of 
lysates was determined and normalised according to the manufacturer’s 
instructions. The BCA assay works on the basis of the reduction of Cu2+ to Cu1+ 
by protein in an alkaline solution and subsequent colorometric detection (light 
blue to purple colour change) of the Cu1+ by BCA. Briefly, a standard curve was 
prepared in the range 0-2000 µg/ml BSA. The protein samples were diluted 1 in 
10 prior to loading on the 96-well plate. 25 µl of each of the samples and 
standards were then loaded onto the plate.  All samples were analysed in 
triplicate and the absorbance values of the standards were corrected for the 
blank value which corresponded to 0 mg/ml BSA. A standard curve of 
absorbance versus BSA concentration was plotted (an example of which can be 
observed in Figure 2.3), and the equation of the line of this graph was used to 
determine the concentration of the unknown samples. Following protein 
concentration determination, aliquots containing equal amounts of protein were 
mixed with an appropriate volume of 5 × SDS sample buffer (250 mM Tris-HCl, 
pH 6.8, 10% SDS, 0.5% Bromophenol blue, 50% Glycerol).   
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Figure 2.3: Typical BCA standard curve 
 
2.2.6.3 Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) 
 
Discontinuous SDS-PAGE was carried out according to the Laemmli method  
(Laemmli, 1970), using the Atto Gel Electrophoresis system. Briefly, the protein 
samples were loaded into the individual wells of a polyacrylamide gel within a 
gel rig containing sodium dodecyl sulphate (SDS) running buffer (25mM Tris, 
0.2M glycine, 0.1% SDS). SDS is an anionic detergent which denatures 
secondary and non–disulfide–linked tertiary structures and applies a negative 
charge to each protein in proportion to its mass. The polyacrylamide gels are 
made up of two major components, acrylamide and N,N-
methylenebisacrylamide, which is a cross-linking agent for the gels. The 
polymerisation is initiated by the addition of ammonium persulfate and is 
catalysed by the addition of N,N,N,N-tetramethylethylenediamine (TEMED). The 
separation of molecules within a gel is determined by the relative size of the 
69 
 
pores which is determined by the amounts of acrylamide and cross-linker 
present in the gel. As the amount of acrylamide increases, the pore size 
decreases, thus molecules will separate at a much lower rate. An electrical field 
was applied across the gel, causing the negatively-charged proteins to migrate 
across the gel towards the anode. After approximately one hour (varying 
depending on the size of the protein(s) of interest), the proteins will have 
differentially migrated based on their size. Volumes of gel components needed 
for the various percentages of resolving gels are shown in Table 2.4. A 5% 
stacking gel was prepared as described in Table 2.4. Samples were resolved 
through the gel at a constant current of 35 mA per gel. Pre-stained protein 
markers were run alongside samples as molecular weight standards. 
2.2.6.4 Transfer of Proteins to Membrane 
The resolved proteins were transferred to ImmobilonTM polyvinylidene difluoride 
(PVDF) membrane (Millipore) using a Trans-Blot Electrophoretic Cell (Bio-Rad). 
The PVDF membrane was activated by soaking in methanol for 30 sec. All 
components were soaked in transfer buffer (25 mM Tris-HCl pH 8.0, 0.2 M 
glycine, 20% methanol). The gel was placed on a layer of filter paper and 
sponge overlaid with the PVDF. A second piece of filter paper was placed on top 
followed by a second sponge. The entire assembly was placed in a cassette, the 
chamber filled with transfer buffer and a constant 200 mA was applied for 1 hr. 
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Table 2.4: Composition of stacking and resolving SDS-PAGE gels 
Running Gel 
 6% 
(>100kDa) 
8%          
(70-100kDa) 
10%       
(30-70kDa) 
12%       
(20-30kDa) 
15% 
(<30kDa) 
H20 7.9 ml 6.9 ml 5.9 ml 4.9 ml 3.4 ml 
1.5 M Tris-HCl 
(pH 8.8) 
3.8 ml 3.8 ml 3.8 ml 3.8 ml 3.8 ml 
Acrylamide: 
Bisacrylamide 
3 ml 4 ml 5 ml 6 ml 7.5 ml 
10% SDS 0.15 ml 0.15 ml 0.15 ml 0.15 ml 0.15 ml 
10% APS 0.15 ml 0.15 ml 0.15 ml 0.15 ml 0.15 ml 
TEMED 6 µl 6 µl 6 µl 6 µl 6 µl 
 
       Stacking Gel 
H2O 4.1 ml 
1 M Tris-HCl (pH 6.8) 0.75 ml 
Acrylamide: Bisacrylamide 1 ml 
10% SDS 60 µl 
10% APS 60 µl 
TEMED 6 µl 
 
2.2.6.5 Antibody Blotting 
Membranes were blocked for non-specific protein binding by incubation in 5%-
10% (w/v) blocking buffer containing non-fat dried milk in Tris Buffered Saline 
(TBS with 0.1% (v/v) Tween) at 4°C overnight or at RT for 1 hr. The 
membrane was then incubated at 4°C overnight or at RT for 1 hr with the 
primary antibody of interest ranging from 1:250 to 1:2,500 dilutions in the 
appropriate blocking buffer, depending on particular antibody. All antibodies 
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and dilutions used are detailed in Table 2.1. In the case of phospho-specific 
antibodies, 5% BSA in TBS-Tween was used to block non-specific binding and 
the primary antibody was diluted in 5% BSA in TBS-Tween and incubated 
overnight at 4°C. The membrane was washed 3 times for 10 min in 1% (v/v) 
TBS-Tween and incubated with the appropriate horse radish peroxidise (HRP)-
linked secondary antibody for 1 hr at RT. The HRP-linked antibody catalyses the 
oxidation of luminol to 3-aminophthalate via several intermediates, producing a 
triplet (excited) carbonyl, which emits light when it decays to the singlet 
carbonyl. This oxidation is catalysed by the oxidising agent, hydrogen peroxide. 
Again, the membrane was washed 3 times for 10 minutes in 1% (v/v) TBS-
Tween. Blots were developed by enhanced chemiluminescence (ECL, Millipore) 
according to manufacturer’s instructions.  
2.2.6.6 Densitometric analysis 
Films were scanned using an Epson Perfection V570 PRO and densitometric 
analysis was carried out using GeneTools from Syngene. The background was 
subtracted, and the signals of the detected bands were normalised to the 
amount of loading control band (α-actinin/β-actin in the case of immunoblots). 
The relative values were presented as fold increase over control bands. 
2.2.7 Immunoprecipitation 
Immunoprecipitation is a technique used to examine protein-protein 
interactions. An antibody specific to the target antigen of interest is allowed to 
form a complex with the antigen in a cell lysate. The immune complex is then 
captured on a solid support (i.e. sepharose beads) to which protein A or G has 
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been immobilised. Proteins that have not been precipitated by the immobilised 
Protein A or G beads are washed away. The components of the bound immune 
complex, including antigen, antibody, and any binding proteins in the protein 
complex are eluted from the support and analysed by SDS-PAGE and western 
blotting. 
2.2.7.1 Antibody Pre-Coupling 
1-2 µg of the relevant antibody was pre-coupled to 50 µl of a 50% slurry of 
either Protein A or Protein G sepharose (pre-washed 3 times in EBC or 
appropriate lysis buffer), per immunoprecipitation sample, overnight at 4°C. 
Following this incubation beads were washed to remove unbound antibody. 
2.2.7.2 Buffer Optimisation 
Initial experiments clearly demonstrated that our co-immunoprecipitation 
protocol was not optimal as interactions between proteins were detected 
weakly. As we had used PBS-based RIPA buffer (PBS containing 1% Nonidet 
P40, 0.5% (w/v) sodium deoxycholate and 0.1% SDS) as the lysis buffer for 
initial experiments, we wished to test whether alternative Tris-based lysis 
buffers had any effect on interaction intensity between proteins, as identified by 
western blotting. Figure 2.4 shows that Tris-based EBC buffer (exact recipe 
outlined in Methods 2.4.1) was the optimal buffer for use on interaction studies. 
As a result, this buffer was introduced as the standard buffer used for co-
immunoprecipitation analysis. 
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Figure 2.4: EBC lysis buffer is optimal for Co-Immunoprecipitation; HEK 293T 
cells were seeded at 2.5 × 105 cells per ml. Cells were transfected for 18 hours with 
empty vector or RIG-I-flag as indicated. Cells were then washed, lysed and 
immunoprecipitated with Protein A sepharose beads pre-coupled to either La or rabbit 
IgG control antibody, as indicated. Samples were then boiled in 5 × SDS buffer with 
DTT at 95°C for 5 minutes and analysed by western blotting.  
 
2.2.7.3 Immunoprecipitation 
Cells were treated as described in the figure legends and treatment terminated 
by washing cells once in ice-cold PBS. Cells were then scraped from plates, re-
suspended in appropriate lysis buffer and incubated with rotation at 4°C for 30 
min. The samples were then sonicated at 20-30% (if necessary) and 
centrifuged at 13,000 rpm for 10 min. 80 µl of supernatant was removed and 
added to 20 µl 5 × sample buffer and stored for further lysate analysis. The 
remaining supernatant was added to the relevant pre-coupled antibody and 
incubated for 1-2 hr at 4°C with gentle rotation. Following incubation, the 
immune complexes were washed 3 times with 1 ml lysis buffer (containing 
protease inhibitors). All supernatant was removed using crimped loading tips so 
as to avoid loss of sample and beads were re-suspended in 30 µl 5 × SB. 
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Samples were boiled and SDS-PAGE and western blot analysis was performed 
on the precipitated complexes. 
2.2.8 RNA Immunoprecipitation 
Cells were seeded in 10 cm dishes at a density of 2 × 105 cells/ml as described 
in 2.2.1. The following day, cells were transfected as indicated in figure legends 
and subsequently incubated for 18 hr at 37°C.  Cells were then lysed for 20 min 
at 4°C on rotation in 250 µl of freshly prepared sterile RNA Immunoprecipitation 
(RIP) buffer (150 mM KCl, 25 mM Tris pH 7.4, 5 mM EDTA, 0.5 mM DTT, 0.5% 
NP-40) supplemented with protease inhibitors and SUPERase RNA inhibitor 
(Sigma). The samples were then sonicated for 15 sec, cell debris was pelleted 
by centrifugation and cell lysates containing RNA were then transferred to fresh 
tubes. 1 µg of biotin labelled poly(I:C) ligand (Invivogen) was then added 
followed by incubation at 4°C for 1-2 hr. The samples were then added to 50 µl 
of pre-washed (3 times) UltraLink NeutrAvidin beads (Pierce) and incubated for 
1 hr at 4°C. The resulting immune complexes were then washed 3 times with 1 
ml RIP buffer and re-suspended in 30 µl 5 × sample buffer. Samples were then 
boiled for 10 min and SDS-PAGE and Western blot analysis was performed on 
the precipitated complexes. 
2.2.9 Recombinant Protein Pull-downs 
2.2.9.1 Preparation of recombinant protein and cell lysis 
BL21 cells which had been transformed with pET plasmids expressing either N-
terminal only (7A) or full-length (8A) La were kindly donated by Dr. Shannon 
Maier-Moore, Oklahoma Medical Research Foundation. 30 µl of these 
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transformed cells were spread on agar plates containing 50 µg/ml kanamycin 
and plates were incubated at 37°C overnight to enable colony growth. The 
following day, a colony was picked and added to 50 ml of LB broth 
supplemented with 50 µg/ml kanamycin and this primary culture was incubated 
aerobically overnight at 37°C and 250 rpm. After incubation, a secondary 
culture was prepared by adding 50 ml primary culture to 450 ml of LB broth 
with 50 µg/ml kanamycin and incubating overnight at 37°C and 250 rpm. 
Secondary cultures were then induced using 1 mM IPTG for 3 hr. Cells were 
pelleted at 4,000 rpm for 30 min and re-suspended in 20 ml binding buffer (20 
mM sodium phosphate, 500 mM NaCl). Lysozyme (final concentration of 1 
mg/ml) and protease inhibitors were added and cell suspension was incubated 
on ice for 30 min. Mixture was incubated on rotation for 10 min at 4°C. Triton-
X, DNase and RNase were then added to a final concentration of 1%, 5 µg/ml 
and 5 µg/ml, respectively. Incubation on rotation at 4°C was continued for a 
further 10 min. Suspensions were then centrifuged at 5,000 rpm for 30 min at 
4°C. Supernatants were then collected in fresh tubes and purification was 
carried out as detailed below. 
2.2.9.2 Purification of recombinant protein using Nickel Agarose 
1 ml nickel agarose gel suspension was added to a 50 ml tube and washed 3 
times with 10 ml equilibration buffer (50 mM sodium phosphate pH8, 0.3 M 
NaCl, 10 mM imidazole). Supernatants containing his-tagged recombinant 
protein were added to nickel agarose. Mixture was gently mixed on an orbital 
shaker at 200 rpm for 20 min followed by 5 min centrifugation at 5,000 × g. 
Beads were then washed three times with 10 ml equilibration buffer. Beads 
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with His-tagged La (7A and 8A) were subsequently retained for analysis of 
protein purification by gel electrophoresis.  
2.2.9.3 Recombinant Protein Pull-down experiments 
Following a gentle wash with ice-cold PBS, lysates of HEK 293T cells transfected 
with various constructs (detailed in figure legends) were prepared by addition 
of 1 ml EBC buffer per 10 cm dish. After sonication for 15 sec and 
centrifugation, the supernatant was incubated with 50 µl Nickel agarose beads 
coupled to either full length (8A) or N-terminal truncated (7A) recombinant La, 
(corresponding to approximately 1 mg of recombinant protein) for 2 hr on 
rotation at 4°C. After incubation, nickel agarose was washed three times by 
addition of 1 ml EBC buffer, with subsequent gentle inversion and 
centrifugation at 5,000 × g. Beads were then re-suspended in 50 µl 5 × SDS 
sample buffer supplemented with 50 nM DTT and boiled at 95°C for 10 min. 
Western blot analysis was then carried out on all samples. 
2.2.10 Nuclear & cytoplasmic fractionation 
This protocol enables separation of the nuclear and cytoplasmic fractions of the 
cells by using a hypotonic buffer to swell the cells prior to needle 
homogenisation to break them open. A series of centrifugations over sucrose 
cushions then follows, giving rise to purified nuclei. Cells were seeded as in 
2.1.1, using 2 × 105 cells per point, and stimulated as appropriate. Cells were 
trypsinised and pelleted at 1000 rpm for 4 min prior to a wash with ice-cold PBS 
and centrifugation again at 1000 rpm for 4 min. Cells were then re-suspended 
in 5 ml of ice-cold Buffer A (10 mM HEPES pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 
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0.5 mM DTT, 1 mM of Sodium orthovanadate (Na3VO4), 1 mM 
Phenylmethylsulfonylfluoride (PMSF), 1 mM Potassium fluoride (KF)) and 
incubated on ice for 5 min. Cells were broken open to release nuclei using a 
pre-chilled 26 ½ µm gauge needle and 5 ml syringe (BD Pharmingen) by 
passing through the needle 15-20 times. Lysates were centrifuged at 228 × g 
for 5 min at 4°C to pellet nuclei. Supernatant was retained as the cytoplasmic 
fraction. The nuclear pellet was then re-suspended in 3 ml of S1 buffer (0.25 
mM sucrose, 10 mM MgCl2, 1 mM Na3VO4, 1 mM PMSF, 1 mM KF) and layered 
over a 3 ml cushion of S3 buffer (0.88 mM sucrose, 0.5 mM MgCl2, 1 mM 
Na3VO4, 1 mM PMSF, 1 mM KF) before centrifugation at 2800 × g for 10 min at 
4°C. This step results in a cleaner nuclear pellet. The supernatant following this 
spin contains the nuclear proteins. 
2.2.11 Polymerase Chain Reaction (PCR) Analysis 
PCR, developed in 1983 by Kary Mullis (Mullis et al., 1986; Mullis and Faloona, 
1987), is a technique used to amplify DNA. It works by using DNA polymerase 
to synthesise a new strand of DNA complementary to the template strand. 
Because DNA polymerase can add a nucleotide only onto a pre-existing 3'-OH 
group, it needs a primer to which it can add the first nucleotide. This makes it 
possible to delineate a specific region of template sequence that requires 
amplification. At the end of the PCR reaction, the specific sequence will be 
accumulated in billions of copies and can be visualised on an agarose gel. In 
this study, RNA was extracted from cells using Trizol reagent. Trizol is a 
monophasic solution of phenol and guanidine isothiocyanate which is designed 
to rapidly isolate separate fractions of RNA, DNA, and proteins from cell and 
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tissue samples of human, animal, plant, yeast, or bacterial origin. Following 
RNA isolation, RNA was reverse transcribed into cDNA which was subsequently 
used to investigate specific genes of interest by PCR. 
2.2.11.1 Extracting RNA using the Trizol Method 
Cells were homogenised in 1 ml of Tri-reagent (Sigma) for 5 min at 15-30°C. 
200 µl of chloroform was added to samples and tubes were shaken vigorously 
by hand for 15 sec and then incubated at RT for 2-3 min. Samples were spun at 
12,000 × g for 15 min at 4°C which resulted in separation into lower red 
phenol-chloroform phase containing cellular proteins, an interphase containing 
the DNA and a colourless upper aqueous phase containing the RNA. The upper 
aqueous phase was transferred to a clean 1.5 ml tube and 500 µl of isopropyl 
alcohol was added to precipitate the RNA. Samples were incubated for 10 min 
at RT and spun at 12,000 × g for 10 min at 4°C. Supernatant was removed and 
the RNA pellet was washed with 1 ml of 70% ethanol. Sample was mixed well 
by vortexing and spun at 7,500 × g for 5 min at 4°C. Supernatant was removed 
and RNA pellet was allowed to air dry. RNA was then dissolved in 30 µl of 
nuclease-free water and concentration as well as purity (a 280/260 absorbance 
ratio between 1.8 and 2 indicated pure RNA) were determined on the nanodrop 
(Mason Technology) before storage at -80°C until needed.  
2.2.11.2 Reverse Transcription 
cDNA was prepared using the GoScript Reverse Transcription kit (Promega), as 
per manufacturer’s instructions. Briefly, this involved a genomic DNA elimination 
reaction on ice using the RNA sample (1 µg) followed by a reverse transcription 
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reaction. Samples were incubated for 1 hour at 42°C and then 15 min at 70°C 
to inactivate reverse transcriptase. cDNA was then stored at -80°C until 
needed.    
2.2.11.3 PCR 
A PCR was carried out on the specific gene of interest using the sample cDNA 
of interest. Each sample for PCR analysis was set up in a total volume of 25 µl 
as outlined in Table 2.5. A list of human primers used in this study can be found 
in Table 2.6. PCR conditions are detailed in Table 2.7. 
Table 2.5: PCR components present in each tube of PCR reaction 
Component Volume (µl) 
cDNA 2.5 
Promega Go Taq Polymerase 0.125 
Promega Go Taq 5 × Colourless Buffer 5 
2 µM Forward Primer                          1 
2 µM Reverse Primer                          1 
2.5 µM dNTPs                                     1 
Water 14.375 
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Table 2.6: Human primers used in this study 
Primer Name Primer Sequence Product 
Size (bp) 
La sense GAAGGAGAGGTGGAAAAAG 372 
La anti-sense AAGCCCCGCAAACAAAAG  
IFN-α4 sense GTGTCTAGATCTGACAACCTCCCAGGGCACA 419 
IFN-α4 anti-sense GTACTGCAGAATCTCTCCTTTCTCCTG  
IFN-β sense CTAGCACTGGCTGGAATGAGA 217 
IFN-β anti-sense CTGACTATGGTCCAGGCACA  
18S sense TTGACGGAAGGGCACCACCA 131 
18S anti-sense GCACCACCACCCACGGAATCG  
GAPDH sense ACCACCATGGAGAAGGCTGG 530 
GAPDH anti-sense CTCAGTGTAGCCCAGGATGC  
Neo-La sense TTCTAGTCTCACCGAAGGCTTGTG 129 
Neo-La anti-sense GATGACAGATTTTGGCCTCCAG  
IFN-λ1 sense GGACGCCTTGGAAGAGTCACT 84 
IFN-λ1 anti-sense AGAAGCCTCAGGTCCCAATTC       
CCL-5 sense CAAGGAGCGGGTGGGGTAGGA 261 
CCL-5 anti-sense ATCCCCCAAACTGGCTGTCCCG  
CXCL-10 sense GGAAGCACTGCATCGATTTTG 519 
CXCL-10 anti-sense CAGAATCGAAGGCCATCAAGA  
CXCL-11 sense GCCTTGGCTGTGATATTGTGTG 686 
CXCL-11 anti-sense CACTTTCACTGCTTTTACCCCAG  
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Table 2.7: PCR conditions 
Temperature Purpose Time 
95ºC Initial Denaturation 10 minutes 
95ºC Denaturation 30 seconds 
55ºC  Annealing 30 seconds 
72ºC Extension 30-60 seconds 
72ºC Final extension 10 minutes 
 
2.2.11.4 Gel Electrophoresis of PCR products 
A 1% agarose gel was prepared by dissolving 0.35 g of agarose in 35 ml of Tris 
acetate–EDTA (TAE) buffer in a glass flask and heated until all of the agarose 
had been fully dissolved. 3.5 µL of Sybr Safe DNA Stain (Invitrogen) was added 
to the flask (to allow for visualisation of the bands) and this was then poured 
into a suitable gel cassette with an appropriate well comb. Sybr Safe binds to 
DNA resulting in a DNA-Sybr Green-complex which absorbs blue light (λmax = 
497 nm) and emits green light (λmax = 520 nm). Once set, the gel was placed in 
a gel rig and gel was covered over with TAE buffer. The gel was then run at 
100 V for 30 min or until dye front reached the end of the gel. DNA bands were 
visualized under UV light. 
2.2.11.5   Real-Time PCR  
1 µl of cDNA was added in triplicate to a 96-well PCR plate. RT-PCR was carried 
out using a SYBR Green Taq ReadyMixTM Kit (Sigma). The master mix (Table 
2.8) was prepared on ice, followed by vortexing and centrifuging briefly to mix 
tube contents. 
35 cycles 
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Table 2.8: RT-PCR master mix components 
Material Volume 
SyBr Green Mix 10 µl 
Reference Dye 0.2 µl 
Forward Primer 2 µl 
Reverse Primer 2 µl 
Nuclease-free water 4.8 µl 
 
19 µl of this mix was added to each sample resulting in a 20 µl total volume in 
each well of plate. The 96-well plate was then run on the ABI Prism 7900 plate-
reader (Applied Biosystems). Real-time PCR data was analysed using the 2-∆∆Ct 
method. Briefly summarised, the Ct values for each reaction – endogenous 
control and test probe for calibrator and test samples, were calculated using the 
SDS software. For each detector/probe, the effect of loading and RNA 
normalisation was corrected by subtraction of the Ct value for the endogenous 
control for each reaction/sample. This gives the ∆Ct value. Then, the ∆Ct value 
of the calibrator sample is subtracted from the ∆Ct of each test sample. The 
resulting ∆∆Ct value is normalised using the formula 2(-∆∆Ct). The resulting value 
is the fold-change in expression for a test sample relative to the calibrator 
sample for that particular detector/probe normalised using an endogenous 
control reference. 
2.2.12 Immunofluorescence 
HeLa cells were seeded at 1 × 105/well in a 12-well plate containing coverslip 
discs and allowed to grow for at least 5 hr. Cells were then transfected, as 
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described in Methods 2.2.3, and allowed to grow for 24-48 hr. Stimulations 
were carried out as indicated in figure legends. Following stimulation, the 
coverslips were washed × 3 in ice-cold filter-sterilised PBS and fixed in 4% 
paraformaldehyde at RT for 10 min. Following fixation of cells, the cells were 
again washed × 3 in PBS prior to permeabilisation for 5 min at RT using 0.2% 
Triton-X in PBS. Cells were once again washed × 3 in PBS for 5 min. PBS was 
removed and at this point, coverslips were carefully extracted from the plate 
and placed on labelled glass slides before delineation using a hydrophobic 
marker. Coverslips were blocked for non-specific binding by incubation in 100 µl 
blocking buffer (PBS with 1.2% Fish Gelatin and 100 mM Glycine) at 37°C for 1 
hr. Coverslips were then incubated at 37°C for 1 hr with 100 µl of the primary 
antibody of interest at 1:100 dilution in blocking buffer. The coverslips were 
washed × 3 for 5 min in PBS and incubated with 100 µl of the appropriate 
fluorescently labelled secondary antibody at 1:200 dilution at 37°C for 1 hr in 
darkness. Again, the coverslips were washed × 3 for 5 minutes in PBS before 
being carefully mounted using ProLong® Gold anti-fade reagent with DAPI onto 
a fresh glass slide. Cells were imaged and captured using the LSM 710 System 
(Carl Zeiss) or imaged under epifluorescent microscope and captured using 
Nikon camera and NIS elements software. 
2.2.13 Analysis of Cytokine Production  
Enzyme-linked Immunosorbance assays are used to determine the relative 
production of cytokines post-treatment. It gives a direct correlation between 
stimulation/infection and cytokine output. In this study, HEK 293T cells were 
seeded at outlined in 2.2.1.  Cells were stimulated or infected with appropriate 
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concentrations of 5’ppp-dsRNA or virus over an appropriate time course, as 
detailed in each figure legend. Following stimulation/infection, supernatants 
were collected into eppendorfs and frozen at -20°C for subsequent cytokine 
analysis. 
2.2.13.1 Enzyme-linked Immunosorbance Assay (ELISA) 
ELISAs were carried out using DuoSet® ELISA Development Kit for human 
Rantes or human IFN-λ1/IL-29 (eBioscience), as per the manufacturer’s 
instructions. Briefly, a 96-well microtitre plate was coated with 100 µl/well of 
the capture reagent (diluted in PBS) overnight at RT. The plate was washed 3 
times with wash buffer (0.1% (v/v) Tween-20 in PBS) and blocked for 1 hr at 
RT in blocking buffer (1% BSA in PBS). The plate was washed 3 times with 
wash buffer and 100 µl of samples or standards, ranging from 0-2000 pg/ml, 
were added to the plate in triplicate and incubated for 2 hr at RT. Again the 
plate was washed 3 times with wash buffer and 100 µl/well of biotinylated 
detection reagent (diluted in 1% BSA in PBS) was added to each well and 
incubated for 2 hr at RT. The plate was washed 3 times with wash buffer and 
100 µl/well streptavidin-HRP (diluted 1:200 in 1% BSA in PBS) was added to 
each well for 20 min at RT. The plate was again washed 3 times with wash 
buffer and 100 µl/well of 3,3',5,5'-Tetramethylbenzidine (TMB) was added for a 
further 20 min at RT. 50 µl/well sulphuric acid was added to stop the reaction. 
The optical density of the standards and samples was immediately read at 450 
nm on the Victor Wallac Multiplate Reader and a standard curve was 
constructed, from which the concentrations in the samples could be 
extrapolated. 
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2.2.13.2 Multiplex 7-spot cytokine analysis 
A Meso Scale Discovery (MSD) Cytokine Assay was used to measure seven 
cytokines (IFN-γ, IL-1β, TNF-α, IL-6, IL-8, IL-10 and IL-12p70) in a 96-well 
multi-spot plate. This technique employs a sandwich immunoassay format 
whereby capture antibodies are coated in a patterned array on the bottom of 
the well (Figure 2.5). Briefly, the MSD plate was then blocked using 25 µl of 
diluent 2 for 30 min at RT. 25 µl of samples or standards (ranging from 0-
10,000 pg/ml) were added to the plate in duplicate and incubated for 2 hr at RT 
with vigorous shaking (1000 rpm). The plate was washed 3 times with wash 
buffer (0.05% Tween in PBS) before the addition of 25 µl/well of 1 × detection 
antibody solution to each well and incubation for 2 hr at RT with vigorous 
shaking (1000 rpm). The plate was again washed 3 times with wash buffer and 
150 µl/well 2 × read buffer was added to each well prior to plate reading using 
the SECTOR instrument (MSD). A standard curve was constructed, from which 
the concentrations in the samples could be extrapolated. 
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Figure 2.5: Cytokine capture antibody is pre-coated on specific spots of a 7-spot MSD 
multi-spot plate. Standards (shown in the first two columns) or samples are incubated 
in the plate and each cytokine binds to its corresponding capture antibody spot. 
Cytokine levels are quantified using a cytokine-specific detection antibody labelled with 
MSD sulfo-tag™ reagent. 
 
2.2.14 Viral Infection 
HEK 293T cells were seeded as described in 2.2.1. Following shRNA knockdown 
for 48 hr, media was discarded and replaced with fresh pre-warmed DMEM 
supplemented with antibiotic only (no FCS), thereby limiting cell growth. Cells 
were then infected with Z and Cantell strains of Sendai virus at a multiplicity of 
infection (MOI) of 10. 1 hr post-infection, inoculums were removed by 
discarding media and replacing with DMEM supplemented with antibiotic and 
1% FCS in order to maintain cell survival while ensuring limited growth. 
Following indicated time points, media was carefully removed and retained for 
subsequent cytokine analysis, cells were gently re-suspended in ice-cold PBS 
and centrifugation was carried out at 2,000 rpm for 5 min to pellet cells. Cells 
were then re-suspended in Trizol reagent for gene expression analysis or 1 × 
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SDS sample buffer supplemented with 50 nM DTT for protein expression 
analysis. 
2.2.15 Patient recruitment 
All patients with SLE included in our study met the American College of 
Rheumatology classification criteria (Heinlen et al., 2007) and were 
recruited from Beaumont Hospital, Dublin, St James Hospital, Dublin and St 
Vincent’s University Hospital, Dublin. SLE patients included in the study 
were female and aged 22–62 years. Age- and sex-matched healthy 
individuals were chosen as controls. The study protocol was approved by 
the institutional review boards of all involved institutions, and written 
informed consent was obtained from all participants. 
2.2.16 Statistical Analysis 
Statistical comparison between groups was carried out using one-way or two-
way ANOVA tests. Where the mean of two data sets were compared, an 
unpaired student t-test was used. Data is graphically represented as mean +/- 
SEM unless otherwise indicated. More detailed statistical analysis related to 
specific experiments is outlined in each figure legend in full. All data was 
analysed using Microsoft Excel or GraphPad Prism (version 5) statistical 
software package, as specified. 
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Chapter 3:  
La inhibits RLR-mediated IFN-β 
induction  
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3.1 Introduction 
Systemic lupus erythematosus (SLE) is an extremely heterogenous disease, 
presenting in many different forms ranging from mild cutaneous symptoms to 
chronic inflammation which can result in kidney nephritis, pleural effusions 
and/or, in severe cases, cardiac and neural involvement. However, one of the 
unifying features of disease is the presence of consistently high levels of type I 
Interferons (IFNs). Since the 1970s, detrimentally high serum and intracellular 
levels of IFN have been observed in the serum and immune cells of SLE 
patients (Blanco et al., 2001; Hooks et al., 1979; Niewold et al., 2008; Niewold 
et al., 2007; Niewold and Swedler, 2005; Ronnblom et al., 1990; Weckerle et 
al., 2011). The consequence of this build-up is increased inflammation, 
cytotoxicity and autoantibody generation, thus contributing to the systemic 
pathogenesis of the disease. 
But what are the molecular mechanisms behind this pathogenic 
overproduction of IFN in SLE? As previously discussed in depth, the key 
pathogen recognition receptors (PRRs) responsible for mediating type I IFN 
production are the RIG-I-like receptors (RLRs) and the endosomally located 
anti-viral Toll-like receptor (TLR) signalling pathways, summarised schematically 
in Figure 3.1. Stimulation of RLRs and anti-viral TLRs triggers signalling 
cascades which culminate in activation of IRF-3 and IRF-7, which are crucial in 
regulating the early and late phase IFN response, as demonstrated by IRF-3-/- 
and IRF-7-/- knockout mouse studies (Lin et al., 2000; Marie et al., 1998; Sato 
et al., 2000).  
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Figure 3.1: Anti-viral RLR and TLR signalling pathways; RNA pol III, RIG-I, 
MDA-5, TLR-3, TLR-7 and TLR-9 induce type I IFN production via recruitment and 
activation of a number of downstream proteins, leading to phosphorylation, 
dimerisation and translocation to the nucleus of transcription factors such as IRF-3, 
IRF-7, AP-1 and NF-κB. Activation of these transcription factors contributes to 
inflammation, anti-viral responses and T cell activation via release of cytokines such as 
TNF-α, IL-1β, Rantes, IFN-α and IFN-β. 
 
Regarding signalling by the RLRs, detection of RNA agonist by RIG-I or 
MDA-5 triggers a conformational change, which opens up the CARDs of the 
proteins for interaction with downstream IFN-β promoter stimulator 1 (IPS-1) 
(Kawai et al., 2005; Kumar et al., 2006; Meylan et al., 2005; Seth et al., 2005; 
Sun et al., 2006; Xu et al., 2005). IPS-1 then associates with TRAF-3, which, in 
a complex with scaffold proteins NAP-1 (Sasai et al., 2005), SINTBAD 
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(Ryzhakov and Randow, 2007) and/or TANK (Gatot et al., 2007; Guo and 
Cheng, 2007; Hemmi et al., 2004; Li et al., 2002a; Perry et al., 2004) activates 
TBK-1 and IKK-ε, thereby mediating IRF-3 activation (Hemmi et al., 2004; 
McWhirter et al., 2004). On the other hand, interactions between IPS-1 and 
TRAF-6/TRAF-2 mediate activation of classical IKKs and NF-κB activation 
(Hacker et al., 2006; Oganesyan et al., 2006; Saha et al., 2006; Xu et al., 
2005). 
 With the exception of TLR-3, the endosomal TLRs recruit adaptor protein 
MyD88, which associates with IRAK-1 upon activation (Barton and Medzhitov, 
2003; Muzio et al., 1997; O'Neill and Bowie, 2007). IRAK-1 then triggers 
subsequent interaction of IRAK-4 with TRAF-6 (Kawai et al., 2004). TRAF-6, 
through the activation of the TAK-1-TAB complex, promotes downstream 
activation of IκB kinases (IKKs), IKKα, IKKβ and NEMO/IKK-γ, thus induction of 
NF-κB. Interestingly, TANK interacts with NEMO to promote interaction with the 
IKKs and also functions to mediate TBK-1- and IKK-ε-mediated activation of NF-
κB (Chariot et al., 2002). TAK-1 activation also results in activation of MAP 
kinases; JNK, p38 and ERK, which in turn leads to phosphorylation and nuclear 
translocation of AP-1 (Wang et al., 2001). TLR-7 and TLR-9-mediated type I 
IFN induction is elicited by the formation of a complex between IRF-7, MyD88, 
IRAK1, IRAK-4 and TRAF-6, which translocates into the nucleus in response to 
TLR stimulation, resulting in robust IRF-7 activation (Honda et al., 2004; 
Hoshino et al., 2006; Kawai et al., 2004; Uematsu et al., 2005). Retention of 
the CpG DNA/TLR-9 complex in the endosome may elicit an IFN-α response, as 
CpG-B, a conventional TLR-9 ligand which usually elicits a poor type I IFN 
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response, was demonstrated to induce IFN-α if manipulated to stay longer in 
the endosome of conventional DCs (Honda et al., 2005a).    
 Conversely, TLR-3 signals in a MyD88-independent manner via TRIF (de 
Bouteiller et al., 2005; Oshiumi et al., 2003; Yamamoto et al., 2003). TRIF can 
interact with TRAF-6 bringing about classical activation of NF-κB, as explained 
in detail above. TRIF can also interact with TRAF-3, leading to phosphorylation 
of TANK-binding kinase 1 (TBK-1) and activation of IRF-3 and IRF-7 (Cao et al., 
1996; Hacker et al., 2006; Kawai and Akira, 2008). Furthermore, TRIF has been 
shown to activate AP-1 by interaction with RIP1 and TRADD leading to 
phosphorylation of the ERK, JNK and p38 kinases (Kaiser and Offermann, 
2005).  
 More recently, RNA polymerase III (RNA pol III), an enzyme involve in 
the transcription of non-coding RNA, was reported to act as an anti-viral PRR by 
regulating type I IFN induction through generation of RIG-I ligand (Ablasser et 
al., 2009; Cao, 2009b; Chiu et al., 2009; Choi et al., 2009; Wilkins and Gale, 
2010). Chiu and colleagues showed that inhibition of RNA pol III activity using 
inhibitor, ML-60218, dose dependently decreased IFN-β induction, as measured 
by real-time PCR (Chiu et al., 2009). Independently, Ablasser and colleagues 
found that RNA pol III was transcribing AT-rich dsDNA into the 5’ppp-dsRNA 
format, for recognition by RIG-I and subsequent IFN induction (Ablasser et al., 
2009).  
 Thus, signalling downstream of the RLRs and nucleic acid-sensing TLRs 
is highly specific and, as such, precise regulatory mechanisms must exist in 
93 
 
order to prevent excessive activation. Regarding regulation or fine-tuning of 
these pathways, the E3 ligase and autoantigen Ro52 (also known as TRIM21), 
has been shown to play a role in direct regulation of type I IFN levels by 
targeting IRF-3, IRF-5, IRF-7 and IRF-8 for ubiquitination (Espinosa et al., 
2009; Espinosa et al., 2011; Higgs et al., 2008; Kong et al., 2007; Yang et al., 
2009; Yoshimi et al., 2009). In addition, a link between Ro60, another of the 
autoantigens in SLE, and IFN has been reported, with Ro60 knockout mice 
reported to spontaneously develop an IFN-regulated autoimmune condition 
characterised by autoantibodies, glomerulonephritis and increased sensitivity to 
UV irradiation, suggesting that Ro60, like Ro52, regulates IFN production (Xue 
et al., 2003).  
 These autoantigens, or extractable nuclear antigens (ENAs), associate 
with 4 small, uridine-rich, cytoplasmic RNA species (hYRNA) in the Ro/La 
complex (Franceschini and Cavazzana, 2005) and given the ability of TLRs and 
RLRs to detect nucleic acids, the possibility exists that other members of this 
complex may also regulate TLR/RLR signalling. Interestingly, complex 
component La has been shown to bind to RNA pol III transcripts, where it 
functions in stabilisation of newly-synthesised RNAs and also in the termination 
and re-initiation of transcription (Chu et al., 1997; Fan et al., 1997; Goodier et 
al., 1997; Goodier and Maraia, 1998; Gottlieb and Steitz, 1989a, b; Maraia, 
1996; Maraia et al., 1994). Given the newly-discovered role for RNA polymerase 
III in viral RNA detection, we hypothesised that La may, like Ro52 and Ro60, 
exert effects on IFN production directly, perhaps downstream of nucleic acid-
sensing PRRs.  
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Aims: 
• To investigate the effect of La in TLR- and/or RLR-mediated IFN 
induction.  
• To elucidate the role of RNA polymerase III in this process. 
• To assess the effect of La knockdown on IFN expression. 
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3.2 Results 
3.2.1 La inhibits RLR-induced, but not TLR-3-induced, activity of the 
full length IFN-β promoter  
From the literature, we hypothesised that La may directly regulate IFN 
induction downstream of RLR and/or TLR pathways. In order to test this 
hypothesis, we employed reporter gene assays to assess the effect of La on 
RIG-I-, MDA-5- and TRIF-induced IFN-β promoter activity. HeLa cells were 
transiently transfected with 40 ng of IFN-β promoter and co-transfected with 50 
ng RIG-I along with increasing amounts (0, 10, 50 and 100 ng) of a plasmid 
encoding full-length La.  As illustrated in Figure 3.2A, 50 ng of RIG-I 
successfully drives the IFN-β promoter-driven reporter gene as expected, with 
increasing La concentration significantly attenuating RIG-I-driven IFN-β 
induction. In all cases western blot analysis demonstrated that the plasmids 
expressed as expected (Figure 3.2B-C). Attenuation of the IFN-β promoter 
activity by La is also observed following driving of the promoter with MDA-5, 
another member of the RLR family of anti-viral receptors (Figure 3.3A, 
expression of MDA-5 shown in figure 3.3B). This inhibitory effect of La was 
subsequently shown to be specific to the RLR pathway, with La having no effect 
on TRIF-driven IFN-β promoter activity, an adaptor critical for TLR-3-driven IFN 
production.  As illustrated in Figure 3.4A, while 50 ng of TRIF (expression of 
TRIF demonstrated in Figure 3.4B) robustly drives the IFN-β promoter as 
expected, this induction is unaffected by increasing La concentrations. 
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Figure 3.2: RIG-I-driven IFN-β promoter activity is attenuated by La; (A) 
HeLa cells were seeded in a 96-well plate at a density of 1 × 105 cells per ml and 
transiently transfected the following day with 40 ng of the IFN-β p125 promoter, 40 ng 
of TK Renilla, 50 ng of either empty pcDNA3.1 vector (EV) or FLAG-tagged RIG-I, and 
increasing concentrations of La, as indicated. Cells were assayed for reporter gene 
activity 18 hr post-transfection. Data shown is a representative experiment of three 
individual experiments, n=3.  ****p<0.0001 as determined by two-way ANOVA using 
GraphPad Prism. (B) Corresponding La expression blot. (C) Corresponding RIG-I 
expression blot. 
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Figure 3.3: MDA-5-driven IFN-β promoter activity is attenuated by La; (A) 
HEK 293T cells were seeded in a 96-well plate at a density of 1 × 105 cells per ml and 
transiently transfected the following day with 40 ng of the IFN-β p125 promoter, 40 ng 
of TK Renilla, 50 ng of either empty pcDNA3.1 vector (EV) or FLAG-tagged MDA-5, and 
increasing concentrations of La, as indicated. Cells were assayed for reporter gene 
activity 18 hr post-transfection. Data shown is the combined average of three 
individual experiments, n=3. ****p<0.0001 as determined by two-way ANOVA using 
GraphPad Prism. (B) Corresponding MDA-5 expression blot. 
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Figure 3.4: TRIF-driven IFN-β promoter activity is unaffected by La; (A) HeLa 
cells were seeded in a 96-well plate at a density of 1 × 105 cells per ml and transiently 
transfected the following day with 40 ng of the IFN-β p125 promoter, 40 ng of TK 
Renilla, 50 ng of either empty pcDNA3.1 vector (EV) or FLAG-tagged TRIF, and 
increasing concentrations of La, as indicated. Cells were assayed for reporter gene 
activity 18 hr post-transfection. Data shown is a representative experiment of three 
individual experiments, n=3. Non-significant (ns, p>0.05) as determined by two-way 
ANOVA using GraphPad Prism. (B) Corresponding TRIF expression blot. 
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3.2.2 La’s inhibitory effect is proximal to RLR receptors  
To elucidate at which point in the RLR pathway La was acting, we next 
assessed its effect on two downstream proteins, namely the adaptor protein, 
IPS-1, and the key effector kinase, TBK-1. IPS-1 acts as a bridging adaptor 
mediating signalling between RIG-I and the TRAF3/NAP1/TANK complex, 
whereas TBK-1 phosphorylates and hence activates the transcription factors 
IRF-3 and IRF-7. HeLa cells were transiently transfected with IPS-1 and 
increasing amounts of La, as before, and effects on the IFN-β promoter 
assessed. As demonstrated in Figure 3.5A, IPS-1-induced IFN activity is 
significantly attenuated with increasing La. Figure 3.5B shows successful 
expression of IPS-1 plasmid. In the case of TBK-1-induced IFN-β activity, 50 ng 
of TBK-1 was seen to drive the p125 promoter as expected, with induction 
unaffected by increasing La concentrations from 0-100 ng (Figure 3.6). The 
finding that TBK-1-induced IFN-β activity is unaffected by La tells us that the 
inhibition is most likely occurring upstream of TBK-1 in the pathway.  
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Figure 3.5: La acts proximal to RLR pathway at IPS-1 level; (A) HeLa cells were 
seeded in a 96-well plate at a density of 1 × 105 cells per ml and transiently 
transfected the following day with 40 ng of the IFN-β p125 promoter, 40 ng of TK 
Renilla, 50 ng of either empty pcDNA3.1 vector (EV) or FLAG-tagged IPS-1 and 
increasing concentrations of La, as indicated. Cells were assayed for reporter gene 
activity 18 hr post-transfection. Data shown is a representative experiment of three 
individual experiments, n=3. **p< 0.01 and ***p<0.001 as determined by two-way 
ANOVA using GraphPad Prism. (B) Corresponding IPS-1 expression blot. 
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Figure 3.6: TBK-1-driven IFN-β promoter activity is unaffected by La; (A) 
HeLa cells were seeded in a 96-well plate at a density of 1 × 105 cells per ml and 
transiently transfected the following day with 40 ng of the IFN-β p125 promoter, 40 ng 
of TK Renilla, 50 ng of either empty pcDNA3.1 vector (EV) or FLAG-tagged TBK-1 and 
increasing concentrations of La, as indicated. Cells were assayed for reporter gene 
activity 18 hr post-transfection. Data shown is a representative experiment of three 
individual experiments, n=3. Non-significant (ns, p>0.05) as determined by two-way 
ANOVA using GraphPad Prism. (B) Corresponding TBK-1 expression blot. 
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3.2.3 La inhibits RLR-induced PRDIII-I activation 
Having established a role for La in negatively regulating IFN-β activity in 
an RLR-specific manner, we next investigated the effect of La on the virus-
induced IFN-β enhanceosome following RIG-I or MDA-5 driving. The IFN-β 
enhanceosome is a 50 bp DNA regulatory element located between -102 and -
55 upstream of the transcriptional start site. It contains four positive regulatory 
domains (PRDs), designated PRDII, PRDIII-I, and PRDIV, which bind NF-κB 
(Fujita et al., 1989; Hiscott et al., 1989; Lenardo et al., 1989; Visvanathan and 
Goodbourn, 1989), IRF-3 and IRF-7 (Hiscott et al., 1999; Sato et al., 2000; 
Sato et al., 1998; Wathelet et al., 1998) and an ATF-2/c-Jun hetero-dimer (Du 
and Maniatis, 1992) respectively, summarised schematically in Figure 3.7. 
These transcription factors, together with high mobility group protein A1 
(HMGA1), form a highly stable complex which activates transcription from IFN-β 
in response to viral infection (Du and Maniatis, 1994; Thanos and Maniatis, 
1992; Yie et al., 1999).  
 Initially the effect of La on RLR-driven PRDII activity was assessed. 
Similar to previous studies, PRDII was driven using 50 ng of RIG-I or MDA-5 
and the effect of increasing concentrations of La on induction was investigated. 
Due to poor induction of this promoter by RIG-I, results were inconclusive 
(Figure 3.8A). MDA-5-driven PRDII activity was modestly attenuated by La 
(Figure 3.8B), suggesting that La may play an inhibitory role in regulating NF-
κB induction of the IFN-β promoter downstream of RLR activation, although 
MDA-5 induction of this promoter was quite low (only two-fold above 
unstimulated control). The specificity of La inhibition on RLR-mediated 
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signalling was underlined given the observation that La has no effect on 
MyD88-driven PRDII activity and again suggests that the effects of La must lie 
proximal to RIG-I and MDA-5 on the pathway (Figure 3.8C-D). Upon attempted 
induction of the PRDIV promoter using 50 ng of RIG-I (Figure 3.9A) or MDA-5 
(Figure 3.9B), no driving of promoter activity was observed.  
  Lastly, investigation into La’s effect on RLR-driven activation of the 
PRDIII-I reporter gene was carried out. The PRDIII-I promoter was induced 
using 50 ng of either RIG-I (Figure 3.10A), MDA-5 (Figure 3.10B), or IPS-1 
(Figure 3.10C) and the effect of increasing concentrations of La was measured. 
La significantly attenuated both MDA-5- and IPS-1-driven PRDIII-I activity and 
a trend towards La inhibiting RIG-I-driven PRDIII-I activity was also observed. 
Overall, our results suggest that La inhibits RLR-driven activation of pathways 
regulating IRF-3- and IRF-7-mediated IFN-β activation, at a point proximal to 
the RLRs themselves. 
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Figure 3.7: PRD binding sites in the IFN-β promoter; The IFN-β enhanceosome 
is a 50 bp DNA regulatory element located between -102 and -55 bp upstream of the 
transcriptional start site. It contains four positive regulatory domains (PRDs), 
designated PRDII, PRDIII-I, and PRDIV, which bind NF-κB, IRF-3, IRF-7 and an ATF-
2/c-Jun hetero-dimer, respectively. These transcription factors, together with high 
mobility group protein A1 (HMGA1), form a highly stable complex which activates 
transcription from IFN-β. 
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Figure 3.8: Effect of La on RLR-driven PRDII activity is inconclusive; HEK 
293T cells were seeded in a 96-well plate at a density of 1 × 105 cells per ml and 
transiently transfected the following day with a reporter construct containing 40 ng of 
the PRDII promoter, 40 ng of TK Renilla, 50 ng of either empty pcDNA3.1 vector (EV) 
or (A) FLAG-tagged RIG-I, (B) FLAG-tagged MDA-5 or (C) MyD88, and increasing 
concentrations of La, as indicated. Cells were assayed for reporter gene activity 18 hr 
post-transfection. Data shown are the combined averages of three individual 
experiments, n=3, in all cases. **p< 0.01 and non-significant (ns, p>0.05) as 
determined by two-way ANOVA using GraphPad Prism. (D) Corresponding MyD88 
expression blot. 
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Figure 3.9: Effect of La on RLR-driven PRDIV activity is inconclusive; HEK 
293T cells were seeded in a 96-well plate at a density of 1 × 105 cells per ml and 
transiently transfected the following day with a reporter construct containing 40 ng of 
the PRIV promoter, 40 ng of TK Renilla, 50 ng of either empty pcDNA3.1 vector (EV) or 
(A) FLAG-tagged RIG-I or (B) FLAG-tagged MDA-5, and increasing concentrations of 
La, as indicated. Cells were assayed for reporter gene activity 18 hr post-transfection. 
Data shown is the combined average of four individual experiments, n=4, in all cases. 
Non-significant (ns, p>0.05) as determined by two-way ANOVA using GraphPad Prism. 
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Figure 3.10: RLR-driven PRDIII activity is significantly attenuated by La; 
HEK 293T cells were seeded in a 96-well plate at a density of 1 × 105 cells per ml and 
transiently transfected the following day with a reporter construct containing 40 ng of 
the PRDIII promoter, 40 ng of TK Renilla, 50 ng of either empty pcDNA3.1 vector (EV) 
or (A) FLAG-tagged RIG-I, (B) FLAG-tagged MDA-5 or (C) FLAG-tagged IPS-1, and 
increasing concentrations of La, as indicated. Cells were assayed for reporter gene 
activity 18 hr post-transfection. Data shown is the combined average of three 
individual experiments, n=3, in all cases. Non-significant (ns, p>0.05), **p< 0.01, 
***p<0.001 and ****p<0.0001 as determined by two-way ANOVA using GraphPad 
Prism 
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3.2.4 Inhibitory function of La is not affected by RNA pol III inhibition 
 As previously discussed, RNA pol III has been identified as a novel DNA 
detection system, which recognises dsDNA and processes this into the dsRNA 
format which is then recognised by RIG-I (Ablasser et al., 2009). Having 
identified the inhibitory role La plays in RIG-I mediated IFN induction, we next 
sought to investigate the potential role of RNA polymerase III in this. To this 
end, commercial RNA pol III inhibitor, ML-60218 (Calbiochem), was employed. 
HEK 293T cells were treated with either 4 µM (low dose) or 20 µM (high dose) 
of ML-60218 for 15 hr. Following this, cells were transiently transfected with 40 
ng of IFN-β promoter and co-transfected with 50 ng RIG-I along with increasing 
amounts (0, 10, 50 and 100 ng) of La.  As illustrated in Figure 3.11, 50 ng of 
RIG-I successfully drives the IFN-β promoter, with increasing La concentration 
significantly attenuating RIG-I-driven IFN-β induction, as expected. However, 
inhibition of the IFN-β promoter by La is unaffected by inhibition of RNA pol III, 
neither at low nor high dose. Together with results observed from previous 
reporter gene assays, this data suggests that the inhibitory effects of La on the 
RLR pathway are independent of RNA pol III.  
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Figure 3.11: La attenuation of IFN-β promoter activity is unaffected by RNA 
polymerase III inhibition; HEK 293T cells were seeded in a 96-well plate at a 
density of 1 × 105 cells per ml, treated with RNA polymerase III inhibitor, ML-60218, 
for 15 hr at concentrations of 4 µM or 20 µM, as indicated, and transiently transfected 
the following day with 40 ng IFN-β p125 promoter, 40 ng of TK Renilla, 50 ng RIG-I 
and increasing concentrations of La as indicated. Cells were assayed for reporter gene 
activity 18 hr post-transfection. Data shown is the combined average of two individual 
experiments, n=2. Non-significant (ns, p>0.05), as determined by two-way ANOVA 
using GraphPad Prism. 
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3.2.5 ShRNA knockdown of La leads to enhanced IFN-α and IFN-β 
mRNA expression in resting cells 
Having observed an RLR-specific role for La in IFN-β promoter activity using 
over-expression of La in luciferase analysis, we next wished to assess the effect 
of knockdown of the La protein on type I IFN levels. RNA interference (RNAi) is 
a natural process through which expression of a target gene can be knocked 
down with high specificity and selectivity. This process can be mediated 
through chemically synthesised small interfering RNA (siRNA) or vector-based 
short hairpin RNA (shRNA). As shRNA is processed in a very similar manner to 
micro RNA and is continuously synthesised by the host cell, it is more efficient 
(McAnuff et al., 2007; Siolas et al., 2005; Vlassov et al., 2007), more durable 
(Ohrt et al., 2006) and displays less off-target effects than siRNA. In addition, it 
is less likely to induce inflammation or IFN responses than siRNA, as it is 
endogenously spliced (Lee et al., 2005; Marques et al., 2006; Robbins et al., 
2006). For this reason, the shRNA method was chosen for our RNAi 
experiments. The mechanisms behind both siRNA and shRNA processing are 
very elegantly reviewed by Rao and colleagues (Rao et al., 2009). 
 Initial optimisation experiments were necessary in order to determine the 
most efficient concentration and transfection duration for depletion of protein 
expression. As such, 5 individual Mission® shRNA plasmids (Sigma) targeting 
various regions of the La sequence were tested alongside a control scrambled 
shRNA plasmid, which is based on a sequence common to C. Elegans and not 
specific for the human genome (CCT AAG GTT AAG TCG CCC TCG CTC GAG 
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CGA GGG CGA CTT AAC CTT AGG). As Figure 3.12A demonstrates, efficient La 
knockdown was only observed with one of the plasmids (termed “La 4”) and 
thus this plasmid was chosen for further optimisation. We initially tested 
concentration ranges from 50-250 ng of shRNA plasmid for durations of 24, 48 
and 72 hours, however no knockdown was observed. Partial knockdown of La 
was apparent with 250 ng of La 4 shRNA at 72 hours (Figure 3.12B). Testing 
increasing amounts of La-specific shRNA plasmid using real-time PCR and 
western blot analysis revealed a concentration of 500 ng of La 4 for a 
transfection time of 48 hours to be most effective in attenuating La expression 
in the HEK 293T cell line, at both mRNA and protein levels (Figure 3.12C-F). 
 Having established the optimal conditions for shRNA knockdown of La, 
we next analysed the effects of La depletion on the expression of type I IFNs, 
IFN-α and IFN-β. As such, HEK 293T cells were transfected with 500 ng of 
scrambled or La shRNA for 48 hours, following which RNA was extracted, 
reverse transcribed into cDNA and analysed by PCR using primers specific to 
IFN-β and IFN-α4. As Figure 3.13 demonstrates, when cells were depleted of 
La, gene expression levels of IFN-α and IFN-β were observed to be increased 
both qualitatively (Figure 3.13A) and, in the case of IFN-β, quantitatively 
(Figure 3.13B). This result further underlines a role for La in negative regulation 
of type I IFN levels in resting cells. 
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Figure 3.12: Optimisation of La shRNA; (A) HEK 293T cells were seeded at 5 × 
104 cells per ml, transfected with 500 ng of either La-specific (La1-La5) or scrambled 
shRNA plasmids (Sigma). Following 48 hr, cells were washed with PBS, RNA was 
extracted, cDNA was prepared and qualitative PCR was carried out for La and 18S (B) 
HEK 293T cells were seeded at 5 × 104 cells per ml and transfected with 50, 100 or 
250 ng of scrambled or La 4 shRNA. Following indicated time points, cells were washed 
with PBS, RNA was extracted, cDNA was prepared and qualitative PCR was carried out 
for La and 18S. (C) HEK 293T cells were seeded at 5 × 104 cells per ml and transfected 
with 500 ng of scrambled or La 4 shRNA. Following 48 hr, cells were washed with PBS, 
RNA was extracted, cDNA was prepared and qualitative PCR and (D) real-time PCR 
were carried out for La and 18S. (E) HEK 293T cells were seeded at 5 × 104 cells per 
ml and transfected with 500 ng of scrambled or La 4 shRNA. Following 48 hr, cells 
were washed, lysed in 5 × sample buffer supplemented with DTT (50 nM) and boiled 
at 95°C for 5 min. Samples “1” and “2” above represent two independent experiments 
assessed for indicated proteins on the same western blot. (F) Optical densitometry 
combined from n=4 of La protein levels normalised to α-actinin protein levels. *p<0.05 
as determined by unpaired t-test using GraphPad Prism.  
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Figure 3.13: shRNA knockdown of La increases IFN-α and IFN-β mRNA 
expression in resting cells; HEK 293T cells were seeded at 5 × 104 cells per ml, 
transfected with 500 ng of La-specific or scrambled shRNA. Following 48 hr, cells were 
washed with PBS, RNA was extracted and cDNA was prepared. (A) Qualitative PCR was 
carried out for IFN-α, IFN-β, La and 18S. Real-time PCR was carried out for (B) IFN-β 
and (C) La. Data from (A) is a representative of two individual experiments, n=2. Data 
from (B) and (C) are combined from two individual experiments, n=2, each repeated in 
triplicate. *p<0.05 as determined by unpaired t-test using GraphPad Prism 
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3.3 Discussion  
SLE is characterised by chronic inflammation driven by immune 
complexes against autoantigens such as Ro52, Ro60 and La. Both Ro52 and 
Ro60 have been shown to contribute to production of inflammatory cytokines 
and type I IFN by diverse mechanisms. La is a 48 kDa RNA-binding protein with 
a known role in binding and stabilising nascent RNA polymerase III (RNA pol 
III) transcripts. Due to the recently uncovered role for RNA pol III as a positive 
regulator of the IFN pathway, we hypothesised that La, like Ro52 and Ro60, 
may play an important role in regulating IFN production. Our findings identified 
La as an important IFN modulatory protein, which functions not only at RNA 
binding level, as previously reported, but also specifically within the RIG-I 
signalling pathway itself. Initial IFN-β promoter reporter gene assays suggested 
that La was mediating its effect on type I IFN regulation specifically at a point 
early on in the RIG-I pathway. Further studies demonstrated a role for La in the 
specific attenuation of PRDIII-I promoter activity, indicating that La is inhibiting 
the ability of IRF-3 and/or IRF-7 transcription factors to drive the IFN-β 
promoter downstream of RIG-I and MDA-5 activation. In confirmation of this, 
elevated IFN-α and IFN-β levels were observed following La knockdown in 
resting cells, compared with cells transfected with scrambled shRNA plasmid. In 
summary, this work demonstrates that La specifically inhibits RLR-driven IFN-β 
transcriptional induction in resting cells (summarised schematically in Figure 
3.14). 
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Figure 3.14: La negatively regulates RLR-induced IFN-β promoter activity 
in resting cells; Schematic showing the specific inhibition by La of RLR-driven type I 
IFN responses, with depletion of La resulting in enhanced IFN-α and IFN-β in resting 
cells. 
 
Both TLR-3 and RIG-I are crucial sensors of viral RNA, albeit at different 
sites in the cell. We observed that transfection of La into HeLa cells resulted in 
a potent inhibition of RIG-I- but not TLR-3-mediated IFN-β promoter activity, a 
finding which was strengthened by the enhanced basal IFN-β production 
observed following La knockdown. Interestingly, RNA pol III has been 
recognised as a novel DNA sensor, which feeds into the RIG-I pathway by 
transcribing dsDNA into a dsRNA agonist (Ablasser et al., 2009; Chiu et al., 
2009). In this respect, La had previously been shown to bind and stabilise RNA 
pol III transcripts (Chu et al., 1997; Fan et al., 1997; Goodier et al., 1997; 
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Goodier and Maraia, 1998; Gottlieb and Steitz, 1989a, b; Maraia, 1996; Maraia 
et al., 1994). Our observations, however, indicated that the inhibitory effect of 
La on RLR-mediated IFN-β induction was not affected by ML-60218 treatment, 
suggesting that La’s role in IFN regulation was independent of RNA pol III. 
While inhibition was not specifically confirmed, measurement of RNA pol III 
transcript RNA species, such as tRNA, hY RNA from RNP complexes and/or U6 
RNA, in the presence and absence of ML-60218 treatment would strengthen 
this finding and act as a positive control, whereas an MTT assay investigating 
cell toxicity would be an ideal control to show that the effects upon RNA pol III 
inhibition are not the result of cell death.  
 An intriguing and perhaps unexpected observation during our studies 
was the discrepancy seen between the inhibition of La on RIG-I-driven full 
length IFN-β promoter and the lack of effect on RIG-I driven PRDIII-I 
promoter. This was even more puzzling upon observation that MDA-5- and IPS-
1-driven PRDIII-I was potently inhibited by La overexpression. A detailed 
inspection of the IFN-β promoter using Mat Inspector software (Genomatix) 
identified a number of transcription factors such as IRF-1, IRF-4, AP-1, SMAD, 
STAT5b and STAT6 as potential binding sites within the IFN-β promoter 
sequence (demonstrated schematically in Figure 3.15). Potentially, La may be 
inhibiting activation of the full length IFN-β promoter by one or more of these 
transcription factors, thus helping to explain why we are seeing such a potent 
effect of La on RIG-I driven full-length IFN-β activity, with no significant effect 
on the PRDIII-I binding site.  For future studies, it would be worthwhile to carry 
out further reporter gene assays to investigate whether IRF-1-, IRF-4-, AP-1-, 
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SMAD- or STAT-driven IFN-β activity is negatively regulated by La and thus 
contributing to the IFN-β inhibition observed in this study. Alternatively, given 
the nucleic acid-binding nature of La, chromatin immunoprecipitation (ChIP) 
experiments investigating the potential of La to physically bind to the IFN-β 
promoter, thus possibly blocking transcription factor binding sites, would also 
be interesting.   
Figure 3.15: IFN-β promoter sequence showing potential binding sites 
inhibited by La; Full-length 1000 bp IFN-β promoter sequence with PRD 
enhanceosome (black & underlined), and other potential transcription factor binding 
sites. Numbers in brackets indicate the matrix similarity with a score of 1 defined as a 
perfect match (with each sequence position corresponding to the highest conserved 
nucleotide at that position in the matrix). Generally, scores >0.80 are considered good 
matches. 
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Potentially, in addition to ligand binding, La may also target RLR protein 
pathway members directly. Interestingly, other dsRNA-sequestering viral 
proteins have also been shown to function in directly targeting RLR signalling. 
The NS1 protein derived from influenza A virus, for example, inhibits IFN-β 
induction downstream of RIG-I, not only by RNA ligand sequestration, but also 
by direct binding to RIG-I (Mibayashi et al., 2007). The Marburg virus VP35 
protein is also capable of antagonising IFN production through direct targeting 
of kinases IKK-ε and TBK-1 (Ramanan et al., 2012). Thus La may have a similar 
role in the context of RLR-induced IFN-β production. As such, uncovering the 
precise molecular mechanism behind La-mediated IFN regulation downstream 
of the RLRs is essential.  
 Due to their ability to stimulate IFN production, both RNA and DNA 
species can potentially be pathogenic if not properly sequestered. It is possible 
that in resting or non-infected cells, La functions in binding and sequestration of 
host nascent RNA species, thereby shielding them from detection by PRRs and 
preventing aberrant activation of RIG-I-mediated type I IFN response 
(explaining increased type I IFN observed upon La depletion in resting cells), 
thus positively contributing to homeostasis of the immune system. Soon after 
La was shown to interact with a large variety of nascent RNAs, it emerged that 
La also binds to a number of viral encoded RNAs such as adenovirus-encoded 
VA RNA I and VA RNA II, leader RNA of negative strand viruses and EBV-
encoded EBER 1 & 2 RNA (Kurilla et al., 1984; Kurilla and Keene, 1983; Lerner 
et al., 1981; Wilusz and Keene, 1984; Wilusz et al., 1983). The functional 
consequence of this binding has recently come to light. Bitko and colleagues 
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showed La distribution from nucleus to cytoplasm following infection with 
respiratory synctcial virus (RSV) and demonstrated that only upon La 
knockdown, was viral RNA found to associate with RIG-I and induce IFN mRNA 
(Bitko et al., 2008). In further support of this manipulation by virus of La 
function, Chang and colleagues observed a direct interaction between La and 
Human Immunodeficiency Virus (HIV) leader RNA (Chang et al., 1994). In 
addition, Costa-Mattioli and colleagues demonstrated that La depletion results 
in a reduction in poliovirus internal ribosome entry site (IRES) function in vitro 
and in vivo (Costa-Mattioli et al., 2004). Domitrovich and colleagues also 
showed an essential requirement for La, as well as polypyrimidine tract-binding 
protein (PTB), for efficient Hepatitis C (HCV) viral replication (Domitrovich et al., 
2005). Finally, a recent study has shown that the La protein is capable of 
enhancing HIV release through lipid rafts mediated by the viral glyco-gag 
protein, gPr80gag (Nitta et al., 2011). Taken together, this suggests that La has 
a more complex role than originally appreciated in the context of IFN regulation 
and may, in fact, have a dual role in the context of infection, one which viruses 
aim to exploit in order to inhibit IFN production and aid viral replication.  
   
 
 
 
120 
 
 
 
 
 
 
Chapter 4:  
La and RIG-I interact to 
regulate IFN-β production – 
uncovering the molecular 
mechanism behind this 
interaction 
 
 
 
 
 
 
 4.1 Introduction
The RLRs (RIG-I, MDA
detect and mediate clearance of viral pathogens by responding to viral nucleic 
acids. As Figure 4.1 demonstrates, a
central DExD/H-box helicase domain, known t
At the N-terminus, both RIG
activation and recruitment domain
interactions with downstream
possesses no CARD domains 
terminal comprises
inactive state by interaction with bo
2008; Saito et al., 2007; Yoneyama et al., 2004)
Figure 4.1: Structure of RIG
terminal CARD domains in tandem (with the exception of LGP
domain, necessary for ligand binding and a C
rendering the receptor inactive through interactions with the CARD and helicase 
domains. 
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As RLRs are cytosolic receptors, it is essential that they avoid recognition 
of host RNA so as to prevent uncontrolled activation of the pathway in the 
absence of viral infection. As such, these receptors recognise distinct patterns 
specific to viral RNA.  The precise kind of RNA recognised by RIG-I is 
controversial, with at least six different ligands proposed; 5’ppp-ssRNA, 5’ppp-
dsRNA, 5’ppp-ssRNA with A/U rich 3’ ends, 300-2000bp dsRNA without 5’ppp,  
blunt-end dsRNA 23-30bp without 5’ppp and blunt-end dsRNA 23-30bp long 
with a 5’ monophosphate (Chiu et al., 2009; Cui et al., 2008; Hornung et al., 
2006; Kato et al., 2008; Kim et al., 2004; Pichlmair et al., 2006). Whilst the 
RIG-I ligand has caused much debate in the literature, the current view on 
MDA-5 activation is that long dsRNAs over 2kb, such as poly(I:C), are required 
to assemble in a web format to activate the receptor (Kato et al., 2008; 
Pichlmair et al., 2009). Through analysis of Rig-I-/- and Mda5-/- mice, RIG-I 
has been shown to be essential for IFN production in response to 
paramyxoviruses, flaviviruses and orthomyxoviruses, while MDA-5 is critical for 
picornavirus detection, as detailed in Table 4.1. It is probable that co-operation 
between RIG-I and MDA-5 has evolved in order to provide the infected host 
with optimum protection against invading viruses. 
   
123 
 
Table 4.1: Viruses recognised by RIG-I and MDA-5 receptors 
RIG-I MDA-5 RIG-I and MDA-5 
Rhabdoviridae: (-) ssRNA 
• Vesicular Stomatitis Virus 
(VSV) (Kato et al., 2005; 
Yoneyama et al., 2005)  
• Rabies Virus (RV) 
(Hornung et al., 2006) 
Paramyxoviridae; (-) ssRNA 
• Sendai Virus (SeV) (Kato 
et al., 2005; Yoneyama et 
al., 2005) 
• Newcastle Disease Virus 
(NDV) (Kato et al., 2005) 
• Respiratory Synctcial Virus 
(RSV) (Loo et al., 2008) 
• Measles Virus (MV) 
(Plumet et al., 2007) 
• Nipah Virus (NV) (Habjan 
et al., 2008) 
Orthomyxoviridae; (-) ssRNA 
• Influenza A Virus (Kato et 
al., 2006) 
• Influenza B Virus (Habjan 
et al., 2008)  
Filoviridae; (-) ssRNA 
• Ebola Virus (Habjan et al., 
2008) 
Flaviviridae; (+) ssRNA 
• Hepatitis C Virus (HCV) 
(Saito et al., 2007) 
• Japanese Encephalitis 
Virus (Kato et al., 2006) 
RNA derived from DNA 
viruses 
• Epstein Barr Virus (EBV) 
(Samanta et al., 2008) 
Picornaviridae; (+) ssRNA 
• Encephalomyocarditis 
Virus (EMCV) (Kato et al., 
2006) 
• Theiler’s Virus (Kato et 
al., 2006) 
• Mengovirus (Kato et al., 
2006) 
Calciviridae; (+) ssRNA 
• Murine norovirus-1 
(McCartney et al., 2008) 
Coronaviridae; (+) ssRNA 
• Murine Hepatitis Virus 
(Roth-Cross et al., 2008) 
 
Flaviviridae; (+) ssRNA 
• Dengue Virus (Loo et 
al., 2008) 
• West Nile Virus 
(Fredericksen et al., 
2008; Loo et al., 
2008)  
Reoviridae; dsRNA 
• Reovirus (Loo et al., 
2008) 
Arenaviridae; (-) ssRNA 
• Lymphocytic 
choriomeningitis virus 
(Zhou et al., 2010) 
 
 
Although RIG-I and MDA-5 recognise distinct viral ligands from different 
viral families, they share a common signal transduction pathway following 
activation. In healthy cells, RIG-I and MDA-5 exist in “closed” conformation, 
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whereby the CARD domains are masked. Upon recognition of ligand, an ATP-
dependant conformational change is triggered in the receptor allowing 
interaction between the second CARD domain of RIG-I/MDA-5 and the 
downstream mitochondrial-associated adaptor, IPS-1 (Kawai et al., 2005; 
Kumar et al., 2006; Meylan et al., 2005; Seth et al., 2005; Sun et al., 2006; Xu 
et al., 2005).  
Subsequent association of IPS-1 with individual members of the TRAF 
family is required to propagate the downstream signalling cascade. Within its 
proline-rich region, IPS-1 contains a TRAF interacting motif (TIM) enabling 
interaction with TRAF-3, vital for activation of IFN-β, as well as TRAF-6 and 
TRAF-2, necessary for NF-κB activation (Hacker et al., 2006; Oganesyan et al., 
2006; Saha et al., 2006; Xu et al., 2005). TRAF-3, in a complex together with 
NAP-1 (Sasai et al., 2005), SINTBAD (Ryzhakov and Randow, 2007) and/or 
TANK (Gatot et al., 2007; Guo and Cheng, 2007; Hemmi et al., 2004; Li et al., 
2002a; Perry et al., 2004) plays a role in assembly and activation of 
downstream IKK-related kinases, TBK-1 and IKK-ε, which in turn phosphorylate 
IRF-3 and IRF-7 (Fitzgerald et al., 2003; Hemmi et al., 2004; McWhirter et al., 
2004; Sharma et al., 2003). Activation of IRF-3 involves C-terminal 
phosphorylation at serines 385-386 as well as a serine/threonine cluster 
between amino acids 396 and 405 (Fitzgerald et al., 2003; Sharma et al., 2003) 
and induces a conformational change that promotes homo- and hetero-
dimerisation of IRF-3 and IRF-7, translocation to the nucleus and association 
with co-activator CBP/p300, thereby retaining the transcription factor in the 
nucleus for transcriptional induction of IFN-β, Rantes and other ISGs (Kumar et 
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al., 2000; Lin et al., 1999). TBK-1 and IKK-ε are also responsible for IRF-7 
activation phosphorylating C-terminal residues located between amino acids 
471 and 487 (Lin et al., 2000). The synergistic activity of the IRF-3 and IRF-7 
transcription factors is crucial for the efficient early response to viral infection. 
Regarding NF-κB activation, the interaction of IPS-1 with TRAF-6 
transmits a signal, again via TANK, to the IKK complex comprising scaffold 
protein IKK-γ (NEMO), IKK-α and IKK-β, resulting in phosphorylation of IκB and 
downstream activation and translocation to the nucleus of NF-κB (Chariot et al., 
2002; Karin and Ben-Neriah, 2000). Fas-associated death domain (FADD) and 
receptor interacting protein 1 (RIP1) also associate with the IPS-1/RIG-I 
signalling complex, activating the NF-κB side of the pathway (Balachandran et 
al., 2004; Takahashi et al., 2006), while TNFR-associated DD (TRADD) 
complexes with IPS-1, TRAF3 and TANK to activate both NF-κB and IRF-3 
(Michallet et al., 2008). 
 
 Figure 4.2: RIG-I like receptor (RLR) Signalling Pathway; 
mediate their anti-viral response by interaction with IPS
to two distinct pathways involving the recruitment of TRAF
type I IFN, and TRAF
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al., 2009; Oshiumi et al., 2009). In addition, mind bomb 1 and 2 (MIB1/2) and 
Nrdp1 activate TBK-1 by promoting its TRAF3-mediated K63-linked 
polyubiquitination (Li et al., 2011). On the other hand, ubiquitination can also 
negatively regulate the pathway. For example, K48-linked ubiquitination by 
RNF125 within the CARD domains of RIG-I, MDA-5 and IPS-1, targets the 
proteins for proteasomal degradation (Arimoto et al., 2007). Similarly, IPS-1 is 
targeted for degradation by RNF5-mediated K-48 linked ubiquitination at K362 
and K461 following SeV infection (Zhong et al., 2010). In addition, de-
ubiquitinases (DUBs) play an important role in RLR regulation. For example, 
cylindromatosis (CYLD) removes K63-linked poly-ubiquitin from RIG-I, IPS-1 
and TBK-1, thereby limiting IFN induction (Friedman et al., 2008; Kayagaki et 
al., 2007; Zhang et al., 2008). Downstream of RIG-I, many other E3 ligases 
play a role in fine tuning the RLR response (Byrne et al., 2012; Eisenacher and 
Krug, 2012). 
 Phosphorylation is another well-established mechanism in the regulation 
of the RLR signalling pathway. Sun and colleagues demonstrated that casein 
kinase (CK2) phosphorylation of RIG-I at threonine 770 and serine 854 inhibits 
the anti-viral response, with dephosphorylation resulting in activation of RIG-I 
(Sun et al., 2011). Gack and colleagues revealed that the molecular mechanism 
behind this inhibition was due to the fact that phosphorylation at threonine 170 
suppresses TRIM 25-mediated ubiquitination, thus rendering RIG-I latent and 
incapable of interaction with IPS-1 (Gack et al., 2010). Nistal-Villán and 
colleagues also showed that serine 8 phosphorylation of RIG-I negatively 
regulates IFN-β production (Nistal-Villán et al., 2010). These studies clearly 
 demonstrate that for RIG
regulator of its activity (Figure 4.3). 
components on the pathway such as tyrosine kinase, c
IPS-1, TBK-1 and TRAF3 in order to enhance IFN induction
2009) and c-Abl, which interacts with and phosphorylates IPS
infection to facilitate propagation of the signal and activation of downstream 
transcription factors, IRF
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Figure 4.3: Regulation of RIG
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that La is capable of directly inhibiting the IFN response within the RLR 
signalling pathway in the absence of viral RNA ligand, indicating that La may 
have a more complex role than initially appreciated in the context of IFN 
regulation. Given that a number of viral dsRNA-sequestering proteins such as 
NS1 and VP35 have been reported to directly target RLR signalling (Mibayashi 
et al., 2007; Ramanan et al., 2012), along with our results demonstrating that 
La was acting independently of RNA pol III and at a point above TBK-1 in the 
RLR pathway, we hypothesised that La may potentially be inhibiting IFN-
β induction not only by RNA sequestration, but also by direct effects on RIG-I or 
RLR signalling proteins.  
Aims: 
• To investigate potential interactions between La and protein members of 
the RLR pathway. 
• To assess the effect of La on localisation and interactions between RLR 
pathway proteins both basally and post-RIG-I stimulation.  
• To determine the functional significance of these interactions. 
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4.2 Results 
4.2.1 La interacts with RIG-I, but not with MDA-5 or LGP-2 
Having determined that La inhibits RIG-I- and MDA-5-induced activation 
of the IFN-β promoter, we first wanted to ascertain whether these effects were 
due to direct physical interaction between La and either RIG-I and/or MDA-5. 
Endogenous La was immunoprecipitated from lysates prepared from HEK 293T 
cells over-expressing RIG-I-flag or empty vector (EV) as a control. As illustrated 
in Figure 4.4A, an interaction was observed between La and RIG-I in cells over-
expressing RIG-I-flag, which was not observed in the rabbit IgG control, nor in 
the lanes transfected with empty vector alone. Having shown that La and RIG-I 
interacted in an overexpression system, the interaction was confirmed in 
unstimulated HeLa cells, where endogenous La was observed to interact with 
endogenous RIG-I following co-immunoprecipitation using an antibody against 
La (Figure 4.4B). In both cases, immunoprecipitation of La from the lysates was 
confirmed by western blotting (lower panels, Figure 4.4A and B).  
 Given that an interaction was observed between La and RIG-I and 
considering the inhibitory effect of La was observed following MDA-5-driven as 
well as RIG-I-driven IFN-β activity (Figure 3.3), we subsequently assessed 
whether La could also interact with MDA-5. As before, endogenous La was 
immunoprecipitated from lysates prepared from HEK 293T cells over-expressing 
MDA-5 or empty vector (EV) as a control. As illustrated in Figure 4.5, no 
interaction between La and MDA-5 was detected, despite successful expression 
of MDA-5 and efficient immunoprecipitation of La (Figure 4.5, lower panel). 
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TRAF-3, a downstream E3 ligase important for signal transduction, also failed to 
interact with La (Figure 4.5, lanes 4 and 9 show immunoprecipitation and 
lysates, respectively). Unsurprisingly, an interaction between La and inhibitory 
RLR, LGP-2, was not apparent (Figure 4.5, lanes 3 and 8 show 
immunoprecipitation and lysates, respectively). An interaction between La and 
RIG-I was observed at high exposure and thus acted as a positive control for 
this experiment (data not shown). This indicates that La interacts specifically 
with RIG-I and not other members of the RLR family or proteins further 
downstream in the pathway.  
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Figure 4.4: La interacts with RIG-I;  (A) HEK 293T or (B) HeLa cells were seeded 
at 2.5 × 105 cells per ml. HEK 293T cells were transfected for 18 hr with empty vector 
(EV) or FLAG-tagged RIG-I, as indicated. In both cases, cells were then washed, lysed 
and immunoprecipitated with Protein A sepharose beads pre-coupled to either La or 
rabbit IgG control antibody, as indicated. Samples were then boiled in 5 × SDS buffer 
with 50nM DTT at 95°C for 5 min and analysed by western blotting. (A) Blots are a 
representative of five individual experiments, n=5. (B) Blot is representative of single 
experiment, n=1. 
  
 
 
 Figure 4.5: La does not interact with RLR family members MDA
HEK 293T were seeded at 2.5 × 10
empty vector (EV), FLAG
(T3), as indicated. Cells were then washed, lysed and immunoprecipitated with Protein 
G sepharose beads pre
antibody, as indicated. Samples we
95°C for 5 min and analysed by western blotting. Blots are a representative of two 
individual experiments, n=2.
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4.2.2 N-terminal of La and CARD domains of RIG-I are sufficient for 
interaction 
RIG-I binds its cognate ligand, 5’ppp-dsRNA, via its helicase domain and 
associates with its downstream adaptor protein, IPS-1, via its CARD domains. 
For La, the N-terminal La motif and central RRM are important for RNA-binding 
activity, with the C-terminal domains important for cellular localisation. Thus in 
an effort to further dissect the functional significance of the RIG-I/La 
association, our next step was to map the domains necessary for the interaction 
to take place. As such, either full-length or N-terminal only His-tagged 
recombinant La was incubated with lysates from HEK 293T cells over-
expressing full-length RIG-I, the CARD domain-only of RIG-I or the helicase 
domain-only of RIG-I. Potential interactions were then studied by SDS-PAGE 
and western blot analysis. As Figure 4.6A demonstrates, an interaction is 
observed between full-length La and full-length RIG-I, as expected, but also 
with the mutant form of RIG-I expressing only the CARD domains of RIG-I. No 
interaction is observed with helicase-only mutant of RIG-I. This indicates that 
the activatory CARDs (spanning AA 1-284) of RIG-I are necessary and sufficient 
for the interaction between La and RIG-I to occur.   A similar experiment was 
then performed with N-terminal-only recombinant La (Figure 4.6B), and 
virtually identical results were observed, with the N-terminal domain of La 
sufficient to mediate interaction with the CARD domains of RIG-I. Attempts 
were then made at pin-pointing the exact domain in the N-terminal of La that 
acted as the RIG-I binding site. Specifically, plasmids encoding various La 
truncation mutants, encompassing amino acids 1-103, 1-194, 105-202 and 105-
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334, were obtained. However due to persistent problems inducing protein 
expression from the pET vectors, these experiments were unsuccessful.  
Regardless it appears the N-terminal RNA-binding domain of La, specifically AA 
1-202, is sufficient for binding to the CARD domains of RIG-I. 
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Figure 4.6: N-terminal of La interacts with CARD domain RIG-I; HEK 293T 
were seeded at 2.5 × 105 cells per ml. HEK 293T cells were transfected for 18 hr with 
2 µg empty vector (EV), FLAG-tagged RIG-I, FLAG-tagged RIG-I-CARD, or FLAG-
tagged RIG-I-Helicase (Heli), as indicated. In both cases, cells were then washed, 
lysed and a pull-down was carried out with Nickel agarose coupled to either (A) wild-
type or (B) N-terminal only mutant recombinant La (Mu-La), as indicated. Samples 
were then boiled in 5 × SDS buffer with 50 nM DTT at 95°C for 5 min and analysed by 
western blotting. Blots are a representative of three individual experiments, n=3. 
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4.2.3 La interaction with RIG-I is inhibited by IPS-1 
Having mapped La binding to the CARD domain of RIG-I, the same domain 
required for downstream association with IPS-1 and hence induction of the 
signalling pathway leading to type I IFN production, our next goal was to 
assess whether La might compete with IPS-1 for interaction with RIG-I. To this 
end, endogenous La was immunoprecipitated from HEK 293T cell lysates over-
expressing FLAG-tagged RIG-I in the presence and absence of over-expressed 
FLAG-tagged IPS-1. Indeed, as Figure 4.7 shows, upon overexpression of IPS-1, 
the ability of La to interact with RIG-I was completely inhibited. Importantly, 
Figure 4.7 also showed that no direct interaction between La and IPS-1 occurs. 
This suggests that the observed inhibitory effect of La on the IFN-β promoter 
activity (Figure 3.2) may potentially be caused by La competing with IPS-1 for 
RIG-I binding, thus preventing the signal transduction. In order to conclusively 
demonstrate this, a reciprocal co-immunoprecipitation experiment was 
attempted, where RIG-I was immunoprecipitated from cells and the ability of 
IPS-1 to bind in the presence of La investigated by western immunoblotting. 
Unfortunately, due to the poor expression of endogenous RIG-I in this cell line 
and hence an inability to immunoprecipitate sufficient amounts of RIG-I, this 
experiment was not possible, despite numerous attempts. As both IPS-1 and 
RIG-I shared the same tag it was impossible to perform this experiment via 
immunoprecipitation of either tagged-construct. Due to time constraints, sub-
cloning of either plasmid into another tagged vector was not considered.  
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Figure 4.7: La interaction with RIG-I is inhibited by IPS-1; (A) HEK 293T cells 
were seeded at 2.5 × 105 cells per ml. Cells were transfected for 18 hr with 2 µg FLAG-
tagged RIG-I, 2 µg FLAG-tagged IPS-1 or 2 µg FLAG-tagged RIG-I with 2 µg FLAG-
tagged IPS-1, as indicated. Cells were then washed, lysed and immunoprecipitated 
with Protein A sepharose beads pre-coupled to either La or rabbit IgG control antibody, 
as indicated. Samples were then boiled in 5 × SDS buffer with 50 nM DTT at 95°C for 
5 min and analysed by western blotting. (B) A proportion of the cell lysates was 
retained and analysed by western blotting for RIG-I and IPS-1 expression, as indicated. 
Blots are a representative of three individual experiments, n=3. 
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4.2.4 La inhibits IPS-1 binding to TRAF-3 
Given that La competed with IPS-1 binding to RIG-I, we next wanted to assess 
whether La consequently had any effect on the formation of the IPS-1-TRAF3 
signalling complex. HEK 293T cells were thus co-transfected with IPS-1 and 
TRAF-3 in the presence or absence of La, IPS-1 was immunoprecipitated from 
cell lysates and potential interactions were assessed by western blotting. As 
Figure 4.8 shows, an interaction is observed between TRAF-3 and IPS-1 upon 
overexpression of both proteins, as expected. However, upon over-expression 
of La, this interaction is disrupted, suggesting that La may be interfering with 
RIG-I-mediated signal transduction, not only by directly binding the RIG-I 
receptor and competing with IPS-1 for RIG-I binding, but also by blocking 
signal propagation at the IPS-1/TRAF-3 interface. Interestingly, we noticed that 
co-transfection of La resulted in decreased IPS-1 precipitation from cell lysates. 
It could be argued that this is merely a result of variable pull-down, however 
this was consistently observed with each repeat experiment and further analysis 
demonstrated that IPS-1 expression was completely abrogated as La 
concentration increased (Figure 4.9), indicating a role for La in regulating IPS-1 
stability and perhaps partially explaining why IPS-1 association with TRAF-3 is 
decreased in the presence of La.  
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Figure 4.8: La disrupts IPS-1 binding to TRAF-3; (A) HEK 293T cells were seeded 
at 2.5 × 105 cells per ml. Cells were transfected for 18 hr with 3 µg empty vector (EV), 
and 1 µg FLAG-tagged IPS-1, FLAG-tagged TRAF-3 or FLAG-tagged La, as indicated. 
Cells were then washed, lysed and immunoprecipitated with Protein G sepharose beads 
pre-coupled to either 2 µg monoclonal IPS-1 or mouse IgG control antibody, as 
indicated. Samples were then boiled in 5 × SDS buffer with 50 nM DTT at 95°C for 5 
min and analysed by western blotting. (B) A proportion of the cell lysates was retained 
and analysed by western blotting for TRAF-3, IPS-1 and La expression as indicated. 
Blots are a representative of three individual experiments, n=3. 
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Figure 4.9: La abrogates IPS-1 expression; HEK 293T cells were seeded at 2.5 × 
105 cells per ml. Cells were transfected for 18 hr with 2 µg empty vector, 1 µg FLAG-
tagged IPS-1 and increasing FLAG-tagged La from 250 ng to 1 µg, as indicated. Cells 
were then washed, lysed, boiled in 5 × SDS buffer with 50 nM DTT at 95°C for 5 min 
and analysed by western blotting. Blots are a representative of three individual 
experiments, n=3. 
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4.2.5 La interaction with RIG-I is inducible following stimulation 
Having tested the association between La and RIG-I in resting cells and in the 
absence of any cognate ligand to RIG-I, we next wanted to test the effect of La 
on RIG-I signalling in the presence of RIG-I ligand. Having determined that La 
interacts specifically with the CARD domain of RIG-I, and demonstrated that La 
over-expression appeared to disrupt the ability of RIG-I and IPS-1/TRAF-3 to 
interact, we wished to investigate how ligand binding to RIG-I affected the 
interaction between La and RIG-I. As such, HEK 293T cells were transiently 
transfected with RIG-I-flag or EV control. 18 hours post-transfection, cells were 
stimulated for 1, 3 or 6 hours with 1 µg 5’ppp-dsRNA prior to cell lysis, co-
immunoprecipitation and subsequent analysis by western blotting. As Figure 
4.10 shows, the interaction between La and RIG-I appears to be induced by 
activation of RIG-I. The inducible nature of the association between these 
proteins was confirmed using confocal microscopy. HeLa cells were transfected 
with GFP-tagged La and flag-tagged RIG-I and stimulated for 6 hours with 1 µg 
5’ppp-dsRNA. Cells were then washed, fixed, permeabilised, stained and 
imaged using the LSM 510 confocal microscope. Figure 4.11 demonstrates La 
translocation from the nucleus to the cytoplasm following stimulation of RIG-I, 
a result which fits with previous studies showing a shift of La from nucleus to 
cytoplasm following viral infection (Costa-Mattioli et al., 2004; Domitrovich et 
al., 2005; Meerovitch et al., 1993). A novel co-localisation of La with RIG-I was 
also apparent following 6 hours stimulation. These experiments collectively 
suggest that RIG-I interacts with La in an inducible manner and that, most 
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likely, RIG-I binds preferentially to La when it is active and in an “open” 
conformation whereby the CARD domains are exposed and free to interact.  
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Figure 4.10: La interaction with RIG-I is inducible by 5’ppp-dsRNA 
stimulation; HEK 293T cells were seeded at 2.5 × 105 cells per ml. Cells were 
transfected for 18 hr with 2 µg empty vector (EV) or 2 µg FLAG-tagged RIG-I. Cells 
were stimulated for 1, 3, or 6 hours with 1 µg 5’ppp-dsRNA (Invivogen). Cells were 
then washed, lysed and immunoprecipitated with Protein G sepharose beads pre-
coupled to either monoclonal La antibody (SW-5) or mouse IgG control antibody, as 
indicated. Samples were then boiled in 5 × SDS buffer with 50 nM DTT at 95°C for 5 
min and analysed by Western blotting. Lanes 7-11 show corresponding lysates for this 
experiment as indicated. Blots are a representative of three individual experiments, 
n=3. 
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Figure 4.11: La and RIG-I co-localise following 5’ppp-dsRNA stimulation; 
HeLa cells were seeded at 1 × 105 cells/ml in 6-well plates onto UV-irradiated 
coverslips.  Cells were then transfected with 2 µg of GFP-tagged La and 2 µg FLAG-
tagged RIG-I for 24 hr. Cells were stimulated with 1µg 5’ppp-dsRNA for 6 hr, before 
fixation with 4% paraformaldehyde, permeabilisation with 0.2% Triton-X and staining 
with α-flag and fluorescently labelled anti-mouse secondary antibody (Alexa 
Fluor®546). Cells were mounted onto glass slides using DAPI ProLong Gold mounting 
media and images were captured under 40 × magnification using the Zeiss LSM 510 
confocal microscope. Images are representative of an individual experiment which was 
repeated twice.  
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4.2.6 La enhances RIG-I binding to RNA ligand 
As the RNA-binding domain of La was required for RIG-I binding, we next 
wished to investigate the effect of La overexpression on the RIG-I interaction 
with RNA. As such, HEK 293T cells were transfected with FLAG-tagged RIG-I 
and increasing concentrations of La from 0-2 µg. Cell lysates were incubated 
with 1 µg biotin-labelled poly(I:C), coupled to NeutrAvidin beads (Pierce), 
poly(I:C)-binding proteins were isolated from cells following pull-down with the 
poly(I:C) beads and potential interactors were analysed by western blot 
analysis. Previous reports have shown that in the context of viral infection, RIG-
I is only capable of RNA interaction upon depletion of La (Bitko et al., 2008). 
However in our hands, we observed a steady enhancement of the ability of 
RIG-I to bind poly(I:C) with increasing La concentrations (Figure 4.12). Thus, 
contrary to our observation in resting cells where La negatively regulates RIG-I 
activity, this result indicates a potential role for La in positive regulation of RIG-I 
signalling following RIG-I activation with RNA ligand.  
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Figure 4.12: La enhances binding of RIG-I to Poly(I:C); HEK 293T cells were 
seeded at 2.5 × 105 cells/ml, transfected the following day with 4 µg empty vector 
(EV) or 2 µg FLAG-tagged RIG-I with increasing FLAG-tagged La, as indicated, for 18 
hr. Cells were then washed, lysed in RIP buffer and incubated with 1 µg of biotin-
labelled poly(I:C) coupled to NeutrAvidin beads. Samples were then boiled in 5 × SDS 
buffer with 50 nM DTT at 95°C for 5 min and analysed by western blotting. A 
proportion of the cell lysates was retained and analysed by western blotting for RIG-I 
and La expression, as indicated. Blots are a representative of three individual 
experiments, n=3. 
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4.2.7 La potentially enters a complex with RIG-I and IPS-1 following 
stimulation 
Having observed the La interaction with RIG-I to be inducible and potentially 
part of a complex necessary for RNA recognition and RIG-I pathway activation, 
we next aimed to elucidate the temporal pattern of La binding, compared with 
that of IPS-1, to RIG-I following stimulation with RNA agonist. To this end, 
HeLa cells were stimulated with 1 µg 5’ppp-dsRNA over a time course from 0 to 
6 hours, endogenous RIG-I was immunoprecipitated from cell lysates and 
potential La and IPS-1 interactions were detected by western blotting. HeLa 
cells were chosen for this experiment due to their relatively high expression of 
RIG-I, IPS-1 and La (as shown in Figure 4.13B). As demonstrated in Figure 
4.13, IPS-1 interacts with RIG-I most intensely following 15-30 min stimulation 
with a decrease in interaction observed as the time course progresses, as 
expected. Intriguingly, La appears to also be bound to RIG-I most intensely at 
15 and 30 minutes post-stimulation, a pattern analogous to IPS-1 binding. La 
also displays increased binding to RIG-I at 3 and 6 hours, a result which agrees 
with our previous observations. This pattern of binding was confirmed by 
densitometric analysis. Interestingly, across all the replicate experiments 
conducted, we observed that the ability of our antibody to RIG-I to 
immunoprecipitate RIG-I from the cells increased following stimulation with 
ligand. One possible suggestion for this was that ligand binding and hence 
induction of a conformational change in RIG-I, revealed the epitope for the 
antibody more effectively so that RIG-I was more efficiently isolated.  Attempts 
to confirm our observations by confocal microscopy were unsuccessful however, 
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due to the fact that the IPS-1 antibody was not of sufficient quality for use in 
immunofluorescence. Our results however suggest that La appears to complex 
with RIG-I and IPS-1 shortly after dsRNA detection by RIG-I. This finding 
supports our previously observed enhancement by La of RIG-I/RNA binding and 
suggests that stimulation may result in a switch in La function towards a role in 
enhancement of RIG-I-mediated signalling. 
 
 
 
 
 
 
 
 
 Figure 4.13: La and IPS
stimulation; (A) HeLa cells were seeded at 2 × 10
cells were stimulated at indicated time points with 1 µg 5’ppp
before washing, lysis and immunoprecipitation with Protein G sepharose beads pre
coupled to RIG-I antibody, as indicated. Samples were then b
with 50 nM DTT at 95°C for 5 min and analysed by western blotting. (B) A proportion 
of the cell lysates was retained and analysed by western blotting for RIG
La expression as indicated. Blots are a representative of two
n=2. 
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4.2.8 La enhances IPS-1 binding to TRAF-3 following 5’ppp-dsRNA 
stimulation 
In our earlier overexpression studies, we observed that La inhibited IPS-1 
interaction with TRAF-3 in resting cells (Figure 4.8). In an attempt to elucidate 
whether La affected the complex formed between IPS-1 and TRAF-3 following 
RNA stimulation, HEK 293T cells were transfected with IPS-1 and TRAF-3 and 
stimulated with 1 µg 5’ppp-dsRNA for 1, 3 and 6 hour time points in the 
presence or absence of La. IPS-1 was immunoprecipitated from cell lysates and 
potential interactions between IPS-1 and TRAF-3 were determined by 
subsequent western blot analysis. As Figure 4.14 shows, an interaction is 
observed between TRAF-3 and IPS-1 upon overexpression of both proteins in 
resting cells and this association is robustly increased following 1 hour 5’ppp-
dsRNA stimulation before returning to basal interaction again after 6 hours 
stimulation, as expected. Upon co-transfection of 1 µg La, this interaction 
seems to be slightly decreased in resting cells, as previously shown (Figure 
4.14A, lanes 2 and 6). However, following stimulation with 5’ppp-dsRNA, La 
seems to both enhance and prolong the IPS-1/TRAF-3 interaction, as a small 
but reproducible increase in the association between the two proteins was 
observed at 1 hour post-stimulation (Figure 4.14A, lanes 3 and 7), with a more 
noticeable increase in association observed 3 hours post-stimulation in the 
presence of La (Figure 4.14A, lanes 4 and 8, Figure 4.14C). In an attempt to 
overcome the variability in IPS-1 immunoprecipitation across the time course 
(which incidentally was observed in all experiments), visualising IPS-1 co-
localisation with TRAF-3 in the presence and absence of La using confocal 
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microscopy was also attempted. However, poor quality images as a result of 
non-specific staining of antibodies meant that results were inconclusive. 
Nonetheless, coupled with previous observations, it appears that whilst La may 
be acting to inhibit RIG-I function in resting cells by promoting complex 
dissociation, our results indicate that in the presence of RIG-I ligand, not only 
does La enhance RIG-I association with its ligand but it also enhances and 
prolongs the formation of the signalling complex containing IPS-1 and TRAF3, 
thus positively effecting RIG-I-dependent pathways.  
 
 
 Figure 4.14: La enhances IPS
293T cells were seeded at 2.5 × 10
3 µg empty vector (EV)
FLAG-tagged La and stimulated with 1 µg 5’ppp
were then washed, lysed and immunoprecipitated with Protein G sepharose beads pre
coupled to either 2 µg monoclonal
Samples were then boiled in 5 
analysed by western blotting. (B) 
analysed by western blotting for TRAF
Optical densitometry showing TRAF
representative of two individual experiments, n=2.
 
 
 
153 
-1 binding to TRAF-3 post-stimulation;
5 cells per ml. Cells were transfected for 18 hr
, and 1 µg FLAG-tagged IPS-1, FLAG-tagged TRAF
-dsRNA (Invivogen), as indicated. Cells 
 IPS-1 or mouse IgG control antibody, as indicated. 
× SDS buffer with 50 nM DTT at 95°C for 5 min and 
A proportion of the cell lysates was retained and 
-3, IPS-1 and La expression as indicated. (C) 
-3 normalised to IPS-1. Blots and graph are a 
 
 
 (A) HEK 
 with 
-3 and/or 
-
154 
 
4.2.9 La enhances IFN-β promoter activity upon stimulation with 
5’ppp-dsRNA agonist 
As a pattern was emerging whereby La differentially functions in the presence 
and absence of RIG-I ligand, we wished to assess the effect of 5’ppp-dsRNA 
stimulation on RIG-I-mediated induction of the IFN-β promoter. To this end, a 
luciferase assay was carried out on the full-length IFN-β promoter, following 
shRNA knockdown of La. Intriguingly, while RIG-I robustly drove the promoter 
as expected, no significant effect was observed following La knockdown. 
Unsurprisingly, due to the lack of basal RIG-I expression in the HEK 293T cell 
line, 5’ppp-dsRNA alone was unable to induce a response.  Upon stimulation of 
over-expressed RIG-I with 5’ppp-dsRNA, an increase in IFN-β promoter activity 
was observed, as compared with RIG-I-driven response alone, with La 
knockdown resulting in significant attenuation of this response (Figure 4.15A). 
Successful knockdown of La is shown in Figure 4.15B.  This finding adds further 
evidence to our observations that La plays a role in enhancement of RIG-I-
driven type I IFN induction upon recognition of viral RNA. 
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Figure 4.15: shRNA knockdown of La results in decreased IFN-β response to 
5’ppp-dsRNA stimulation; HEK 293T cells were seeded in a 12-well plate at a 
density of 5 × 104 cells per ml and transfected the following day with 500 ng scrambled 
or La shRNA, as indicated. Following a change of media and a period of 4 hr 
incubation, cells were transiently transfected with a reporter construct containing 250 
ng IFN-β p125 promoter, 250 ng of TK Renilla, 500 ng of either empty vector (EV) or 
RIG-I, and 500 ng 5’ppp-dsRNA (Invivogen). Cells were assayed for reporter gene 
activity 18 hr post-transfection. Data shown are combined from three individual 
experiments, n=3, each carried out in triplicate.  ****p<0.0001 as determined by two-
way ANOVA using GraphPad Prism. (B) A proportion of the cell lysates was retained 
and analysed by western blotting for La and α-actinin expression, as indicated. Blots 
are  representative of three individual experiments, n=3. 
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4.3 Discussion: 
The RLR signalling pathway leads to a robust anti-viral response which results 
in clearance of viral pathogens. In the absence of viral infection however, this 
pathway must be very tightly controlled in order to prevent inappropriate 
activation, avoid excessive cytokine production and ultimately maintain 
homeostasis. Having previously identified La as a negative regulator of RLR-
mediated IFN induction in resting cells, this chapter aimed to assess its precise 
molecular mechanism of action. Our findings demonstrate that La directly and 
specifically binds RIG-I and that the N-terminal domain of La and CARD domain 
of RIG-I are critical for interaction. In addition, disruption by La of the IPS-
1/TRAF-3 complex assembly at the mitochondria was observed. These results 
indicate that in resting cells, the role of La may be to ensure that the RIG-I 
pathway does not become hyper-activated, thereby maintaining innate immune 
balance. 
 Intriguingly, subsequent studies revealed a more complex role for La 
than a simple negative regulator of type I IFN downstream of RIG-I. Upon 
activation of RIG-I, La appears to promote anti-viral responses by enhancing 
and prolonging RIG-I-IPS-I-TRAF-3 complex formation. In addition, 
overexpression of La enhanced RIG-I binding to poly(I:C), the overall 
consequence of which was increased IFN induction. Hence, a dual role exists 
for La in the context of RIG-I-mediated type I IFN production, with the protein 
capable of both inhibition in resting cells, most likely in an attempt to prevent 
inappropriate IFN induction, and enhancement in stimulated cells, in an effort 
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to protect the host by limiting viral replication and promoting the clearance of 
the pathogen (Figure 4.16). 
 
Figure 4.16: La plays a dual role in RIG-I-mediated IFN induction; (A) 
In resting cells, La binding to RIG-I is inhibited by overexpression of IPS-1. 
Overexpression of La results in attenuation of IPS-1 binding to TRAF-3 contributing to 
reduced type I IFN induction. (B) Upon stimulation of the RIG-I receptor, La binds to 
and enhances RIG-I-RNA complex formation. Further downstream La promotes signal 
propagation by increasing complex formation between RIG-I and IPS-1 and between 
IPS-1 and TRAF-3, ultimately culminating in upregulation of IFN induction. 
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The RLR pathway is crucial in mediating both IFN and pro-inflammatory 
production, yet it is important that it is extremely tightly regulated in order to 
maintain homeostasis. For this reason, the expression and/or activity of virtually 
all individual mediators of this pathway are strictly controlled by processes such 
as phosphorylation and ubiquitination, as previously discussed. Our findings 
demonstrated that La disrupted complex formation between IPS-1 and TRAF-3 
in resting cells. Interestingly, disruption of complex formation has been 
reported to be an important mechanism in controlling RLR signalling. For 
example, MIP-T3 (intra-flagellar transport subcomplex B component) binds 
specifically to TRAF-3, impeding the formation of functional complexes with 
IPS-1, TBK-1, IKK-ε and IRF-3 and thereby terminating IFN-β production (Ling 
and Goeddel, 2000; Ng et al., 2011). In addition, suppressor of IKK-ε (SIKE) 
sequesters TBK-1/IKK-ε in an inactive state by interaction with TBK-1 in resting 
cells but upon TLR-3 stimulation or viral infection, SIKE dissociates from TBK-1, 
thereby releasing the protein and enabling IFN induction (Huang et al., 2005). 
Furthermore, ISG56 inhibits anti-viral responses by disruption of the IPS-1-
STING-TBK-1 complex (Li et al., 2009). Ubiquitination is another common 
negative regulator of RLR signalling. For example, E3 ligases RNF125, RNF5 and 
Triad3A target RIG-I, MDA-5, IPS-1 and TRAF-3 (respectively) for K48-linked 
ubiquitination and proteasomal degradation. Indeed, K48-linked ubiquitination 
may also play a role in the La-mediated disruption of IPS-1/TRAF-3 complex 
formation, considering the apparent decreased IPS-1 expression observed upon 
La overexpression. Further studies into the ubiquitination status of IPS-1 in the 
presence and absence of La may provide further insight into this. Thus, along 
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with a host of other key players in negative regulation of RLR signalling, it 
appears that La is an additional protein that functions in keeping RLR proteins 
in an inactive state in resting cells thereby maintaining homeostatic balance and 
preventing inappropriate activation of these pathways and hence protecting 
against autoimmunity.  
While we have demonstrated a molecular mechanism by which La 
mediates its IFN-modulatory effects within the RIG-I pathway, the observation 
that MDA-5-driven IFN-β was also inhibited by La, despite the lack of physical 
interaction between the proteins, suggests that La may negatively regulate RLR 
signalling via additional mechanisms. La has been recently shown to globally 
upregulate microRNAs (miRs) by binding to and stabilising pre-miRs (Liang et 
al., 2013). A role for miRs in regulating type I IFN production is starting to 
emerge in the literature. For example, miR-146a, induced following VSV 
infection, functions in inhibiting type I IFN production by targeting key 
mediators on the pathway such as IRAK1, IRAK2 and TRAF6 (Hou et al., 2009). 
In addition, miR-466l has been demonstrated to bind the 3’UTR of IFN-α thus 
decreasing its expression post-infection (Li et al., 2012). Thus it is highly 
probable that La also indirectly controls IFN induction downstream of RIG-I 
activation via upregulation of the miRs discussed above as well as other RLR-
targeting miRs yet to be identified. In order to determine whether La mediated-
upregulation of miR-146a indirectly contributes to negative regulation of IFN-β 
production following RIG-I activation, analysis of the expression levels of these 
miRs, in the presence and absence of La would also be worthwhile. 
160 
 
On the other hand, once pathogenic RNA is detected, these mechanisms 
regulating RIG-I and other PRRs must be turned off in order to ensure 
appropriate cytokine production, suppression of microbial infection and 
limitation of viral replication. Here, we have demonstrated that upon viral 
sensing by RIG-I, La binds to RIG-I, strengthens its binding to its agonist 
consequently increasing the activity of RIG-I and promotes the assembly of the 
downstream signalling complex comprising IPS-1 and TRAF3 at the 
mitochondria, thus promoting IFN induction. Our results however, although 
cummatively indicating that La functions to positively regulate signalling 
complex formation following ligand detection, must be interpreted with caution 
given the highly variable levels of RIG-I immunoprecipitated from cells. In 
addition, stimulation seemed to positively affect the ability to isolate RIG-I from 
cells by immunoprecipitation. We suspected that this may be due to the change 
in conformation of RIG-I between basal and activated states. Indeed, the 
epitope recognised by the RIG-I antibody is between amino acids 201 and 713 
i.e. the helicase domain, which is partially obscured in resting cells (Kolakofsky 
et al., 2012). This may, at least in part, explain why we observe minimal 
immunoprecipitation of RIG-I in resting cells and why this dramatically 
increases following stimulation, and hence unfolding, of the protein. Similar 
difficulties were also observed when studying the IPS-1/TRAF-3 complex further 
downstream. These IPS-1 immunoprecipitations were complicated by our 
observation that overexpression of La results in attenuated IPS-1 expression. As 
such, perhaps a better strategy for these complex formation experiments would 
be size exclusion chromatography (SEC), a chromatographic technique involving 
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separation of molecules on the basis of molecular weight (Li and Giometti, 
2007). This technique would enable us to further understand the effect of La on 
complex formation between RIG-I and IPS-1 and between IPS-1 and TRAF-3 in 
resting cells and the precise way in which this function changes following RIG-I 
activation. 
 But is this dual function of La really feasible? Similarly to what we have 
shown for La, NEMO-related polyubiquitin-binding protein, Optineurin (OPTN) 
appears to play dual and opposing roles in the context of IFN regulation. While 
OPTN has been reported to negatively regulate IFN production by binding to 
and targeting TBK-1 to a Golgi-associated compartment in the cell, thus 
preventing complex formation in quiescent cells (Mankouri et al., 2010), 
Gleason and colleagues demonstrated that following TLR stimulation, OPTN 
positively regulates TBK-1 activity by binding to poly-ubiquitin chains, thus 
enabling IRF-3 phosphorylation and IFN-β production (Gleason et al., 2011). 
The autoantigen Ro52 (also known as TRIM21) which exists in an RNA complex 
with La, has been reported to stabilise IRF-8 via ubiquitination and thus 
promote IL-12p40 gene expression in murine macrophages (Kong et al., 2007). 
However, at later stages post-pathogen challenge, p62 was later shown to 
interact with Ro52 leading to K48-linked polyubiquitination and destabilisation 
of IRF-8, thereby turning off IL-12p40 expression (Kim and Ozato, 2009). Thus, 
Ro52 is another example of a protein with a complex role in both promoting 
homeostasis and ensuring the correct response to a challenge.  
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Regarding the molecular mechanism behind the ‘switch’ in function, for 
Ro52, Stacey and colleagues demonstrated that tyrosine phosphorylation of 
Ro52 at Y393 and Y388 positively regulated Ro52/IRF interaction and thus 
enhanced IFN-β promoter activity (Stacey et al., 2012). With regard to OPTN, 
the stimulation-dependent change in function of the protein is brought about by 
IKK-β- and TBK-1-mediated Serine 177 and Serine 513 phosphorylation of 
OPTN itself upon TLR pathway activation (Gleason et al., 2011). Given the 
opposing roles for La in IFN regulation, it is likely that, like Ro52 and OPTN, a 
molecular switch exists that is crucial in determining its function in the context 
of IFN modulation.   
Thus these “dual function proteins” such as OPTN, Ro52 and now La, 
most likely have evolved to protect the host from both extremes of IFN 
dysregulation, initially functioning to protect the cells from inappropriate type I 
IFN production in the presence of host nucleic acids or during chromic exposure 
to viral or bacterial challenge thus protecting against autoimmunity, while 
simultaneously ensuring that responses to pathogenic challenge are sufficient in 
order to promote the innate antiviral immune response thus contributing to 
clearance of the microbe.   
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Chapter 5:  
The role of La in infection and 
autoimmunity and molecular 
insights into its opposing 
functions 
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5.1 Introduction: 
The PRRs, in particular RIG-I and anti-viral TLRs, are critical for early detection 
of viral infection and initiation of the defence mechanisms necessary for killing 
of the pathogen by recognition of viral RNA or DNA and initiation of signalling 
pathways which culminate in IFN expression. RIG-I is an essential type I and 
type III IFN-inducing receptor required for the detection of negative-sense 
single stranded RNA ((-) ssRNA) viruses such as Paramyxoviridae, 
Rhabdoviridae and Orthomyxoviridae (Habjan et al., 2008; Hornung et al., 
2006; Kato et al., 2005; Loo et al., 2008; Plumet et al., 2007; Yoneyama et al., 
2005). Sendai virus (SeV) belongs to Respirovirus genus of the Paramyxoviridae 
family and is composed of a single unsegmented viral nucleocapsid surrounded 
by a lipoprotein envelope. First isolated in 1952 by Kuroya and colleagues from 
the lung of a newborn child who had died of fatal pneumonia, primary isolations 
were made in mice and caused influenza-like lesions in the lungs (Kuroya et al., 
1952). While Kuroya’s group hypothesised that SeV was a new disease-causing 
organism of respiratory infection in humans, Fukami and colleagues proposed 
that the mice used for isolation were contaminated with a new virus and that 
this resulted in what we now identify as SeV (Fukami et al., 1979). Regardless, 
SeV is now appreciated as a serious rodent pathogen with worldwide 
distribution (Parker et al., 1964; Zurcher et al., 1977). Following infection, the 
virus rapidly replicates with SeV titres in the lung peaking on day 4 post-
infection (Appell et al., 1971; Breider et al., 1987; Parker and Reynolds, 1968). 
However 11 days post-infection, the virus is no longer detectable. This viral 
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elimination is achieved by host immune system processes such as cell 
accumulation (Blandford et al., 1971; Sangster et al., 1995), MHC activation 
(Chen et al., 1998; Hou et al., 1992), antibody production (Zhong et al., 2000) 
and IFN production (Brownstein and Winkler, 1986; Ertl et al., 1982; Mo et al., 
1995). There are several strains which differ greatly in virulence and this is 
thought to be a result of mutations in the nucleotide sequence of viral HN, F 
and M proteins, thereby compromising viral entry (Itoh et al., 1987; Mochizuki 
et al., 1988; Yamaguchi et al., 1988). The two strains employed in this study 
are conventional laboratory type III IFN-inducing Z strain and the Cantell strain, 
which induces an additional robust type I IFN response, much stronger than 
other negative-strand RNA viruses (Lopez et al., 2003; Lopez et al., 2004). 
 Three classes of IFN have been identified to date; Type I, II and III 
IFNs.  Type I IFNs, discovered in the early 1950s (Isaacs and Lindenmann, 
1957; Isaacs et al., 1957), include IFN−α,−β,−ω, −κ and -ε and bind the IFN-α 
receptor that consists of IFNαR1 and  IFNαR2 chains (Donnelly and Kotenko, 
2010). Type I IFNs are the first line of defence against most types of viral 
infection and act in an autocrine and paracrine manner to induce an anti-viral 
state in host cells. Type I IFN synthesis occurs in virtually all cell types 
downstream of RIG-I in response to viral RNA/DNA and, once secreted by the 
virally-infected cell, can activate the IFNαR, a cell surface receptor coupled to 
Janus-family tyrosine kinases, JAK1 and Tyk2, which phosphorylate signal-
transducing activators of transcription (STAT) proteins, STAT1 and STAT2 
(Lackmann et al., 1998; O'Shea et al., 1997). Activated STATs then form homo- 
and hetero-dimers and translocate into the nucleus resulting in activation of the 
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IRF-3-responsive IFN-stimulated gene factor 3 (ISGF3), a complex made up of 
STAT1, STAT2 and IRF-9 (Honda et al., 2005a; Honda et al., 2005b; Horvath et 
al., 1996; Li et al., 1997; Sato et al., 2000). As illustrated in Figure 5.1, the 
ISGF3 complex then binds to the IFN-stimulated response element (ISRE) 
binding site in the promoter region of IFN stimulated genes (ISGs), such as 
IFN-induced protein with tetratricopeptide repeats 1 (IFIT1), IFIT2, IFIT4, 
TRIM22, viperin, RIG-I, TLR-3, 2’5’ oligoadenylate synthetase 1 (OAS1) and 
OAS2, involved in apoptosis, growth inhibition and innate as well as adaptive 
immune cell activation (Brierley et al., 2006). The induction of ISGs leads to 
inhibition of transcription and translation of viral proteins (Clemens and Elia, 
1997; Stark et al., 1998), induction and synthesis of MHC class I expression 
thus making the cell more susceptible to CD8 cytotoxic T cells  (Epperson et al., 
1992; Hermann et al., 1998; Honda et al., 2005b; Le Bon et al., 2006a; Le Bon 
et al., 2006b), activation of NK cells which selectively kill viral-infected cells 
(Salazar-Mather et al., 1996; Trinchieri et al., 1981), maturation of DCs (Le Bon 
et al., 2003) and B cell responses (Le Bon et al., 2001; Le Bon et al., 2006b). 
Type I IFNs are also known to have anti-tumour activity and are used in the 
treatment of a wide range of cancers including leukaemias, multiple myeloma, 
non-Hodgkin’s lymphoma, renal cell carcinoma, Kaposi’s sarcoma and 
metastatic melanoma (Donnelly and Kotenko, 2010). 
 The type II IFN group consists of IFN−γ only, which is secreted by a 
more limited population of cells than type I IFNs, such as T lymphocytes, NKs 
and monocytes, macrophages and DCs (Peng et al., 2008; Pitha and Kunzi, 
2007). IFN−γ production is controlled by IL-12 and IL-18 and, once secreted, it 
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binds to IFNγR that consists of IFNγR1 and IFNγR2 (Schroder et al., 2004) 
(Figure 5.1). IFN−γ secretion is important for early host defence but 
predominantly crucial for the adaptive immune response. Anti-viral mechanisms 
induced by IFN−γ include protein kinase R (PKR) activation, amplification of 
antiviral activity induced by type I IFN, inhibition of viral replication by limiting 
trans-synaptic transmission, prevention of viral re-activation and inhibition of 
viral-induced apoptosis (Chesler and Reiss, 2002b). In addition, IFN−γ regulates 
tumour development by promoting protective host responses to tumours and 
facilitating tumour escape from immune attack (Ikeda et al., 2002). 
 While type III IFNs are structurally and genetically distinctive from type I 
IFNs and act through a separate receptor system, they share an identical 
mechanism of induction, signal transduction and biological function (Uze and 
Monneron, 2007). Type III IFNs are induced downstream of TLR-3 and RLR 
signalling (Okabayashi et al., 2011; Onoguchi et al., 2007; Stone et al., 2013; 
Zhou et al., 2009). The type III IFN group consists of three functional 
members; IFN-λ1 (IL-29), IFN- λ2 (IL-28A) and IFN- λ3 (IL-28B), as well as 
pseudogene IFN−λ4ψ, and signal through a cell-surface receptor complex 
consisting of IL10R2 (also called CRF2-4) and IFN-λR1 (also called IL-28RA) 
(Kotenko et al., 2003; Sheppard et al., 2003). While the type I IFN receptor is 
ubiquitously expressed, the expression of the IFN-λR1 component of the type 
III IFN receptor complex appears to be more limited and restricted to epithelial 
cells, plasmacytoid DCs, macrophages, monocyte-derived DCs and intra-hepatic 
NKs, with virtually undetectable mRNA levels in fibroblasts and endothelial cells 
(Ank et al., 2008; Jordan et al., 2007; Melchjorsen et al., 2006; Mennechet and 
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Uze, 2006; Sommereyns et al., 2008). Upon type III IFN binding to the 
receptor, a signal transduction cascade ensues involving activation of JAK1, 
JAK2 and Tyk2, STAT activation and ISG expression, almost identical to that 
induced by type I IFN receptor and described above (Dumoutier et al., 2003; 
Kotenko et al., 2003). In addition to ISRE binding by the ISGF3, type III IFN 
receptor activation results in the formation of STAT1 homo-dimers, which 
translocate to the nucleus and bind to gamma activated site (GAS) elements in 
the promoter of ISGs (Figure 5.1). Type III IFNs are induced following infection 
with Dengue virus, VSV, ECMV, HSV-1, HSV-2, IAV, measles, mumps and RSV 
in lymphoid, myeloid or epithelial cell lines (such as HeLa, HuH7 or HT29), as 
well as following dsRNA stimulation in PBMCs (Ank et al., 2006; Coccia et al., 
2004; Diegelmann et al., 2010; Kotenko et al., 2003; Osterlund et al., 2005; 
Robek et al., 2005; Sheppard et al., 2003; Spann et al., 2004). Furthermore, 
local administration of recombinant IFN-λ has been shown to inhibit viral 
replication of HSV1, HSV2 and Influenza A in the vagina and lungs (Ank et al., 
2006; Mordstein et al., 2008). In addition, type III IFNs can regulate the 
adaptive immune response, with differentiating DCs beginning to express the 
IFN-λR1 and IFN-λ-stimulated DCs demonstrating increased levels of MHC class 
I, II and the chemokine receptor CCR7, important for migration of DCs (Gad et 
al., 2010). Similar to the other classes of IFN, type III IFNs have been shown to 
have anti-proliferative and apoptotic effects in vitro (Li et al., 2008; Maher et 
al., 2008).  
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Figure 5.1: Type I, type II and type III IFN signalling; Type I, II and III IFNs 
bind to their cognate receptor and recruit Janus family tyrosine kinase (JAK) family 
members, leading to translocation of phosphorylated transcription factor homo- and 
hetero-dimers to the nucleus where binding to the IFN-stimulated response element 
(ISRE) or gamma activated sequence (GAS) occurs. The IFN-stimulated gene factor 3 
(ISGF3) is induced downstream of type I and III IFN signalling, leading to binding of 
the ISRE and activation of ISGs, while a STAT1 homo-dimer is induced downstream of 
type II signalling, leading to binding of the GAS element and induction of IFN-gamma-
activated genes (IAGs). 
 
 While type I IFNs have a critically important role in protecting the host 
from viral infection, it is of utmost importance that IFN induction is tightly 
regulated, in order to prevent uncontrolled or inappropriate activation of the 
innate immune system, which leads to exacerbated cytokine, chemokine and 
anti-microbial peptide induction and ultimately culminates in development of 
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autoimmune diseases, such as SLE. As discussed in detail in previous chapters, 
RIG-I and TLR signalling pathways are very tightly controlled by processes such 
as phosphorylation, ubiquitination and protein interactions to prevent such 
hyper-activation. For example, CK2 mediates the phosphorylation of RIG-I 
which antagonises TRIM25-mediated ubiquitination and activation of the 
receptor thereby locking RIG-I in an inactive state (Sun et al., 2011).  
 Phosphorylation of La, too, appears to be crucial in determining its 
function. The ability of La to interact with RNA transcripts in the cytoplasm is 
achieved by the non-phosphorylated protein (Fairley et al., 2005; Fan et al., 
1997). Casein kinase 2 (CK2)-mediated phosphorylation at Serine 366 limits 
binding of La to 5’ TOP mRNA, while increasing non-phosphorylated La leads to 
enhanced association, suggesting that phosphorylation of La can affect 
production of the translational machinery (Schwartz et al., 2004). More 
recently, AKT-mediated phosphorylation at threonine 301 has been shown by 
Brenet and colleagues to regulate nuclear trafficking of La (Brenet et al., 2009). 
As such, determining the phosphorylation status of La following RIG-I pathway 
activation, as well as the effect of this post-translational modification on 
interaction with the receptor, may potentially elucidate the mechanism behind 
the two opposing roles we have uncovered for La in IFN regulation.  
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Aims: 
• To assess the effect of La depletion prior to infection with Sendai 
paramyxovirus. 
• To study the potential regulation of opposing La functions by 
phosphorylation 
• To investigate expression levels of La in SLE patients in resting cells and 
in cells stimulated with viral RNA. 
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5.2 Results 
5.2.1 Sendai viral infection efficiency is increased following shRNA 
knockdown of La  
Sendai virus is a murine paramyxovirus which relies entirely on RIG-I to elicit an 
anti-viral immune response (Melchjorsen et al., 2005). Having demonstrated a 
role for La in driving type I IFN responses following RIG-I activation thereby 
promoting anti-viral immunity, Sendai infection studies were carried out in an 
effort to further understand the role of La in the context of infection. Initially 
we wanted to confirm viral infection efficiency in our HEK 293T cells. To this 
end, HEK 293T cells were transfected with 500 ng of either scrambled or La-
specific shRNA and 48 hours post-transfection, cells were infected with a GFP-
tagged strain of the Z strain of SeV, and infection efficiency analysed by UV 
microscopy, following 24 hours. Analysis of fluorescence intensity was carried 
out on both scrambled and La knockdown cells using Image J software and 
results were compared using Graphpad Prism. As Figure 5.2 shows, SeV 
efficiently infected both scrambled and La shRNA transfected cells, indicating 
that transfection of cells with the shRNA plasmid did not impair the ability of the 
SeV to infect the cells. Interestingly, a higher titre of SeV infection of cells 
depleted of La was observed when compared with scrambled controls. This 
observation was found to be statistically significant upon eGFP-positive 
percentage monolayer analysis, suggesting that knockdown of La may enhance 
viral infectivity. This effect may potentially be a result of the previously shown 
role for La in enhancing RIG-I driven IFN responses (chapter two), as SeV has 
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been shown to mediate type III IFN production via the RIG-I pathway (Stone et 
al., 2013).  
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Figure 5.2: Depletion of La in HEK 293T results in a modest increase in 
Sendai viral infection efficiency; HEK 293T cells were seeded at a density of 5 × 
104 cells/ml and transfected the following day with 500 ng of La-specific or scrambled 
Mission® shRNA (Sigma) for 48 hr. Cells were then infected with GFP-tagged Z strain 
of Sendai virus at an MOI of 10 and incubated for 24 hours before visualisation using a 
Nikon eclipse TE2000-U and a Hamamatsu ORCA ER camera. Image analysis 
(percentage GFP-positive cells) was carried out using Image J software. *p<0.05, as 
determined by unpaired t test using GraphPad prism.  
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5.2.2 SeV-induced mRNA expression of IFN-β and IFN-λ is attenuated 
in La-depleted cells  
As both type I and type III IFNs are induced by the RIG-I pathway, we next 
investigated the effect of La knockdown on IFN-β and IFN-λ1 mRNA expression 
in cells following infection with SeV in order to definitively characterise the 
involvement of La in IFN production. As stated above, the Z strain of SeV 
induced a strong type III IFN response but no type I IFN, whereas the SeV 
Cantell induced a robust type I IFN response in addition to type III IFNs (Lopez 
et al., 2003; Lopez et al., 2004). Following 48 hours shRNA knockdown of La, 
HEK 293T cells were infected with SeV Cantell and SeV Z strains for 8, 24 and 
48 hours, after which mRNA was extracted from cells and real-time PCR was 
carried out. In keeping with our previous results implicating La as a positive 
regulator of RIG-I-mediated response to viral infection, a significant reduction in 
IFN-β mRNA levels was observed following Cantell infection at both 8 and 24 
hours in La-depleted cells compared with scrambled control cells (Figure 5.3A). 
IFN-β is not induced following infection with Z strain, as expected (Figure 5.3D). 
Interestingly, IFN-λ1 expression  was also demonstrated to be decreased in La-
depleted cells both basally and following infection at 8, 24 and 48 hours with 
the Cantell strain of SeV, although only at the later time point of 48 hours post-
infection in Z-strain infected cells (Figure 5.3B & D). Figure 5.3C & F represent 
La mRNA expression levels for Cantell- and Z-infected cells, respectively. While 
a significant reduction in La expression was observed in this representative 
experiment, some variability in La knockdown in individual experiments 
following SeV infection was observed. A very recent study by Seo and 
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colleagues demonstrating that RIG-I and MDA-5 contribute to inhibition of RISC 
efficiency may potentially explain this observation (Seo et al., 2013). 
Regardless, collectively these results provide an explanation for the increased 
infection efficiency observed following La depletion (Figure 5.2) and indicate 
that the association between La and RIG-I is required for the global RIG-I-
mediated IFN response. 
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Figure 5.3: Decreased IFN-β and IFN-λ mRNA expression in La-depleted cells 
following SeV infection; HEK 293T cells were seeded at a density of 5 × 104 
cells/ml and transfected the following day with 500 ng of either La-specific or 
scrambled Mission® shRNA (Sigma) for 48 hours. Cells were then infected with Cantell 
(A-C) or Z (D-F) strains of Sendai virus at an MOI of 10 and incubated for the indicated 
time points. Cells were lysed in Trizol, RNA was extracted and reverse transcribed, and 
real-time PCR was carried out to measure IFN-β (A, D), IFN-λ1 (B, E) and La (C, F) 
gene expression.  Data shown is a representative of three individual experiments, n=3. 
*p<0.05, **p< 0.01, ***p<0.001 and ****p<0.0001 as determined by two-way 
ANOVA using GraphPad Prism. 
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5.2.3 Expression of Interferon-stimulated genes CCL-5, IP-10 and 
CXCL-11 is compromised in La-depleted cells following SeV infection 
Having seen a marked decrease in IFN production in the absence of La, a 
number of IFN-stimulated genes (ISGs) were subsequently measured in an 
effort to confirm these observations. Rantes (CCL-5), IP-10 (CXCL-10) and 
CXCL-11 were chosen for analysis as these genes are induced following both 
IFN-β and IFN-λ production. As Figure 5.4 demonstrates, expression of IFN-
regulated chemokines CXCL-11 and IP-10 is significantly attenuated by La 
depletion following 24 hour Cantell infection, compared with scrambled 
controls. A decrease in expression of these chemokines was also observed 
following 8 hours infection between La knockdown and scrambled control cells, 
although not statistically significant. SeV-induced Rantes expression was not 
significantly affected by La depletion, although a trend towards attenuated 
expression was apparent (Figure 5.4C). No significant difference was observed 
in ISG expression levels between La-depleted cells and scrambled controls 
following 48 hours infection in the case of Cantell infection (Figure 5.4A-C). ISG 
expression was also attenuated in response to infection with the Z strain of 
SeV, although at a later time point. Following 48 hours infection, IP-10 and 
Rantes expression was significantly attenuated by La depletion. This finding was 
concomitant with the delayed La inhibition of IFN-λ1 induction previously seen 
(Figure 5.4D and F). No significant difference was observed in Z-strain-induced 
CXCL-11 expression. In support of our previous studies, these experiments 
collectively underline a role for La in the positive regulation of both type I and 
type III IFN responses following viral infection. 
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Figure 5.4: Decreased ISG mRNA expression was observed in La-depleted 
cells following SeV infection; HEK 293T cells were seeded at a density of 5 × 104 
cells/ml and transfected the following day with 500 ng of either La-specific or 
scrambled Mission® shRNA (Sigma) for 48 hr. Cells were then infected with the Cantell 
(A-C) or Z (D-F) strains of Sendai at an MOI of 10 and incubated for indicated time 
points. Cells were lysed in Trizol, RNA was extracted and reverse transcribed, and real-
time PCR was carried out to measure IP-10 (A, D), CXCL-11 (B, E) and Rantes (C, F) 
expression. Data shown is a representative of three individual experiments, n=3. 
***p< 0.001 as determined by two-way ANOVA using GraphPad Prism. 
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5.2.4 Rantes and IFN-λ1 release is significantly decreased in La-
depleted cells following Sendai infection 
 
Having observed a dramatic attenuation in mRNA expression of IFN-β, IFN-λ1 
and ISGs in La-depleted cells following SeV infection, anti-viral cytokine release 
was subsequently measured. As such, HEK 293T cells were transfected with 
500 ng of La-specific or scrambled shRNA prior to infection with Cantell or Z 
strains of SeV. Rantes and IFN-λ1 levels from supernatants of infected cells 
were then measured by ELISA. In agreement with our gene expression studies, 
sub-optimal Rantes release was observed following both 24 and 48 hours 
Cantell infection in La-depleted cells, compared with control cells (Figure 5.5A). 
Unsurprisingly, (given that Rantes is only induced at mRNA level following 48 
hours infection (Figure 5.4F)), no Rantes release was detected following 
infection with Z strain across the time course of infection, nor was any 
significant difference observed in La-depleted cells, compared with scrambled 
controls (Figure 5.5C). IFNλ1 (IL-29) release was completely abrogated in La-
depleted cells, compared with controls, following infection with both SeV-Cantell 
and SeV-Z, further supporting our findings suggesting that La interaction with 
RIG-I is crucial for the global IFN response downstream of viral infection 
(Figure 5.5B and D).   
 The release of pro-inflammatory cytokines IL-1β, TNF-α, IL-6, IL-8, IL-
10, IL-12p70 and IFN-γ was subsequently measured in supernatants from 
Cantell-infected HEK 293T cells using a multi-plex ELISA (Meso Scale 
Discovery). Although detectable cytokine levels were only observed for IL-6, IL-
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8 and TNF-α, the release of both IL-8 and TNF-α was unaffected by La 
depletion (Figure 5.6A and C). Interestingly, a significant but modest reduction 
in IL-6 release was observed in La-depleted cells following 24 hours infection. 
However on the whole, these experiments further demonstrate a clear role for 
La in specifically enhancing the RIG-I-mediated type I and III IFN response to 
SeV infection, with the pro-inflammatory response predominantly unaffected by 
La depletion. 
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Figure 5.5: Rantes & IFN-λ1 release is attenuated in La-depleted cells 
following SeV infection; HEK 293T cells were seeded at a density of 5 × 104 
cells/ml and transfected the following day with 500 ng of either La-specific or 
scrambled Mission® shRNA (Sigma) for 48 hr. Cells were then infected with Cantell (A-
B) and Z strains (C-D) of Sendai at an MOI of 10 and incubated for indicated time 
points. Rantes (A, C) and IFN-λ1 (B, D) cytokine release was measured from cells 
supernatants using DuoSet® ELISA Development Kits (eBioscience). Data shown is the 
combined average of three individual experiments, n=3, all of which were measured in 
triplicate. **p<0.01, ***p<0.001 and ****p<0.0001 as determined by two-way 
ANOVA using GraphPad Prism. 
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Figure 5.6: Pro-inflammatory cytokine response to SeV infection is 
unchanged in La-depleted cells; HEK 293T cells were seeded at a density of 5 × 
104 cells/ml and transfected the following day with 500 ng of either La-specific or 
scrambled Mission® shRNA (Sigma) for 48 hr. Cells were then infected with Cantell 
strain of SeV at an MOI of 10 and incubated for indicated time points. Cytokine release 
was measured from cells supernatants using a multi-plex human pro-inflammatory 7-
spot assay (MSD). Shown above are supernatant levels for IL-8 (A), IL-6 (B) and TNF-
α (C). Data shown is the combined average of three individual experiments, n=3, all of 
which were measured in triplicate. **p<0.01 as determined by two-way ANOVA using 
GraphPad Prism. 
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5.2.5 Activation of RIG-I and SeV infection alters La phosphorylation 
pattern 
 
Phosphorylation of proteins is a common regulatory mechanism and many 
proteins that are known regulators of signalling downstream of innate immune 
receptors are known to be phosphorylated, such as IRAK-1, MyD88 and Mal. In 
some cases phosphorylation acts as a negative switch by triggering 
ubiquitination and degradation of the targeted protein, as in the case of Mal, or 
locking proteins in an inactive state, such as that described for RIG-I. Indeed, 
phosphorylation of regulatory proteins is known to be targeted by viruses in an 
effort to evade the anti-viral innate immune response. For example, SeV 
suppresses STAT phosphorylation at early stages of viral infection and SeV C 
proteins antagonise IFN and render cells unresponsive to both type I IFNs and 
type II IFN-γ, thereby counteracting immune defences (Gotoh et al., 2001, 
2003; Kato et al., 2004; Sakaguchi et al., 2003). In addition, phosphorylation 
plays an important role in determining La function, with phosphorylated La 
predominantly in the nucleus and non-phosphorylated La found in the 
cytoplasm. As such, we wished to assess whether activation of the RIG-I 
pathway had any effect on the phosphorylation status of La. HeLa cells were 
stimulated across a 6 hour time course, following which cells were lysed and 
expression of phosphorylated La (pLa), total La and α-actinin were analysed by 
western blotting. As demonstrated in Figure 5.7, an increase in pLa was 
observed following RIG-I stimulation, with phosphorylation peaking following 1 
hour RIG-I activation. Interestingly, following 6 hours phosphorylation levels 
appeared to be attenuated. Given our findings demonstrating an interaction 
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between La and RIG-I at 3 and 6 hours post-stimulation, this result suggests 
that the non-phosphorylated form of La may be the form necessary for RIG-I 
binding. As shown in Figure 5.8, HeLa cells stimulated with TLR-3 ligand 
poly(I:C) did not demonstrate any change in pLa levels across the time course, 
indicating that the phosphorylation of La induced by stimulation was specific to 
the RIG-I pathway activation.  
 We subsequently investigated phosphorylation levels following a short 
time course of SeV-Cantell infection. As Figure 5.9 demonstrates, we see a 
decrease in phosphorylation following 1 and 24 hours infection (Lanes 2 and 5), 
similar to that observed 3-6 hours post-stimulation. Given our real-time PCR 
studies demonstrating that La potently promoted anti-viral responses following 
24 and 48 hours (Figure 5.3-5.5), this finding further suggests that the non-
phosphorylated form of La may potentially be required for mediating positive 
regulation of IFN induction following viral infection. The observation that the 
time points for infection studies do not match our stimulation studies may be 
explained by the time required for viral entry and replication. These infection 
studies indicate a potential biphasic role for non-phosphorylated La in 
promoting IFN induction downstream of viral stimulation. Collectively, these 
studies suggest that RIG-I-mediated phosphorylation may potentially be the 
mechanism by which La function, in the context of IFN induction, is controlled. 
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Figure 5.7: RIG-I stimulation alters phosphorylation of La; (A) HeLa cells were 
seeded at a density of 2 × 105 cells/ml and stimulated the following day at indicated 
time points with 1 µg/ml 5’ppp-dsRNA (Invivogen). Following the indicated time 
course, cells were washed, lysed, and protein concentration was determined and 
normalised using the BCA assay before addition of 5 × sample buffer supplemented 
with DTT (50 nM) and boiling at 95°C for 5 min. Samples were assessed for 
phosphorylated La and total La levels by western blot. Blots are representative of three 
individual experiments, n=3. (B) Optical densitometry was performed on pLa band 
intensities and normalised to La. Graph demonstrates the mean + SEM of three 
individual experiments. 
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Figure 5.8: Phosphorylation of La is unaffected by Poly(I:C) stimulation; (A) 
HeLa cells were seeded at a density of 2 × 105 cells/ml and stimulated the following 
day at indicated time points with 1 µg/ml Poly(I:C) (Invivogen). At indicated time 
points, cells were washed, lysed, and protein concentration was determined and 
normalised using the BCA assay before addition of 5 × sample buffer supplemented 
with DTT (50 nM) and boiling at 95°C for 5 min. Samples were assessed for 
phosphorylated La and total La levels by western blot. Blots are a representative of 
three individual experiments, n=3. (B) Optical densitometry was performed on pLa 
band intensities and normalised to La. Graph demonstrates the mean + SEM of three 
individual experiments. 
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Figure 5.9: SeV infection results in a decrease in La phosphorylation; HEK 
293T cells were seeded at a density of 5 × 104 cells/ml, infected with the Cantell strain 
of Sendai at an MOI of 10 and incubated for indicated time points. Cells were then 
washed, lysed, boiled in 5 × SDS buffer with 50 nM DTT at 95°C for 5 min and 
analysed by western blotting. Blot is representative of two individual experiments, n=2. 
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5.2.6. Casein Kinase 2 is responsible for early RIG-I-mediated La 
phosphorylation 
Serine/threonine-specific casein kinase (CK2) has been reported to 
phosphorylate both RIG-I and La. CK2 phosphorylates La at C-terminal site, 
Serine 366 and, in doing so, limits RNA binding (Schwartz et al., 2004), while 
phosphorylation of RIG-I at Serine 8, Threonine 170, Threonine 770 and Serine 
854 suppresses receptor activity (Sun et al., 2011). Having determined that La 
is phosphorylated following RIG-I activation, we next sought to determine the 
potential role for CK2 in this process.  As such, we employed commercial CK2-
specific ATP/GTP-competitive inhibitor 4,5,6,7-Tetrabromo-2-azabenzimidazole 
(TBB). An initial experiment was carried out to assess the effect of this chemical 
on cell viability, whereby HeLa cells were treated with increasing concentrations 
of TBB from 0 to 400 µM for an incubation time of 6 hours. This incubation time 
was chosen based on a review of the literature using TBB in this cell type. As 
demonstrated in Figure 5.10A, 0.4 and 40 µM concentrations had no effect on 
cell viability and, as such, a concentration of 40 µM was chosen for future 
studies using the inhibitor. 
 In an effort to assess the effect of CK2 activity on RIG-I-mediated 
phosphorylation of La, HeLa cells were treated with 40 µM of TBB prior to 
5’ppp-dsRNA stimulation across a 6 hour time course, following which La and 
pLa protein levels were analysed by western blot. As previously shown, RIG-I-
inducible La phosphorylation was observed at 30 min, following treatment with 
the DMSO vehicle control (Figure 5.10B, lanes 1-2). In support of our previous 
experiments, a decrease in phosphorylation at later time points following 5’ppp-
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dsRNA stimulation was again observed (Figure 5.10B, lanes 1 & 3-5). However, 
as demonstrated in Figure 5.10B, (lanes 6-10), phosphorylation of La was 
inhibited by TBB treatment in resting cells and following 5’ppp-dsRNA 
stimulation. These results indicate that CK2 is an important kinase for 
phosphorylation of La in resting cells and following early 5’ppp-dsRNA detection 
by RIG-I. 
 
 
 
 
 
 
 
 
 
 
 
191 
 
 
 
Figure 5.10: TBB treatment inhibits RIG-I-mediated phosphorylation of La; 
(A) HeLa cells were seeded in a 96-well plate at a density of 1 × 105 cells per ml and 
treated the following day with increasing concentrations of CK2 inhibitor, TBB, or 
vehicle control, DMSO, for 6 hr as indicated. An MTT assay was then carried out to 
assess cell viability, following which results were normalised and displayed as 
percentage viability using GraphPad Prism. Graph demonstrates an experiment which 
was carried out once, n=1. (B) HeLa cells were seeded at 1 × 105 cells per ml and 
treated the following day with 40 µM TBB or DMSO for 6 hr before stimulation with 1 
µg/ml 5’ppp-dsRNA, as indicated. Cells were then washed, lysed, boiled in 5 × SDS 
buffer with 50nM DTT at 95°C for 5 min and analysed by western blotting. Blots are 
representative of three individual experiments, n=3. 
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5.2.7 CK2 phosphorylation negatively regulates La interaction with 
RIG-I  
Having demonstrated an important role for CK2 in the phosphorylation of La 
downstream of RIG-I activation, we next sought to ascertain whether this had 
an effect on the interaction between RIG-I and La. As such, HEK 293T cells 
were transfected with 2 µg flag-tagged RIG-I, treated the following day with 40 
µM TBB for 6 hours and stimulated with 5’ppp-dsRNA in order to test the effect 
of TBB on the inducibility of the interaction. Following this, cells were washed, 
lysed, endogenous La was immunoprecipitated from lysates and RIG-I 
association was determined by western blot analysis. As Figure 5.11 
demonstrates, TBB treatment lead to a dramatic increase in RIG-I binding to La 
(Figure 5.11, lane 2 compared with lane 3), an increase comparable to that 
observed following 6 hours stimulation with 5’ppp-dsRNA (Figure 5.11, lanes 3 
and 4). This suggests that phosphorylation of La and/or RIG-I by CK2, inhibits 
the interaction between the two proteins. While TBB treatment had a marked 
effect on the interaction in resting cells, it didn’t appear to affect the 5’ppp-
dsRNA enhancement of interaction (Figure 5.11, lane 4 compared with lane 5).  
This result fits with our hypothesis that the non-phosphorylated form of La is 
crucial for promoting anti-viral responses.  
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Figure 5.11: Inhibition of CK2 enhances RIG-I interaction with La; HEK 293T 
cells were seeded at 2.5 × 105 cells per ml. Cells were transfected for 18 hr with empty 
vector or 2 µg FLAG-tagged RIG-I, as indicated, treated for 6 hr with 40 µM CK2 
inhibitor, TBB, prior to overnight stimulation with 1 µg 5’ppp-dsRNA. Cells were then 
washed, lysed and immunoprecipitated with Protein G sepharose beads pre-coupled to 
either La or mouse IgG control antibody, as indicated. Samples were then boiled in 5 × 
SDS buffer with 50 nM DTT at 95°C for 5 min and analysed by western blotting. Blots 
are a representative of four individual experiments, n=4. 
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5.2.8 La expression is altered in SLE patients 
Given the inhibitory role demonstrated for La on the anti-viral response in 
resting cells (chapter one), we hypothesised that La may be protective in 
autoimmunity by preventing inappropriate or excessive production of type I 
IFN. As such, PBMCs from SLE patients and healthy controls were seeded at a 
density of 1 × 106 cells/ml and stimulated as indicated, following which protein 
expression was determined by western blot analysis. As Figure 5.12 
demonstrates, there is a trend towards decreased La expression in resting cells 
from SLE patients compared with controls. Subsequently, the mRNA expression 
of La in unstimulated PBMCs from a cohort of 30 SLE patients was measured 
and, in support of our protein data, a significant decrease in La levels between 
SLE patients and healthy controls was observed (Figure 5.13). Viral infection is 
a known risk factor in SLE and is a significant cause of both hospitalisation and 
mortality associated with disease (Alarcon et al., 2001; Duffy et al., 1991; 
Edwards et al., 2003; Goldblatt et al., 2009; Noel et al., 2001; Petri and 
Genovese, 1992). In addition, by way of inducing IFN expression and driving 
inflammation, viral infection is also known to induce flare in SLE patients 
(Pisetsky and Vrabie, 2009; Ramos-Casals et al., 2008; Zandman-Goddard and 
Shoenfeld, 2005). As such, we sought to investigate La expression following 
viral stimulation in SLE patients and healthy controls. Interestingly and in 
support of the previously demonstrated role for La in promoting IFN responses 
following viral detection, La levels are significantly increased in SLE patients 
following stimulation with poly(I:C), as compared with controls (Figure 5.12). 
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Collectively, these results suggest that La may be an important player in 
controlling IFN balance in SLE patients. 
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Figure 5.12: La protein levels are decreased basally in SLE patients 
compared with controls but increase following Poly(I:C) stimulation; 
Peripheral Blood Mononuclear Cells (PBMCs) were seeded in a 12-well plate at a 
density of 1 × 106 cells and stimulated at indicated time points with 1 µg poly(I:C). 
Cells were then washed, lysed and re-suspended in 1 × sample buffer supplemented 
with DTT (50 nM) and boiled at 95°C for 5 min. Samples were assessed for total La, 
and α-actinin levels by western blot, optical densitometry was performed on La band 
intensities and normalised to α-actinin. (A) Data shown are combined from five 
individual SLE patients and corresponding matched controls, n=5. *p<0.05, as 
determined by two-way ANOVA using GraphPad Prism. (B) Representative blot 
showing La and α-actinin expression levels from a single patient. 
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Figure 5.13: La mRNA expression is decreased basally in SLE patients 
compared with controls; Peripheral Blood Mononuclear Cells (PBMCs) were seeded 
in a 12-well plate at a density of 5 × 106 cells. The following day, cells were washed 
and lysed in Trizol, RNA was extracted and reverse transcribed, and real-time PCR was 
carried out to measure La and 18S gene expression. Data shown are combined from 
thirty individual SLE patients and sixteen healthy controls. ***p<0.001 as determined 
by unpaired two-tailed t-test using GraphPad Prism.  
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5.2.9 RIG-I protein expression is enhanced following viral stimulation 
in SLE patients 
Having provided evidence that La specifically acts through the RIG-I signalling 
pathway to mediate its inhibitory effects on IFN induction, RIG-I receptor levels 
were subsequently determined in SLE patients. As before, PBMCs from SLE 
patients and healthy controls were seeded at a density of 1 × 106 cells/ml and 
stimulated as indicated, following which protein expression was determined by 
western blot analysis. As Figure 5.14 demonstrates, while no change was 
observed in receptor levels basally, increased levels of RIG-I were apparent 
following 1 and 24 hours poly(I:C) stimulation in SLE patients, compared with 
controls. These enhanced levels of RIG-I suggest that SLE patients may be 
hyper-responsive to viral infection, which is perhaps unsurprising when we 
consider the role that viral infection has been shown to play in exacerbation of 
disease in SLE patients. These findings indicate a potential functional relevance 
for the relationship between La, RIG-I and IFN induction in the context of SLE 
pathogenesis.  
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Figure 5.14: RIG-I protein levels are increased following Poly(I:C) 
stimulation in SLE patients compared with controls; Peripheral Blood 
Mononuclear Cells (PBMCs) were seeded in a 12-well plate at a density of 1 × 106 cells 
and stimulated at indicated time points with 1 µg poly(I:C). Cells were then washed, 
lysed and re-suspended in 1 × sample buffer supplemented with DTT (50nM) and 
boiled at 95°C for 5 min. Samples were assessed for total RIG-I, and α-actinin levels 
by western blot, optical densitometry was performed on RIG-I band intensities and 
normalised to α-actinin. (A) Data shown are combined from five individual SLE patients 
and corresponding matched controls, n=5. **p<0.01, as determined by two-way 
ANOVA using GraphPad Prism. (B) Representative blot showing RIG-I and α-actinin 
expression levels from a single patient. 
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5.2.10 Neo-La:La ratio is increased in SLE patients  
Bachmann and colleagues previously identified a mutant form of La in Sjögrens 
Syndrome (SS) patients containing a frameshift mutation in exon 7 of the La 
gene, whereby the 12 amino acids from AA 192-204 are replaced with novel 
amino acids and a premature stop codon within the reading frame of the 
protein (Bachmann et al., 1996). This stop codon results in a truncation mutant 
of La lacking the C terminal domain and hence the NLS and therefore this 
29kDa (neo-La) mutant remains cytoplasmic (Bachmann et al., 1997) (Figure 
5.15A). Work from our collaborator Dr. Maier-Moore demonstrated that in a 
group of 63 anti-La+ SS patients, 15 individuals were also anti-neo-La positive 
(24%), suggesting that this mutant isoform of La was successfully translated 
and may contribute to autoimmunity. In support of this, 46.67% (7 out of 15) 
of patients expressing neo-La developed renal disease. However, of the anti-La+ 
SS patients who were anti-Neo-La-, only 16.67% (8 out of 48) developed renal 
disease (Figure 5.15B). This suggests that expression of this La mutant favours 
development of systemic autoimmunity.  
 An accumulation of the already-high autoantibody burden is one possible 
explanation for this. Another however, ties in with our observations 
demonstrating a role for La in regulating IFN induction. Does this mutant form 
of La favour positive enhancement of the IFN response and thus contribute to a 
build-up of IFN and resulting organ destruction in autoimmune conditions such 
as SS and SLE? In an effort to answer this question, we next assessed the 
mRNA expression levels of this mutant neo-La in a cohort of 30 SLE patients. As 
such, PBMCs from SLE patients and healthy controls were seeded at a density 
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of 5 × 106 cells/ml and incubated overnight. Subsequent cell lysis, mRNA 
extraction and cDNA preparation was carried out and RT-PCR analysis revealed 
that while neo-La expression, like full-length La, was significantly decreased in 
SLE patients, compared with controls (Figure 5.16), the ratio of neo-La 
compared to La was significantly higher in SLE patients than in healthy controls 
(1:13 compared with 1:0.68, respectively, Figure 5.17). This indicates that, as 
in the case of SS, neo-La may be contributing to disease pathogenesis and/or 
severity in SLE patients. While a correlation was not observed between full-
length or neo-La with IFN-β, a weak correlation was observed with IFN-λ1 
(Table 5.1). Work is currently underway to investigate potential correlations 
between La or neo-La levels and clinical phenotypes such as skin rash, kidney 
involvement and neural complications. 
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Figure 5.15: Neo-La mutant contributes to systemic autoimmunity in SS; (A) 
Structure of full-length La (top) and 29kDa truncation mutant Neo-La (bottom). (B) 63 
anti-La+ SS patients were analysed, 15 of these were also anti-neo-La+. Of these 
patients, 7 out of 15 developed renal disease, while of the anti-La+ SS patients who 
were anti-Neo-La-, only 8 out of 48 developed renal disease. Figure 5.15B courtesy of 
Dr. Maier-Moore. 
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Figure 5.16: Neo-La mRNA expression is decreased basally in SLE patients 
compared with controls; Peripheral Blood Mononuclear Cells (PBMCs) were seeded 
in a 12-well plate at a density of 5 × 106 cells. The following day, cells were washed 
and lysed in Trizol, RNA was extracted and reverse transcribed, and real-time PCR was 
carried out to measure Neo-La and 18S gene expression. Data shown are combined 
from thirty individual SLE patients and sixteen healthy controls. ***p<0.001 as 
determined by unpaired two-tailed t-test using GraphPad Prism. 
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Figure 5.17: Neo-La:La ratio is increased in SLE patients compared with 
healthy controls; Peripheral Blood Mononuclear Cells (PBMCs) were seeded in a 12-
well plate at a density of 5 × 106 cells. The following day, cells were washed and lysed 
in Trizol, RNA was extracted and reverse transcribed, and real-time PCR was carried 
out to measure neo-La, La and 18S gene expression in (A) healthy controls or (B) SLE 
patients. (C) Table showing the ratio of La:Neo-La in controls (black) compared with 
SLE patients (red). Data shown are combined from thirty individual SLE patients and 
sixteen healthy controls. *p<0.05, ***p<0.0001 and ****p<0.00001 as determined 
by unpaired two-tailed t-test using GraphPad Prism.  
 
 
 
 
 
 
 
 
 
 
205 
 
Table 5.1: Relationship between La & Neo-La and type I and type III IFN 
expression in SLE patients; mRNA expression of La, neo-La, IFN-β and IFN-λ1 was 
measured by RT-PCR in a cohort of 30 SLE patients and values were subsequently 
analysed for any potential correlations. 
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5.3 Discussion: 
Thus far, La has been demonstrated to play both negative and positive 
regulatory roles in the context of RIG-I-mediated type I IFN induction 
depending on activation state of the cell. In this chapter, the opposing dual 
roles for La in the context of IFN regulation were further explored by viral 
infection and autoimmunity studies. Knockdown of La resulted in increased 
Sendai viral infection efficiency, decreased IFN-β, IFN-λ1 and ISG mRNA 
expression and attenuated Rantes and IL-29 release, compared with control 
cells (Figure 5.18). While type I IFN regulation is well characterised, the 
mechanisms which regulate type III IFN induction are quite poorly understood. 
A very recent study by Swider and colleagues identified BLIMP-1 and ZEB1 as 
novel negative regulators of TLR-3-driven IFN-λ1 in human colon epithelial cells 
(Swider et al., 2013). We have identified La as a novel positive regulator of 
RIG-I-driven IFN-λ1 induction downstream of viral challenge. Understanding 
the molecular mechanisms behind regulation of these relatively new cytokines 
will provide insight into the possibility of therapeutic targeting of type III IFNs 
for up- or down-regulation in the case of human disease.  
Many recent reports have identified a role for La in viral growth and 
replication. While some groups have described La as being manipulated by 
viruses to block the IFN response and enhance viral release and replication 
within cells (Bitko et al., 2008; Costa-Mattioli et al., 2004; Domitrovich et al., 
2005; Nitta et al., 2011), other studies have demonstrated the exact opposite; 
that La is essential for limiting viral spread (Liu et al., 2011b). Our findings were 
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in agreement with observations from the Liu group, who showed a role for La in 
promoting the anti-viral response to a self-replicating flock house virus (FHV), 
with La depletion resulting in increased FHV expression. In contrast, Bitko and 
colleagues demonstrated that La knockdown promoted the association of viral 
RNA with RIG-I and hence induced enhanced IFN-β mRNA. This group also 
showed enhanced IFN-β mRNA levels and decreased viral titres upon siRNA 
depletion of La (Bitko et al., 2008). However, while an increase in IFN-β mRNA 
was observed at 8 hours post-RSV infection in the absence of La, a decrease 
from 40-fold to 10-fold was observed after 15, 20 and 25 hours infection in La-
depleted cells. This pattern of La inhibiting the IFN response early in infection 
but enhancing later in infection is in agreement with our experiments, 
particularly our phosphorylation studies. Thus it is possible that the dual roles 
that we have demonstrated for La may be time-dependent following viral 
infection.  
Another explanation for contradictions between studies regarding the 
function of La post viral infection may be viral strain-specific manipulation of La. 
Viruses are well known to target IFN production in a number of ways, including 
limitation of RNA synthesis and detection, inhibition of RLR members and their 
downstream adaptors, interference with kinase complex formation, suppression 
of IFN-β promoter activity and inhibition of JAK-STAT signalling, as reviewed by 
(Ramachandran and Horvath, 2009). For example, the RSV-derived NS2 protein 
binds to RIG-I and blocks its interaction with IPS-1, thereby preventing IRF-3 
activation (Goswami et al., 2013; Ling et al., 2009). This is particularly 
interesting, since RSV was used in one of the studies proposing a role for La in 
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inhibition of the anti-viral response upon viral challenge (Bitko et al., 2008). In 
addition Hepatitis C virus, which was used in some other studies demonstrating 
a negative role for La in IFN induction (Costa-Mattioli et al., 2004; Domitrovich 
et al., 2005), is widely reported to target the RIG-I pathway in order to mediate 
viral replication efficiently. For example, HCV-derived NS3/4A was shown to 
degrade IPS-1 (Cheng et al., 2006; Li et al., 2005; Loo et al., 2006). HCV core 
and E2 proteins are also capable of suppression of IFN induction in hepatocytes 
and pDCs (Florentin et al., 2012; Oshiumi et al., 2010). Thus, it may be the 
case that the IFN inhibition observed in these studies was compromised by viral 
manipulation of the RIG-I-mediated IFN response rather than a direct inhibitory 
role by La. In addition, previous studies investigating the role of La in viral 
infection have not accounted for the phosphorylation status of La.  Thus it is 
possible that La, similar to the proteins discussed above, is targeted by certain 
strains of virus for hyper-phosphorylation following viral infection and that this 
serves both to exploit the function of La in IFN inhibition, a role which is 
ordinarily necessary to maintain homeostasis, as well as prevent La from 
mediating its positive regulation of anti-viral responses following viral infection.  
 Interestingly, our observations have identified phosphorylation of La to be 
key in the negative regulation of IFN production, with RIG-I stimulation 
triggering CK2-mediated phosphorylation of La early in viral detection. 
Subsequent studies demonstrated that CK2 phosphorylation negatively 
regulates the interaction between La and RIG-I. Collectively, these results 
indicate that CK2-mediated phosphorylation is essential for La’s inhibitory effect 
on IFN induction, with de-phosphorylation playing an important part in the 
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switch to a positive modulatory role. As phosphorylated La is predominantly 
localised to the nucleus, with de-phosphorylation resulting in cytoplasmic 
translocation, we propose that in resting cells, La resides in its phosphorylated 
form in the nucleus functioning in transcriptional inhibition of IFN induction, as 
detailed in chapter one. However upon viral infection, La translocates to the 
cytoplasm where it interacts with RIG-I and promotes the IFN response (as 
shown in Figure 4.11 and outlined in the schematic overview in Figure 5.18). In 
order to definitively validate this model, confocal microscopy and functional 
studies into the phosphorylation of La and its implications on IFN regulation are 
required. 
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Figure 5.18: A model for the role of La in the cell; In resting cells, La exists in a 
phosphorylated form in the nucleus where it mediates transcriptional inhibition of IFN-
β induction. Following SeV infection, La is de-phosphorylated and translocates to the 
cytoplasm where it interacts with RIG-I, enhances RIG-I detection of ligand, RIG-I 
activation and propagation of the signal, culminating in TBK-1 phosphorylation, IRF-3 
activation and induction of type I and III IFNs and ISGs such as IP-10, CXCL-11 and 
Rantes.  
 
Regarding the role of La in autoimmunity, decreased La expression was 
observed in SLE patients compared with healthy controls in unstimulated cells, 
with increased La expression observed following viral RNA stimulation in SLE 
patients, compared with controls. These studies collectively suggest a 
previously unappreciated role for La, like autoantigens Ro52 and Ro60, in 
maintaining IFN homeostasis in autoimmune conditions such as SLE. In 
addition, RIG-I is over-expressed in SLE patients following stimulation, 
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indicating that RIG-I-mediated hyper-responsiveness to viral detection may be 
an important contributory factor in the IFN signature seen in SLE patients and 
suggesting a clinical importance to the relationship we have described between 
La and RIG-I. It must be noted however that due to our limited sample size for 
protein analysis, further studies must be carried out in a larger patient cohort to 
confirm these observations and add weight to this hypothesis. Nonetheless, it 
would be interesting to correlate the La expression levels with RIG-I levels post 
stimulation and assess whether a potential increased association between these 
two proteins contributes to increased IFN levels in lupus. Furthermore, given 
the important newly-identified role for phosphorylation in regulating La 
function, it would be interesting to determine phosphorylation status of La in 
SLE patients compared with controls. Interestingly, we have demonstrated that 
the mutant N-terminal-only neo-La is increased compared with full-length La in 
SLE patients, with decreased neo-La:La ratio in healthy controls. A logical 
progression from this finding would be to ascertain whether this increased ratio 
of neo-La:La in SLE patients correlates to disease severity, development or 
predisposition to certain clinical phentotypes, as was observed in the case of 
SS. Work is currently underway to assess this in our cohort of patients. 
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Chapter 6: 
General Discussion 
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6.1 Discussion: 
The induction of type I IFN expression is a crucially important part of the innate 
anti-viral immune response, not only for destruction of viral RNA and limitation 
of viral spread but also for activation of adaptive immunity and selective killing 
of virally-infected host cells. On the other hand, the type I IFN response can 
become pathogenic if inappropriately or excessively activated, leading to a 
failure of homeostasis and the development of autoimmune disease such as 
SLE or SS. Given the critical role for these potent anti-viral cytokines in 
protection of the host as well as the obvious ramifications of overproduction of 
IFNs, regulation is critical and, as such, there are a variety of proteins 
responsible for both positive and negative IFN regulation. The aim of this work 
was to investigate if the autoantigen and RNA-binding protein, La, was one 
such regulator and, if so, to elucidate its mechanism of action and the potential 
implications of this in disease. 
 Our findings have highlighted a dual and complex role for La in the 
regulation of type I IFN production, as schematically summarised in Figure 
5.18. Initial studies in resting cells demonstrated that La was mediating an 
inhibitory effect on IRF-driven IFN-β promoter transcriptional activity 
downstream of RIG-I and MDA-5 activation. In confirmation of this, elevated 
IFN-α and IFN-β levels were observed following La knockdown in resting cells, 
compared with scrambled controls. These observations indicate that in resting 
cells, the role of La is to ensure that the RIG-I pathway does not become 
hyper-activated, thereby maintaining a healthy innate immune balance. This 
modulation is most likely achieved by a combination of transcriptional regulation 
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of IFNs and ISGs, inhibition of pathway activation and RNA sequestration. While 
we have provided evidence for the former two mechanisms, in order to 
conclusively determine if this is the case, it would be interesting to perform RNA 
pull-downs and assess potential interactions between host RNA and La in 
resting cells and following stimulation.  
  Interestingly, subsequent studies revealed a more complex role for La 
than merely a negative regulator of type I IFN. Upon activation of RIG-I with 
RNA ligand, La appears to promote anti-viral responses by direct interaction 
with RIG-I, enhancing and prolonging complex formation at the mitochondria 
and enhancing RIG-I binding to RNA ligand. Sendai infection experiments 
supported these findings with depletion of La leading to increased viral infection 
efficiency and decreased IFN responses, compared with control cells. Overall, 
these findings highlight an essential role for La in mediating optimal IFN 
responses following viral challenge in an effort to protect the host by both 
limiting viral replication and promoting the clearance of the pathogen.   
 Like La, the Ro52 autoantigen has a known dual role in the context of 
IFN regulation, important for both stabilisation of IRF family members basally, 
yet playing a role in their degradation following stimulation (Kim and Ozato, 
2009; Kong et al., 2007). The molecular switch behind this change in function is 
known to be tyrosine phosphorylation (Stacey et al., 2012). Similarly, we have 
demonstrated the molecular switch between positive and negative IFN 
regulation by La to be CK2-mediated phosphorylation.  Furthermore, and in line 
with this dual role, expression levels of Ro52 are increased in resting SLE 
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patient cells, compared with controls, but attenuated following stimulation, a 
trend which is mirrored in the case of La, as discussed below. This 
phosphorylation-regulated dual function suggests that La activity may be 
therapeutically manipulated to regulate IFN levels, although further work is 
required to characterise the specifics of this regulation of La in the context of 
IFN production.  
 Cytosolic nucleic acids can be highly pathogenic, unless properly 
sequestered and degraded. For example, TREX-1, an enzyme involved in the 
clearance of cell-intrinsic ssDNA (Mazur and Perrino, 2001; Morita et al., 2004), 
was shown to be crucial in preventing autoimmunity, with mutations in the 
human trex1 gene culminating in development of chilblain lupus and Aicardi-
Goutiéres syndrome (AGS), a condition which phenotypically overlaps with SLE 
(Olivieri et al., 2013; Stetson et al., 2008). Interestingly, our studies showed 
decreased La expression in SLE patients compared with healthy controls in 
unstimulated cells, both at mRNA and protein level, thus underlining the 
observation that in resting cells, La, like TREX-1, functions to prevent 
autoimmunity. In addition, we have demonstrated that while the mutant neo-La 
is lower in expression than full-length La in healthy individuals, the proportion 
of neo-La expressed in SLE patients is dramatically increased compared to full-
length La. As we have demonstrated the N-terminal of La to be sufficient for 
RIG-I binding and induction of the IFN response, it is possible that neo-La is 
leading to prolonged RIG-I pathway activation and contributing to the increased 
type I and type III IFN levels responsible for driving pathogenesis in SLE 
patients (Blanco et al., 2001; Hooks et al., 1979; Niewold et al., 2008; Niewold 
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et al., 2007; Niewold and Swedler, 2005; Ronnblom et al., 1990; Weckerle et 
al., 2011; Wu et al., 2011), as has previously been demonstrated for 
phenotypically similar autoimmune condition SS. 
6.2 Future perspectives: 
While this work has collectively demonstrated a role for La in both positive and 
negative regulation of type I IFNs, elucidated mechanisms by which this 
regulation is achieved and shown the significance of these findings in the 
context of human health, there are some areas which need further investigation 
and additional questions which need to be addressed. In our initial studies we 
demonstrated that La was capable of negative regulation of both MDA-5- and 
RIG-I-driven IFN-β promoter activity, yet further studies demonstrated that La 
associated only with the RIG-I receptor and not MDA-5. Thus further dissection 
into additional mechanisms by which La negatively affects the RLR pathway of 
IFN induction would be worthwhile, including assessing whether RIG-I, IPS-1 or 
TRAF-3 protein ubiquitination and/or miRNA levels are affected by La.  
 Another interesting experiment would be to perform site directed 
mutagenesis on the Serine 366 phosphorylation site on La and serine 8, 
threonine 170, threonine 770 and Serine 854 RIG-I sites to generate mutant 
constructs for use in luciferase and co-immunoprecipitation studies. This 
approach would enable us to pinpoint the precise phosphorylation sites 
necessary and sufficient for RIG-I/La association and also elucidate more clearly 
the exact phosphorylation sites that steer La function towards positive or 
negative in IFN regulation. Since the phosphorylated form of La is 
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predominantly localised to the nucleus, with de-phosphorylation apparently 
concomitant with a shift of the protein to the cytoplasm, it would also be 
interesting to avail of transmission electron microscopy (TEM) to assess the 
effect of viral infection on La localisation to the mitochondrial-associated IPS-1 
signal transduction complex, as this technique allows high resolution 
visualisation of individual organelles within the cell. 
 Having seen the direct regulation of IFN by La and considering the 
evidence demonstrating that neo-La contributes to SS pathogenesis, it would be 
interesting to investigate whether neo-La, which has been demonstrated to be 
confined to the cytoplasm due to loss of its NLS and NRE, is hyper-activating 
RIG-I and leading to excessive IFN production thus contributing to disease 
severity. Finally it would be interesting to compare the expression levels and/or 
ratios of phosphorylated La and non-phosphorylated La in SLE patients 
compared with controls.  
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Appendix: 
A. pFLAG-CMV vector map 
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B.  pEGFP vector map 
 
 
 
C. pcDNA3.1 vector map 
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D. pEF-Bos-FLAG vector map 
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E. pGL4 Vector Map 
 
 
F. pLKO.1 Vector Map 
 
 
